

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
15 August 2002 (15.08.2002)

PCT

(10) International Publication Number
WO 02/062380 A2

(51) International Patent Classification⁷: **A61K 39/116**,
A61P 31/04

(74) Agent: **LUBIENSKI, Michael, John**; GlaxoSmithKline
CN925.1, Corporate Intellectual Property, 980 Great West
Road, Brentford, Middlesex TW8 9GS (GB).

(21) International Application Number: PCT/EP02/01356

(22) International Filing Date: 8 February 2002 (08.02.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0103169.9 8 February 2001 (08.02.2001) GB

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG,
SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN,
YU, ZA, ZM, ZW.

(71) Applicant (*for all designated States except US*):
SMITHKLINE BEECHAM BIOLOGICALS S.A.
[BE/BE]; Rue de l'Institut 89, B-1330 Rixensart (BE).

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR,
GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent
(BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,
NE, SN, TD, TG).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **BERTHET,**
Francois-Xavier Jacques [BE/BE]; GlaxoSmithKline
Biologicals S.A., Rue de l'Institut 89, B-1330 Rixensart
(BE). **LOBET, Yves** [BE/BE]; GlaxoSmithKline Biolog-
icals S.A., Rue de l'Institut 89, B-1330 Rixensart (BE).
POOLMAN, Jan [BE/BE]; GlaxoSmithKline Biologicals
S.A., Rue de l'Institut 89, B-1330 Rixensart (BE). **VER-**
LANT, Vincent, Georges, Christian, Louis [BE/BE];
GlaxoSmithKline Biologicals S.A., Rue de l'Institut 89,
B-1330 Rixensart (BE).

Published:

— *without international search report and to be republished
upon receipt of that report*

*For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*

WO 02/062380 A2

(54) Title: VACCINE COMPOSITION

(57) Abstract: The present invention relates to the field of Gram-negative bacterial vaccine compositions, their manufacture, and the use of such compositions in medicine. More particularly it relates to the field of useful Gram-negative bacterial outer membrane vesicle (or bleb) compositions comprising heterologously expressed *Chlamydia* antigens, and advantageous methods of rendering these compositions more effective and safer as a vaccine.

VACCINE COMPOSITION

FIELD OF THE INVENTION

The present invention relates to the field of Gram-negative bacterial vaccine compositions, their manufacture, and the use of such compositions in medicine. More particularly it relates to the field of useful Gram-negative bacterial outer membrane vesicle (or bleb) compositions comprising heterologously expressed *Chlamydia* antigens, and advantageous methods of rendering these compositions more effective and safer as a vaccine.

BACKGROUND OF THE INVENTION

Chlamydiae are obligate intracellular Gram negative bacteria which replicate only in cytoplasmic inclusions of eukaryotic cells. They have a unique developmental cycle which is represented by two major forms, the spore-like elementary body (EB) which is the infectious form transmitted from cell to cell, and the non infectious, metabolically active reticulate body (RB) which replicates within the host-cell.

Of the four known chlamydial species, *Chlamydia trachomatis* and *C. pneumoniae* are the important human pathogens. The recently defined species *C. pneumoniae* (Grayston 1989) is now recognized as a major cause of respiratory tract infections (Grayston 1993) and data are now growing for an association with atherosclerosis. The association is supported by seroepidemiological studies, studies demonstrating the presence of the bacterium in the atherosclerotic lesions, studies showing *C. pneumoniae* capability to replicate in the different cell types present in the atherosclerotic lesions, interventional trials with antibiotics in patients with coronary artery disease and experimental respiratory tract infection in rabbits or apolipoprotein-E deficient mice which leads to inflammatory changes in the aorta (Danesh 1997, Fong 1997, Laitinen 1997, Moazed 1997). Overall, those data implicate *C. pneumoniae* as a causative and/or aggravating factor of atherosclerosis.

C. trachomatis is a major human pathogen; transmitted from human to human (there is no known animal reservoir), it causes ocular and genital infections which can result in long term sequelae. Trachoma, a chlamydial ocular infection, is endemic in several developing countries and is the world's leading cause of preventable blindness with millions people affected by the disease. Genital chlamydial infections constitute

the most common bacterial sexually transmitted disease (STD) worldwide. In 1996, WHO generated a new set of global estimates for four major STDs drawing an extensive review of the published and unpublished prevalence data (Gerbase 1998). It has been estimated that in 1995, 4 and 5.2 million new cases of *C. trachomatis* infection occurred in individuals aged 15-49 for North America and Western Europe, respectively; worldwide, *C. trachomatis* totaled an estimate of 89.1 million new cases. Collectively, data show higher infection rates in women as compared to men (Washington 1987, Peeling 1995, Cates 1991); higher incidence is found in adolescent and young adults, approximately 70% of the chlamydial infections being reported in the 15-24 years of age group (Peeling 1995).

There is a clear need for effective vaccines against *Chlamydia trachomatis* and *Chlamydia pneumoniae*.

Outer membrane vesicles (blebs)

Gram-negative bacteria are separated from the external medium by two successive layers of membrane structures. These structures, referred to as the cytoplasmic membrane and the outer membrane (OM), differ both structurally and functionally. The outer membrane plays an important role in the interaction of pathogenic bacteria with their respective hosts. Consequently, the surface exposed bacterial molecules represent important targets for the host immune response, making outer-membrane components attractive candidates in providing vaccine, diagnostic and therapeutics reagents.

Whole cell bacterial vaccines (killed or attenuated) have the advantage of supplying multiple antigens in their natural micro-environment. Drawbacks around this approach are the side effects induced by bacterial components such as endotoxin and peptidoglycan fragments. On the other hand, acellular subunit vaccines containing purified components from the outer membrane may supply only limited protection and may not present the antigens properly to the immune system of the host.

Proteins, phospholipids and lipopolysaccharides are the three major constituents found in the outer-membrane of all Gram-negative bacteria. These molecules are distributed asymmetrically: membrane phospholipids (mostly in the inner leaflet), lipooligosaccharides (exclusively in the outer leaflet) and proteins (inner and outer leaflet lipoproteins, integral or polytopic membrane proteins). For many

bacterial pathogens which impact on human health, lipopolysaccharide and outer-membrane proteins have been shown to be immunogenic and amenable to confer protection against the corresponding disease by way of immunization.

The OM of Gram-negative bacteria is dynamic and, depending on the environmental conditions, can undergo drastic morphological transformations. Among these manifestations, the formation of outer-membrane vesicles or "blebs" has been studied and documented in many Gram-negative bacteria (Zhou, L *et al.* 1998. *FEMS Microbiol. Lett.* 163: 223-228). Among these, a non-exhaustive list of bacterial pathogens reported to produce blebs include: *Bordetella pertussis*, *Borrelia burgdorferi*, *Brucella melitensis*, *Brucella ovis*, *Chlamydia psittaci*, *Chlamydia trachomatis*, *Escherichia coli*, *Haemophilus influenzae*, *Legionella pneumophila*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Pseudomonas aeruginosa* and *Yersinia enterocolitica*. Although the biochemical mechanism responsible for the production of OM blebs is not fully understood, these outer membrane vesicles have been extensively studied as they represent a powerful methodology in order to isolate outer-membrane protein preparations in their native conformation.

Examples of bacterial species from which bleb vaccines can be made have been reviewed in WO 01/09350 (incorporated by reference herein). For example, *N. meningitidis* serogroup B (menB) excretes outer membrane blebs in sufficient quantities to allow their manufacture on an industrial scale. Such multicomponent outer-membrane protein vaccines from naturally-occurring menB strains have been found to be efficacious in protecting teenagers from menB disease and have become registered in Latin America. An alternative method of preparing outer-membrane vesicles is via the process of detergent extraction of the bacterial cells (EP 11243).

SUMMARY OF THE INVENTION

The present inventors have found that Gram-negative bacterial blebs are an ideal context to present *Chlamydia* outer membrane proteins. In particular gonococcal blebs are useful in the case of presenting *C. trachomatis* OMPs and meningococcal blebs are useful in the case of presenting *C. pneumoniae* OMPs. This is because a) these outer-membrane proteins can integrate into such blebs in a native (or near-native) conformation thus retaining a useful immunological effect; b) blebs

(particularly from *Neisseria* strains) can be produced in industrial quantities, c) blebs may be mucosally administered, and d) the combination of *Chlamydia* antigens with native bleb antigens can have important interactions for certain conditions such as salpingitis.

5 The present invention thus provides advantageous Gram-negative bacterial bleb preparations (derived from bleb-producing bacterial strains listed above, and preferably not derived from *Chlamydia*) presenting on its surface one or more recombinant (and preferably heterologous) protein antigens from *Chlamydia trachomatis* or *Chlamydia pneumoniae*. Advantageous vaccine formulations and
10 methods of administration are also provided.

DESCRIPTION OF THE INVENTION

15 The present invention provides a Gram-negative bacterial bleb presenting on its surface one or more outer membrane protein from *Chlamydia*.

In the context of this application the term "presenting on its surface" indicates that the *Chlamydia* protein should be exposed to the outer surface of the bleb and tethered to the outer membrane (preferably by being integrated into the outer
20 membrane). Most preferably it should take up its native fold within the heterologous bleb context.

An efficient strategy to modulate the composition of a Bleb preparation in this way is to deliver one or more copies of a DNA segment containing an expression cassette comprising a gene encoding said *Chlamydia* outer membrane protein into the
25 genome of a Gram-negative bacterium.

A non exhaustive list of preferred bacterial species that could be used as a recipient for such a cassette includes: *Bordetella pertussis*, *Borrelia burgdorferi*, *Brucella melitensis*, *Brucella ovis*, *Chlamydia psittaci*, *Chlamydia trachomatis*, *Escherichia coli*, *Haemophilus influenzae*, *Legionella pneumophila*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Pseudomonas aeruginosa* and *Yersinia enterocolitica*. *Neisseria meningitidis*, *Neisseria gonorrhoeae*, *Moraxella catarrhalis*, *Haemophilus influenzae*, *Pseudomonas aeruginosa*, *Chlamydia trachomatis*, *Chlamydia pneumoniae* are more preferred for this purpose, and
30

Neisseria gonorrhoeae and *Neisseria meningitidis* are most preferred for making the blebs of this invention. Preferably the *Chlamydia* OMPs are expressed heterologously, and in such situations *Chlamydia* strains should not be used to make the blebs of the invention.

5 The gene(s) contained in the expression cassette may be homologous (or endogenous) (i.e. exist naturally in the genome of the manipulated bacterium) or, preferably, heterologous (i.e. do not exist naturally in the genome of the manipulated bacterium). The introduced expression cassette may consist of unmodified, "natural" promoter/gene/operon sequences or engineered expression cassettes in which the
10 promoter region and/or the coding region or both have been altered. A non-exhaustive list of preferred promoters (preferably strong) that could be used for expression includes the promoters *porA*, *porB*, *lbpB*, *tbpB*, *p110*, *lst*, *hpuAB* from *N. meningitidis* or *N. gonorrhoeae*, the promoters *p2*, *p5*, *p4*, *ompF*, *p1*, *ompH*, *p6*, *hin47* from *H. influenzae*, the promoters *ompH*, *ompG*, *ompCD*, *ompE*, *ompB1*, *ompB2*, *ompA* of
15 *M. catarrhalis*, the promoter λ pL, *lac*, *tac*, *araB* of *Escherichia coli* or promoters recognized specifically by bacteriophage RNA polymerase such as the *E. coli* bacteriophage T7.

 In a preferred embodiment of the invention the expression cassette is delivered and integrated in the bacterial chromosome by means of homologous and/or site
20 specific recombination (as discussed in WO 01/09350 incorporated by reference herein). Integrative vectors used to deliver such genes and/or operons can be conditionally replicative or suicide plasmids, bacteriophages, transposons or linear DNA fragments obtained by restriction hydrolysis or PCR amplification. Integration is preferably targeted to chromosomal regions dispensable for growth *in vitro*. A non
25 exhaustive list of preferred loci that can be used to target DNA integration includes the *porA*, *porB*, *opa*, *opc*, *rmp*, *omp26*, *lecA*, *cps*, *lgtB* genes of *Neisseria meningitidis* and *Neisseria gonorrhoeae*, the *P1*, *P5*, *hmw1/2*, *IgA-protease*, *fimE* genes of NTHi; the *lecA1*, *lecA2*, *omp106*, *uspA1*, *uspA2* genes of *Moraxella catarrhalis*. Alternatively, the expression cassette used to modulate the expression of bleb
30 component(s) can be delivered into a bacterium of choice by means of episomal vectors such as circular/linear replicative plasmids, cosmids, phasmids, lysogenic bacteriophages or bacterial artificial chromosomes. Selection of the recombination event can be selected by means of selectable genetic marker such as genes conferring

resistance to antibiotics (for instance kanamycin, erythromycin, chloramphenicol, or gentamycin), genes conferring resistance to heavy metals and/or toxic compounds or genes complementing auxotrophic mutations (for instance *pur*, *leu*, *met*, *aro*). Blebs may be made from the resulting modified strain.

5 The expression of some heterologous proteins in bacterial blebs may require the addition of outer-membrane targeting signal(s). The preferred method to solve this problem is by creating a genetic fusion between a heterologous gene and a gene coding for a resident OMP as a specific approach to target recombinant proteins to blebs. Most preferably, the heterologous gene is fused to the signal peptides sequences
10 of such an OMP.

A particularly preferred application of this invention is the introduction of *Chlamydia* (*trachomatis* or *pneumoniae*) protective antigens (preferably outer membrane proteins) into Gram-negative bacterial blebs (preferably not from
15 *Chlamydia* strains). This has several advantages including the fact that such blebs (and vaccines comprising them) are extremely suitable for mucosal administration, which is beneficial as a mucosal (IgA) immune response against the *Chlamydia* antigens present in the bleb will be more protective against *Chlamydia* infections which manifest themselves in the mucosa. Recombinant bacteria capable of producing blebs
20 of the invention, processes of making such bacteria, and processes of making bleb preparations are further aspects of this invention.

***Chlamydia trachomatis* antigens integrated into a Gram negative bacterial bleb**

A particularly preferred embodiment is in the field of the prophylaxis or
25 treatment of sexually-transmitted diseases (STDs). It is often difficult for practitioners to determine whether the principal cause of a STD is due to gonococcus or *Chlamydia trachomatis* infection. These two organisms are major causes of salpingitis – a disease which can lead to sterility in the host. It would be useful if a STD could be vaccinated against or treated with a combined vaccine effective against
30 disease caused by both organisms. The Major Outer Membrane Protein (MOMP or OMP1 or OMPI) of *C. trachomatis* has been shown to be the target of protective antibodies. However, the structural integrity of this integral membrane protein is important for inducing such antibodies. In addition, the epitopes recognised by these

antibodies are variable and define more than 10 serovars. The bleb context of the invention allows the proper folding of one or more MOMP or other Chlamydia membrane proteins for vaccine purposes. The engineering of (preferably) a gonococcal strain expressing one or more *C. trachomatis* MOMP serovars and/or one or more other protective Chlamydia OMPs in the outer membrane, and the production of blebs therefrom, produces a single solution to the multiple problems of correctly folded membrane proteins, the presentation of sufficient MOMP serovars and/or other Chlamydia OMPs to protect against a wide spectrum of serovars, and the simultaneous prophylaxis/treatment of gonococcal infection (and consequently the non-requirement of practitioners to initially decide which organism is causing particular clinical symptoms – both organisms can be vaccinated against simultaneously thus allowing the treatment of the STD at a very early stage). Preferred loci for gene insertion in the gonococcal chromosome are give above. Other preferred, protective *C. trachomatis* genes that could be incorporated are HMWP, PmpG and those OMPs disclosed in WO 99/28475 (incorporated by reference herein).

A particularly preferred embodiment of the invention provides a Gram-negative bacterial bleb (preferably gonococcal) presenting on its surface the PorB outer membrane protein (see below) from *Chlamydia trachomatis*. A bacterial strain capable of producing such a bleb is a further aspect of the invention.

PorB *Chlamydia trachomatis* serovar D (D/UW-3/Cx) DNA sequence

ATGAGTAGCAAGCTAGTGAACATCTCCGTTTGACTTTCCTATCTTTTTAGGGATCGCATCTACTTCATTAGACGCTAT
GCCTGCGGGGAATCGGCGTTTCCAGTCATCCCGGGGATTAAATATTGAACAGAAAAATGCCTGTCTTCGATTTATGTA
ATCTTATGATGTACTATCCGCACTGTCCGGTAACCTGAAGCTCTGCTTCTGCGGAGATTATATCTTTTCAGAGAAGCT
CAGGTAAAGATGTCCCTGTCGTACCTCTGTGACAACAGCTGGGGTTGGTCCCTCTCCTGATATTACTCGACAACCAA
AACGCGAAATTTGATCTCGTGAACCTGTAATCTCAATACAACTGTGTAGCTGTAGCTTTTCCCTTCTGATCGTTCCG
TGAGCGCGATTCTCTGTTTGTGAGTTTCGAAGTGAAAGTAGGAGGACTGAAACAATACTACCGCCTTCCCATGAAT
GCCTATCGAGACTTCACCTCGGAACCTCTCAATTCTGAATCAGAAAGTTACGGACGGGATGATTGAAGTACAGTCCAATTA
CGGATTTGTTTGGGATGTTAGCTTGAAAAAGTCATATGGAAAGATGGCGTTTCTTTGTAGGCGTCGGTGCAGACTATC
GCCATGCTTCTTGCCCTATTGACTACATCAATTGCAACAGTCAAGCTAATCCAGAAGTATTCATCGCTGACTCGGATGGG
AACTGAACTCAAGGAGTGGAGTGTCTGCGTAGGCTTACTACCTATGTGAATGACTACGTTCTTCTTACTTAGCGTT
TTCTATAGGGAGTGTCTCGCCAAGCTCCGGACGACAGCTTCAAAAAATTAGAAGATCGCTTCACTAACCTCAAAATTA
AAGTTCGTAAAAATTACCAGCTCTCATCGTGGAACATCTGCATCGGAGCGACAAACTATGTGCGCCGATAACTTCTCTAC
AACGTAGAAGGAAGATGGGGAAGCCAGCGCGCTGTGAACGTCTCCGGAGGATTCCAATTCTAA

Translated amino acid sequence

MSSKLVNYLR LTFLSFLGIA STSLDAMPAG NPAFFVIPGI
NIEQKNACSF DLCNSYDVLS ALSGNLKLCF CGDYIFSEE QVKDVPVVT
VTAGVGPSF DITSTTKTRN FDLVNCNLNT NCVAVAFSLP DRSLSAIPLF
DVSFEVKVGG LKQYYRLPMN AYRDTSEPL NSESEVTDGM IEVQSNGYGFV
WDVSLKKVIW KDGVSVFVG VADYRHASCP I DYILANSQAN PEVFIADSDG
KLNFKESVVC VGLTTYVNDY VLPYLAFIG SVSRQAPDDS FKKLEDRFTN

LKFKVRKITS SHRGNICIGA TNYVADNFFY NVEGRWGSQR AVNVSGGFQF

The presence of PorB in the blebs means that the antigen can be mucosally administered more easily, and provides more effective protection than if administered alone.

The present invention additionally provides a Gram-negative bacterial bleb (preferably gonococcal) presenting on its surface one or more of the following proteins from *Chlamydia trachomatis*, or *C. trachomatis* PorB in combination with one or more of the following proteins. It will be clear to a skilled person that instead of the sequences below (and the PorB sequence above), the natural analogue of the sequences from other *C. trachomatis* serovars or serotypes could be used, as could genes encoding functional analogues of the proteins comprising insertions, deletions or substitutions from the recited sequences which unaffected the immunological properties of the encoded protein. Preferably a sequence from a serovar D strain should be selected. A bacterial strain capable of producing such a bleb is a further aspect of the invention.

>gi|6578118|gb|AAC68456.2| predicted Protease containing IRBP and DHR domains [Chlamydia trachomatis]
 MKMNRILWLLLTFFSSAIHSPVQGESLVCKNALQDLSFLEHLLQVKYAPKTWKEQYLGWDLVQSSVSAQQK
 LRTQENPSTSFCCQVLADFIGGLNDFHAGVTFFAIESAYLPYTVQKSSDGRFYFVDIMTFSSEIRVGDEL
 LEVDGAPVQDVLATLYGSNHKGTAEESSAALRTLFSRMASLGHKVPSGRTTLKIRRPFGTTREVRVKWRY
 VPEGVGDLATIAPSIRAPQLQKSMRSFFPKDDAFHRSSSLFYSPMVPFWAELRNHYATSGLKSGYNIG
 25 STDGFLPVIGPVIWESEGLFRAYISSVTDGDKSHKVGFLRIPTYSWQDMEDFDPSGPPPWEEFAKIIQV
 FSSNTEALIIDQTNNPGGSVLVLYALLSMLTDRPLELPKHRMILTQDEVVDALDWLTLLNVDVTVNESRL
 ALGDNMEGYTVDDLQVAEYLKSFGRQVLNCWSKGDIELSTPIPLFGFEKIHPPHPRVQYKPKICVLINEQDF
 SCADFFPVVLKDNDRALIVGTRTAGAGGFVFNVPFNRTGIKTCSLTGS LAVREHGAFIENIGVEPHIDL
 PFTANDIRYKGYSEYLDKVKKLVCQLINNDGTIILAEDGSF
 30 >gi|3329331|gb|AE001359.1:101-1906,
 ATGAAAATGAATAGGATTGGCTATTACTGCTTACCTTTTCTTCTGCCATACATTCTCCTGTACAAGGAG
 AAAGCTTGGTTTGCAAGAATGCTCTTCAAGATTGAGTTTTTTAGAGCATTTATTACAGGTTAAATATGC
 TCCTAAACATGGAAAGAGCAATACTTAGGATGGGATCTTGTTCAAAGCTCCGTTTCTGCACAGCAGAAG
 CTTCTGTACACAAGAAAATCCATCAACAAAGTTTTTGCCAGCAGGTCCTTGCTGATTTTATCGGAGGATTAA
 35 ATGACTTTTCACGCTGGAGTAACCTTTCTTTCGATAGAAAAGTGCTTACCTTCTTATACCGTACAAAAAG
 TAGTGACGGCCGTTTCTACTTTGTAGATATCATGACTTTTCTTCAGAGATCCGTGTTGAGATGAGTTG
 CTAGAGGTGGATGGGGCGCCTGTCCAGATGTACTCGCTACTCTATATGGAAGCAATCACAAAGGGACTG
 CAGCTGAAGAGTCGGCTGCTTTAAGAACTACTTTCTCGCATGGCCTCTTTAGGGCACAAAGTACCTTC
 TGGGCGCACTACTTTAAAGATTGCTGCTCCTTTTGGTACTACGAGAGAAGTTCGTGTGAAATGGCGTTAT
 40 GTTCTGAAGGTGTAGGAGATTGGCTACCATAGCTCCTTCTATCAGGGCTCCACAGTTACAGAAATCGA
 TGAGAAGCTTTTCCCTAAGAAAGATGATGCGTTTCATCGGTCTAGTTCTGCTATTCTACTCTCCAATGGT
 TCCGCATTTTGGGCGAGAGCTTCGCAATCATTATGCAACGAGTGGTTTGAAAAGCGGGTACAATATTGGG
 AGTACCGATGGGTTTCTCCCTGTCTATTGGGCTGTATATGGGAGTCGGAGGGTCTTTCCGCGCTTATA
 TTTCTTCGGTGACTGATGGGGATGGTAAGAGCCATAAAGTAGGATTCTAAGAATTCCTACATATAGTTG
 45 GCAGGACATGGAAGATTTTGATCCTTCAGGACCGCTCCTTGGGAAGAATTGCTAAGATTATTCAAGTA
 TTTCTTCTTAATACAGAAGCTTTGATTATCGACCAACGAACAACCCAGGTGGTAGTGTCTTTATCTTT
 ATGACTGCTTTCCATGTTGACAGACCGTCTTTAGAACTTCTAAACATAGAATGATTCTGACTCAGGA
 TGAAGTGGTTGATGCTTTAGATTGGTTAACCTGTTGGAAAACGTAGACACAAACGTGGAGTCTCGCCTT

- GCTCTGGGAGACAACATGGAAGGATATACTGTGGATCTACAGGTTGCCGAGTATTTAAAAAGCTTTGGAC
GTCAAGTATTGAATTGTTGGAGTAAAGGGGATATCGAGTTATCAACGCCTATTCTCTTTTGGTTTTGA
GAAGATTCATCCACATCCTCGAGTTCAATACTCTAAACCGATTGTGTTTTGATCAATGAGCAAGACTTT
TCTTGTGCTGACTTCTTCCCTGTAGTTTTGAAAGACAATGATCGAGCTCTTATTGTTGGTACTCGAACAG
5 CTGGAGCTGGAGGATTTGTCTTTAATGTGCAGTTCCCAAATAGAAGTGAATAAAAACTTGTCTTTAAC
AGGATCATTAGCTGTTAGAGAGCATGGTGCCTTCATTGAGAACATCGAGTCGAACCGCATATCGATCTG
CCTTTTACAGCAATGATATTTCGTATAAAGGCTATTCCGAGTATCTTGATAAGGTCAAAAAATTGGTTT
GTCAGCTGATCAATAACGACGGTACCATTATTCTTGCGGAAGATGGTAGTTTTTAA
- 10 >gi|6578109|gb|AAC68227.2| CHLPN 76kDa Homolog [Chlamydia trachomatis]
MKKYFYKGFVGLALLACGSTNLAFQAASSMDSQLWSVEDLDSYLSSKGFVETRKRDGVLRLAGDVRRARI
YAKEDLETTQTPAKPMLPTNRYRSEFNLYVDYTAANSWMTSKMNWVTIAGGESSAAGLDINRAFLGYRFY
KNPETQAEVFAEIGRSLGDI FDSVDVQFNSNFDGIHLAARRISEKLFPTMIVHGGPFVVMMAEKEYAWV
VEAILNKLPGNFVVKTSVVDWNTLTAKTNDPADASAAQPAKPNTKYDYLWQWLVGKSTAMPWFNGQTKN
15 LYTYGAYLFNPLAEIPENWKQSTTPTTKITNGKENHAWFIGCSLGGVRRAGDWSATVRYEYVEALAIPEI
DVAGIGRGNQMKYWFQAQAIKQGLDPKESNGFTNYKGVSYQFVMGLTDSVSFRAYAAYSKPANDNLGSDFT
YRKYDLGLISSF
- >gi|3329068|gb|AE001333.1:c3495-2197,
ATGAAAAAATACTTTTATAAAGGGTTTGTAGGCGCGCTTTTATTAGCTTGTGGGTCTACAACTTGGCTT
20 TTGCGCAGGCTAGTTTCGATCGATAGCCAGCTATGGTCTGTTGAAGATTTAGATTCTATTTGAGTTCCAA
AGGTTTTGTCGAGACTCGTAAGCGCGATGGAGTTCTACGTTTAGCTGGAGATGTCCGCGCTCGATGGATT
TATGCAAAAAGAGGATCTTGAAGACAACCTAGACTCTGCTAAACCTATGTTACCTACCAATCGGTATCGTA
GTGAATTCATTTGTATGTGGATTACACCGCTGCTAATAGTTGGATGACTTCGAAAATGAATTGGGTAAC
GATTGCTGGCGGAGAATCTTCTGCAGCAGGGTTAGATATTAATCGTGCCTTCTTAGGATACCGATTCTAC
25 AAAAACCAGAAACGCAAGCAGAGTATTTGCAGAGATTGGTCTGCTTGGATTGGGAGATATTTTGGATT
CCGACGTTCAAGTTAATAGTAATTTGCAGCGAATTCATTTATACGCTGCGCGACGTATTAGTGAGAACT
TCCCTTTCACCATGATTGTTTCATGGTGGTCTTTTGTCTGTAATATGGCAGAGAAAGAGTATGCTTGGGTCT
GTGGAAGCTATTTTGAATAAACTCCAGGAATTTTCGTTGTGAAAACGAGTGTGTTGACTGGAATACGT
TAACAGCAAAAACGAATGATCCAGCAGACGCAAGCGCTGCACAACAGCTAAACCTAATACCAAGTACGA
30 TTATTTAGTATGGCAATGTTGGTTGGGAAAGAGCACAGCTATGCCATGTTTAAATGGACAAACAAAAAT
CTTTACACTTACGGAGCCTATCTCTTTAATCCATTAGCGGAAATACCAGAGAACTGGAAACAAATCAACAA
CTCTTACAAACCAAAATACAAATGGTAAGGAAACCATGCTTGGTTTCATCGGCTGCTCTCTAGGCGGTGT
TCGACGAGCTGGAGACTGGTCTGCAACAGTTTCGTTATAGTATGTTGAAGCTTTAGCGATTCCAGAAATT
GATGTCGCGGGTATTGGTTCGCGGAAACCAATGAAATATTGGTTTGTCTCAAGCTATCAAACAAGGATTGG
35 ATCCTAAAGAATCTAACCGCTTTACTAACTATAAAGGAGTTTCTTATCAGTTTGTATGGGTCTGACAGA
TTCGGTTTCTTTCGAGCTTATGCTGCTTATTCTAAGCCTGCTAACGATAACCTTGGTAGCGACTTCACC
TATCGTAAGTATGACCTAGGTTTAAATTTCTTCAATTCTAA
- 40 >gi|3329350|gb|AAC68472.1| Putative Outer Membrane Protein I [Chlamydia
trachomatis]
MRPDHMFCCCLCAAILSSSTAVLFGQDPLGETALLTKNPNHVVCTFFEDCTMESLFPALCAHASQDDPLYV
LGNSYCWVFSKLHITDPKEALFKEKGLDSIQNFRFLSFTDCSSKLESSPSIIHQKNGQLSLRNNGSMSFCR
NHAEGSGGAISADAFSLQHNYLFTAFENSSKNGGGAIQATFSLSRNVSPISFARNRADLNGGAICCSN
LICSQNVNPLFFTGNSATNGGAICCSIDLNTSEKGSLSLACNQETLFASNSAKEKGGAIIYAKHMLVRYNG
45 PVSFINNSAKIGGAIATQSGGSLSLAGEGSLVLFQNNQRTSDQGLVRNAIYLEKDAILSSLEARNGDIL
FFDPIVQESSSKESPLPSSLQASVTSPTPATASPLVIQTSANRSVIFSSERLSEBEKTPDNLTSQLQOPI
ELKSGRLVLKDRVLAPSLSQDPQALLIMEAGTSLKTSDDLKLATLSIPLHSLDTEKSVTIHAPNLSIQ
KIFLSNSGDNENFYENVLLSKEQNNIPLLTLSKEQSHLHLPDGNLSSHFGYQGDWTFWKSQDSDEHSLIA
NWTPKNYVPHPERQSTLVANTLWNTYSDMQAVQSMINTIAHGGAYLFGTWGSAVSNLFYAHDSGKPIDN
50 WHHRSGLYLFGISHTSLDDHSFCLAAGQLLGKSSDSFITSTETTSYIATVQAQLATPLMKISAQACYNES
IHELKTKYRSFSGEFGSWHSVAVSGEVCASIPVSNNGSGLFSSFSIFSGLQGFSGTQDGFEESSGEIRS
FSASSFRNISLPMGITFEKKSQKTRNYFFLGAYIQDLKRDVESGPVVLKNAVSWDAPMANLDSRAYMF
RLTNQRALHRLQTLNVSIVLRGQSHSYSLDLGTTYRF
- >gi|3329348|gb|AE001361.1:c3451-815,
ATGCGACCTGATCATATGAACCTCTGTTGTCTATGTGCTGCTATTTTGTATCCACAGCGGTCTCTCTTGT
55 GCCAGGATCCCTTAGGTGAAACCGCCCTCTCACTAAAAATCCTAATCATGTCGTCTGTACATTTTTTGA
GGACTGTACCATGGAGAGCCTCTTTCCTGCTCTTTGTGCTCATGCATCACAAGATGATCCTTTGTATGTA
CTTGGAATTCCTACTGTTGGTTTCGTATCTAACTCCATATCACGAGCCCCAAGAGGCTCTTTTTAAAG
AAAAAGGAGATCTTTCCATTCAAAATTTTCGCTTCCTTTCTTCCACAGATTGCTCTTCAAGGAAAGCTC
60 TCCTTCTATTATTCATCAAAAGAAATGGTCAGTTATCCTTGCAGCAATAATGGTAGCATGAGTTTCTGTCTGA
AATCATGCTGAAGGCTCTGGAGGAGCCATCTCTGCGGATGCCTTTTCTCTACAACAACACTATCTTTTCA
CAGCTTTTGAAGGAATTTCTTAAAGGAAATGGCGGAGCAATTCAGGCTCAAACCTTCTCTTTATCTAG
AAATGTGTGCGCTATTTCTTTCGCGGTAATCGTGCAGATTAAATGGCGGCGCTATTGCTGTAGTAAT
CTTATTTGTTTCAAGGAATGTAAACCTCTCTTTTCACTGGAAACTCCGCCACGAATGGAGGCGCTATTT
65 GTTGATCAGCGATCTAAACACCTCAGAAAAAGGCTCTCTCTCTCTTGCTTGTAAACCAAGAAACGCTATT
TGCAAGCAATCTGCTAAAGAAAAAGGCGGGGCTATTATGCCAAGCACATGGTATTGCGTTATAACGGT

CCTGTTTCCTTCATTAAACAACAGCGCTAAATAGGTGGAGCTATCGCCATCCAGTCCGGAGGGAGTCTCT
 CTATCCTTGCAGGTGAAGGATCTGTTCTGTTCCAGAATAACTCCCAACGCACCTCCGACCAAGGTCTAGT
 AAGAAACGCCATCTACTTAGAGAAAGATGCGATTCTTTCTTCCTTAGAAGCTCGCAACGGAGATATTCTT
 TTCTTTGATCCTATTGTACAAGAAAGTAGCAGCAAAGAATCGCCTCTTCCCTCCTCTTTGCAAGCCAGCG
 5 TGACTTCTCCACCCCAGCCACCGCATCTCCTTTAGTTATTAGACAAGTGCAAACCGTTTCAGTGATTTT
 CTGAGCGAACGTCTTTCTGAAGAAGAAAACTCTGTATAACCTCACTTCCCAACTACAGCAGCCTATC
 GAACTGAAATCCGGACGCTTAGTTTAAAAGATCGCGCTGTCTCTTCCGCGCCTTCTCTCTCAGGATC
 CTCAAGCTCTCCTCATTATGGAAGCGGGAACCTCTTTAAAAAATCTCTCTGATTTGAAGTTAGCTACGCT
 AAGTATTTCCCTTCATTCTCTTAGATACTGAAAAAGCGTAACCTATCCACGCCCTTAACCTTTCTATCCAA
 10 AAGATCTTCTCTCTAATTCTGGAGATGAGAAATTTTATGAAAATGTAGAGCTTCTCAGTAAAGAGCAAA
 ACAATATTCTCTCTCTTACTCTCTCTAAAGAGCAATCTCATTACATCTTCTGATGGGAACCTCTCTCT
 TCACCTTTGGATATCAAGGAGATTGGACTTTTTCTTGGAAAGATTCTGATGAAGGGCATTTCTGATTGCT
 AATTGGACGCTTAAAACTATGTGCTCATCCAGAACGTCAATCTACACTCGTTGCGAACACTCTTTGGA
 ACACCTATTCCGATATGCAAGCTGTGCACTCGATGATTAATACAATAGCGCACGGAGGAGCCTATCTATT
 15 TGGACGTGGGGATCTGCTGTTTCTAATTTATTCTATGCTCAGACAGCTCTGGGAAACCTATCGATAAT
 TGGCATCATAGAAGCCTTGGCTACCTATTTCGGTATCAGTACTCAGTTTAGATGACCATTTCTTTCTGCT
 TGGCTGCAGGACAATTACTCGGGAAATCGTCCGATTCTTTATTACGTCTACAGAAACGACCTCTATAT
 AGCTACTGTACAAGCGCAACTCGCTACCCCTCTAATGAAAATCTCTGCACAGGCATGCTATAATGAAAGT
 ATCCATGAGCTAAAAACAAAATATCGCTCCTTCTCTAAAGAAGGATTTCGGATCCTGGCATAGCGTTGCAG
 20 TATCCGGGAAGTGTGCGCATCGATTCTTATGTATCCAATGGTTCGGACTGTTTCAGCTCCTTCTCTAT
 TTTCTCTAAACTGCAAGGATTTTCAGGAACACAGGACGGTTTGGAGGAGAGTTTCGGGAGAGATTCGGTCC
 TTTTCTGCCAGCTCTTTTCAGAAATATTTCACTTCTCTATGGGAATAACATTTGAAAAAAAATCCCAAAAA
 CACGAACTACTATTACTTTTGGGAGCCTACATCCAAGACCTAAACGTGATGTGGAATCGGGACCTGT
 AGTGTTACTCAAAAATGCCGTCTCTGGGATGCTCTATGGCGAAGTTGGATTTCGCGAGCCTACATGTTT
 25 AGGCTTACGAATCAAAGAGCTCTGCATAGACTTCAGACGCTGTTAAATGTGTCTTACGTACTGCGCGGGC
 AAAGCCATAGTTACTCCCTGGATCTGGGGACCACTTACAGGTTCTAG

>gi|3329346|gb|AAC68469.1| Putative Outer Membrane Protein G [Chlamydia
 trachomatis]

30 MQTSFHKFFLSMILAYSCCSLSGGGYAAEIMIPQGIYDGETLTVSFPYTVIGDPSGTTVFSAGELTLKLN
 DNSIAALPLSCFGLNLLGSFTVLGRGHSITFENIRTSTNGAALSDDSANSGLFTIEGFKELSFNSCNLLAV
 LPAATTNNGSQPTTTTSTPSNGTIYSKTDLLLLNNEKFSFYSNLVSGDGGAIIDAKSLTVQGISKLCVQFE
 NTAQADGGACQVVTFSFAMANEAPIAFIANVAGVRGGGIAAVQDQGVSSSTSTEDPVVSFSRNTAVEF
 DGNVARVGGGIYSYGNVAFLLNNGKTLFLNNAVSPVYIAEQPTNGQASNTSDNYGDGGAIFCKNGAQAAG
 35 SNNSGSVSFDGEGVVFSSNVAAGKGGAIYAKKLSVANCGPVQFLGNIANDGGAIYLGESGELSLSADYG
 DIIIFDGNLKRKTAKENAADVNGVTVSSQAI SMGAGGKITT LRKAGHQILFNDPIEMANGNNQPAQSSEPL
 KINDGEGYTGDIVFANGNSTLYQNVITIEQGRIVLREKAKLSVNSLSQTGGSLYMEAGSTLDFVTPQPPQQ
 PPAANQLITLSNLHLSSLANNAVTPNPPNPPAQDHPAIIIGSTTAGSVTISGPIFFEDLDDTAYDRY
 DWLGSNQKIDVLKQLGTPSANAPSDLTLGNEMPKYGYQGSWKLAWDPNTANNPYTLKATWTKTGYNP
 40 GPERVASLVPNLSLWGSILDIRSAHSAIQASVDGRSYCRGLWVSGVSNFFYHDRDALGQGYRISGGYSLG
 ANSYFGSSMFGLAFTVEFGRSKDYVVCRSNHHACIGSVLSTKQALCGSYLFGDAFIRASYGFGNQHMKT
 SYTFABESDVRWDNNCLVGEIGVGLPIVITPSKLYLNLRLPFVQAEFSYADHESFTEEGDQARAFRSGHL
 MNLSVPVGVKFDRCSSTHPNKYSFMGAYICDAYRTISGTQTTLLSHQETWTTDAFHLARHGIVIRGSMYA
 SLTSNIEVYGHGRYERDTSRGYGLSAGSKVRF

45 >gi|3329342|gb|AE001360.1:7736-10777,
 ATGCAAACGTCTTTCCATAAGTTCTTTCTTCAATGATTCTAGCTTATTCTTGCTGCTCTTTAAGTGGGG
 GGGGGTATGCAGCAGAAATCATGATTCTCTCAAGGAATTACGATGGGGAGACGTTAAGTGTATCATTTC
 CTACTGTTATAGGAGATCCGAGTGGGACTACTGTTTTCTGTCAGGAGAGTTAACGTTAAAAAATCTT
 GACAATTCTATTGCACTTTGCTTTTAAAGTTGTTTTGGGAACTTATTAGGGAGTTTTACTGTTTTAGGGA
 50 GAGGACACTCGTTGACTTTTCGAGAACATACGGACTTCTACAAATGGAGCTGCACTAAGTGACAGCGCTAA
 TAGCGGGTTATTACTATTGAGGGTTTTAAAGAATTATCTTTTCCAAATGCAACTCATTACTTGCCGTA
 CTGCCTGCTGCAACGACTAATAATGGTAGCCAGACTCCGACGACAACATCTACACCGTCTAATGGTACTA
 TTATTCTAAAACAGATCTTTTGTACTCAATAATGAGAAGTTCTCATTCTATAGTAATTTAGTCTCTGG
 AGATGGGGGAGCTATAGATGCTAAGAGCTTAACGGTTCAAGGAATTAGCAAGCTTTGTGTCTTCCAAGAA
 55 AATCTGCTCAAGCTGATGGGGGAGCTTGTCAAGTAGTCACAGTTTCTCTGCTATGGCTAACGAGGCTC
 CTATTGCTTTTATAGCGAATGTTGCAAGGATTAAGAGGGGAGGATTGCTGCTGTTTCAGGATGGGCAGCA
 GGGAGTGTCTATCTACTTCAACAGAAGATCCAGTAGTAAGTTTTTCCAGAAATACTGCGGTAGAGTTT
 GATGGGAACGTAGCCCGAGTAGGAGGAGGATTTACTCTACGGGAACGTTGCTTTCTGAATAATGGAA
 AAACCTTGTCTTCAACAATGTTGCTCTCTGTTTACATTGCTGCTGAGCAACCAACAATGGACAGGC
 60 TTCTAATACGAGTGATAATTACGGAGATGGAGGAGCTATCTTCTGTAAGAATGGTGCCGCAAGCAGCAGGA
 TCCAATAACTCTGGATCAGTTTCTTTGATGAGGAGGAGTAGTTTTCTTTAGTAGCAATGTAGCTGCTG
 GGAAGGGGGAGCTATTTATGCCAAAAAGCTCTCGGTTGCTAACTGTGGCCCTGTACAATCTTAGGGAA
 TATCGCTAATGATGGTGGAGCGATTATTTAGGAGAATCTGGAGAGCTCAGTTTATCTGCTGATTATGGA
 GATATTATTTTCGATGGGAATCTTAAAGAAGACGCCAAAGAGAAATGCTGCCGATGTTAATGGCGTAACGTG
 65 TGCTCTCACAGCCATTTTCGATGGGATCGGGAGGGAAAATAACGACATTAAGAGCTAAAGCAGGGCATCA
 GATTCTCTTTAATGATCCATCGAGATGGCAAACGGAAATAACGACCCAGCGCAGTCTTCCGAACCTCTA

- AAAATTAACGATGGTGAAGGATACACAGGGGATATTGTTTTTGCCTAATGGAACAGTACTTTGTACCAAA
 ATGTTACGATAGAGCAAGGAAGGATTGTTCTTCGTGAAAAGGCAAAATTATCAGTGAATTCTCTAAGTCA
 GACAGGTGGGAGTCTGTATATGGAAGCTGGGAGTACATTGGATTTTGTAACTCCACAACCACCACAACAG
 CCTCCTGCCGCTAATCAGTTGATCAGCTTTCCAATCTGCATTTGTCTTTCTTTCTTTGTTAGCAAAACA
 5 ATGCAGTTACGAATCCTCCTACCAATCCTCCAGCGCAAGATTCTCATCTCTGCAATCATTGGTAGCACAAC
 TGCTGGTTCTGTTACAATTAGTGGGCCATCTTTTTTGGAGATTGGGATGATACAGCTTATGATAGGTAT
 GATTGGCTAGGTTCTAATCAAAAAATCGATGCTCTGAAATTACAGTTAGGGACTCAGCCCTCAGCTAATG
 CCCCATCAGATTTGACTCTAGGGAATGAGATGCCAAGTATGGCTATCAAGGAAGCTGGAAGCTTGCCTG
 GGATCCTAATACAGCAAATAATGGTCCTTATACTCTGAAAGCTACATGGACTAAAAGCTGGGTATAATCCT
 10 GGGCCTGAGCGAGTAGCTTCTTTGGTTCCAAATAGTTTATGGGGATCCATTTTATAGATATACGATCTGCGC
 ATTCAGCAATTCAAGCAAGTGTGGATGGGCGCTCTTATTGTGCGAGGATTATGGGTTTCTGGAGTTTCGAA
 TTTCTTCTATCATGACCGCGATGCTTTAGGTACGGGATATCGGTATATTAGTGGGGGTTATTCCTTAGGA
 GCAAATCCTACTTTGGATCATCGATGTTTGTCTAGCATTTTACCGAAGTATTTGGTAGATCTAAAGATT
 ATGTAGTGTGTCGTTCCAATCATCATGCTTGCATAGGATCCGTTTATCTATCTACCAACAAGCTTTATG
 15 TGGATCCTATTTGTTCCGAGATGCGTTTATCCGTGCTAGCTACGGGTTTGGGAACCAGCATATGAAAACC
 TCATACACATTTGCAGAGGAGAGCGATGTTGCTGGGATAATAACTGTCTGGTTGGAGAGATTGGAGTGG
 GATTACCGATTGTGATTACTCCATCTAAGCTCTATTGAATGAGTTGCGTCTCTTTCGTGCAAGCTGAGTT
 TTCTTATGCCGATCATGAATCTTTTACAGAGGAAGCGATCAAGCTCGGGCATTAGGAGTGGACATCTC
 ATGAATCTATCAGTTCCGTGTTGGAGTAAATTTGATCGATGTTCTAGTACACACCCCTAATAAATATAGCT
 20 TTATGGGGGCTTATATCTGTGATGCTTATCGCACCATCTCTGGGACTCAGACACACTCCTATCCCATCA
 AGAGACATGGACAACAGATGCCTTTTCAATTTGGCAAGACATGGAGTCATAGTTAGAGGGTCTATGTATGCT
 TCTCTAACAAGCAATATAGAAGTATATGGCCATGGAAGATATGAGTATCGAGATACTTCTCGAGGTTATG
 GTTTGAGTGCAGGAAGTAAAGTCCGGTTCTAA
- 25 >gi|3329345|gb|AAC68468.1| Putative Outer Membrane Protein F [Chlamydia
 trachomatis]
 MIKRTSLSPACLSPFFYLSTISILQANETDTLQFRRTFSREIQFVLDPASLITAQNIVLSNLQSNGTGA
 CTISGNTQTQIFNSVNTTADSGGAFDMVTTSTASDNANLLFCNNYCTHNKGGGAIRSGGPIRFLNNQD
 VLFYNNISAGAKYVGTGDHNEKNRGGALYATTITLTGNRTLAFINNMSGDCGGAISADTQISITDVKGI
 30 LFENNHTLNHPIYPTQAEENMARGGAICSRDLCSISNNSGPIVFNYNQGGKGAISATRCVIDNNKERIIF
 SNNSSLGWSQSSASNGGAIQTTQGFTLRNKGSIYFDSNTATHAGGAINCGYIDIRDNGPVYFLNNSAA
 WGAAPNLKSPRSATNYIHTGTGDIVFNNNVFTLDGNLLGKRKLFINNNEITPYTSLGAKKDRIFYFY
 DLFQWERVKENTSNNPPSPTSRNTITVNPETEFSGAVVFSYNQMSSDIRTLMGKEHNYIKEAPTLLKFGT
 LAIEDDAELEIFNIPTQNPSTLLALGSGATLTGKHKGLNITNLGVILPIILKEGKSPPCIRVNPQDMT
 35 QNTGTGQTPSSSTSSISTPMIIFNGRLSIVDENYESVYDSMDLSRGKAEQLILSIETTNDGQLDSNWQSSL
 NTSLLSPPHYGYQLWTPNWITTTTITLNNSSAPTSATSIAEQKKTSETFTPSNTTTASIPNIKASAG
 SGSGSASNSGEVTITKHTLVVNWAPVGYIVDPIRRGLDIANSVLHSGRNMGLRSLLPDNSWFALQGA
 TTLFTKQKRLSYHGYSSASKGYTVSSQASGAHGKFLLSFSQSSDKMKEKETNNRLSSRYLSALCFEH
 PMFDRIALIGAAACNYGTHNMRSFYGTTKSSKGKFHSTTLGASLRCEL RDSMPLRSIMLTPFAQALFSRT
 40 EPASIRESGDLARLFTLEQAHTAVVSPIGIKGAYSSDTWPTLSWEMELAYQPTLYWKRP LNLNTLLIQNNG
 SWVTNTPLAKHSFYGRGSHSLKFSHLKLFANYQAEVATSTVSHYINAGGALVF
 >gi|3329342|gb|AE001360.1:c7571-4467,
 ATGATTAAGAAGAACTTCTCTATCCTTTGCTTGCCCTCAGTTTTTTTTTATCTTTCAACTATATCCATTTTGC
 AAGCTAATGAAACGGATACGCTACAGTTCCGGCGATTACTTTTTTCGGATAGAGAGATTTCAGTTCTGCTCT
 45 AGATCCCGCCTCTTTAATTACCGCCAAAACATCGTTTATCTAATTTACAGTCAAACGGAACCGGAGCC
 TGTACCAATTTACGGCAATACGCAAACTCAAATCTTTCTAATTCGGTTAAACACCACCGCAGATTCTGGTG
 GAGCCTTTGATATGGTTACTACCTCATTCACGGCCTCTGATAATGCTAATCTACTCTTCTGCAACAATA
 CTGCACACATAATAAAGGCGGAGGAGCTATTGCTTCCGGAGGACCTATTCGATTCTTAAATAATCAAGAC
 GTGCTTTTTTATAATAACATATCGGCAGGGGCTAAATATGTTGGAACAGGAGATCACACGAAAAAATA
 50 GGGGCGGTGCGCTTTATGCAACTACTATCACTTTGACAGGGAATCGAACTCTTGCCTTTATTAACAATAT
 GTCTGGAGACTGCGGTGGAGCCATCTCTGCTGACACTCAAATATCAATAACTGATACCGTTAAAGGAATT
 TTATTTGAAAACAATCACACGCTCAATCATATACCGTACACGCAAGCTGAAAATATGGCAGGAGGAGAG
 CAATCTGTAGTAGAAGAGACTTGTGCTCAATCAGCAATAATTCTGGTCCCATAGTTTTTAATAACA
 AGGCGGGAAAGGTGGAGCTATTAGCGCTACCCGATGTGTTATTGACAATAACAAAGAAAGAATCATCTTT
 55 TCAAAACAATAGTTCCCTGGGATGGAGCCAATCTCTCTGCAAGTAACGGAGGAGCCATTCAAACGACAC
 AAGGATTTACTTTACGAAATAATAAAGGCTCTATCTACTTCGACAGCAACACTGCTACACACGCCGGGG
 AGCCATTAACTGTGGTTACATTGACATCCGAGATAACGGACCCGCTATTTTCTAAATAACTCTGCTGCC
 TGGGGAGCGGCCCTTAATTTATCGAAACCACGTTTCAGCGACAAAATTATATCCATACAGGGACAGCGGATA
 TTGTTTTTAATAATAACGTTGTCTTTACTCTTGACGGTAATTTATTAGGGAAACGGAAACTTTTTCATAT
 60 TAATAATAATGAGATAACACCATATACATTGTCTCTCGGCGCTAAAAAAGATACTCGTATCTATTTTAT
 GATCTTTTCCAATGGGAGCGTGTAAAGAAAATACTAGCAATAACCCACCATCTCTTACCAGTAGAACA
 CCATTACCGTTAACC CGGAACAGAGTTTTCTGGAGCTGTTGTGTTCTCTACAATCAAATGTCTAGTGA
 CATACGAACTCTGATGGGTAAAGAACACAATTACATTAAGAAAGCCCCAACTACTTTAAATTCGGAACG
 CTAGCCATAGAAGATGATGCAGAAATAGAAATCTTCAATATCCCGTTTACCCAAAATCCGACTAGCCTTC
 65 TTGCTTTAGGAAGCGGCGCTACGCTGACTGTTGGAAAGCACGGTAAGCTCAATATTACAAATCTTGGTGT
 TATTTTACCATATTCTCAAGAGGGGAAGAGTCCGCCTTGTATTTCGCGTCAACCCACAAGATATGACC

CAAAATACTGGTACCGGCCAACTCCATCAAGCACAGTAGTATAAGCACTCCAATGATTATCTTTAATG
 GGCGCTCTCAATTTGTAGACGAAAAATATGAATCAGTCTACGACAGTATGGACCTCTCCAGAGGGAAAGC
 AGAACAACTAATTTCTATCCATAGAAACCACTAATGATGGGCAATTAGACTCCAATTGGCAAAGTTCTCTG
 AATACTTCTCTACTCTCTCTCCACACTATGGCTATCAAGGTCTATGGACTCCTAATTGGATAACAACAA
 5 CCTATACCATCACGCTTAATAATAATTTCTTCAGCTCCAACATCTGCTACCTCCATCGTGTAGCAGAAAAA
 AACTAGTGAACTTTTACTCCTAGTAACACAACCTACAGCTAGTATCCCTAATATTAAAGCTTCCGCAGGA
 TCAGGCTCTGGATCGGCTTCCAATTCAGGAGAAGTTACGATTACCAAACATACCCTTGTGTAACTGGG
 CACCAGTCGGCTACATAGTAGATCCTATTCTGATAGGAGATCTGATAGCCAATAGCTTAGTACATTTCAGG
 AAGAAACATGACCATGGGCTTACGATCATTACTCCCGGATAACTCTTGGTTTGTCTTTCGAAGGAGCTGCA
 10 ACAACATTATTTACAAAACAACAAAACGTTTGGATTATCATGGCTACTCTTCTGCATCAAAGGGGTATA
 CCGTCTCTTCTCAAGCATCAGGAGCTCATGGTCATAAGTTTCTTCTTCTTCTCCAGTCTATCTGATAA
 GATGAAAGAAAAAGAAACAAATAACCGCCTTTCTTCTCGTTACTATCTTCTGCTTTATGTTTCGAACAT
 CCTATGTTTGATCGCATTGCTCTTATCGGAGCAGCAGCTTGCAATTATGGAACACATAACATGCGGAGTT
 TCTATGGAATAAAAAATCTTCTAAAGGGAAATTTCACTCTACAACCTTAGGAGCTTCTTCTCGTGTGA
 15 ACTACGCGATAGTATGCCTTTACGATCAATAATGCTCACCCCATTTGCTCAGGCTTTATTCTCTCGAACA
 GAACCAGCTTCTATCCGAGAAAGCGGTGATCTAGCTAGATTATTTACATTAGAGCAAGCCCATACTGCCG
 TTGTCTCTCCAATAGGAATCAAAGGAGCTTATTCTTCTGATACATGGCCAACACTCTCTTGGGAAATGGA
 ACTAGCTTACCAACCCACCTCTACTGGAACGCTCTCTACTCAACACACTATTAATCCAAAATAACCGT
 TCTTGGGTACCCACAAATACCCCATTAGCTAAACATTCTTTTATGGGAGAGGTTCTCACTCCCTCAAT
 20 TTTCTCATCTGAACTATTTGCTAACTATCAAGCAGAAGTGGCTACTTCCACTGTCTCACTACATCAA
 TGCAGGAGGAGCTCTGGTCTTTTAA

 >gi|3329344|gb|AAC68467.1| Putative Outer Membrane Protein E [Chlamydia
 trachomatis]
 25 MKKAFFFFLIGNSLSGLAAREVPSRIFLMPNSVPDPTKESLSNKISLTGDTNHLTNCYLDNLRILAILQK
 TPNEGAAVTITDYLSTFFDTQKEGIYFAKNLTPESGGAGIYASPNSTVEIRDITGPVIFENNTCCRLFTW
 RNPYAADKIREGGAIHAQNLINHNHDVVGFMKNFSYVQGAISTANTFVSENQSCFLFMDNICIQNT
 AGKGGAIYAGTSNSFESNNCDLFFINNACCAGGAIIFSICSLTGNRGNIVFYNNRCFKNVETASSEASDG
 GAIKVTTRLDVDVTGNRGRIFSDNITKNYGGAIYAPVVTLDVNGPTYFINNIANNKGGAIYIDGTSNSKIS
 30 ADRHAIIFNENIVTNVINGTSTSANPPRRNAITVASSSGEILLGAGSSQNLIFYDPIEVSNAGVSVSF
 NKEADQTSVVFSGATVNSADPHQRNLQTKTPAPLTLNGLFLCTIEDHAQLTVNRFQTGGVVSLLNGAVL
 SCYKNGTDSASNASITLKHIGLNLSSILKSGAEIPLLWVEPTNNSNNYTADTAATFSLSDVKLSLIDDY
 GNSPYESTDLTHALSSQPMLSISEASDNQLQSENIDFSLNVPHYGWQGLWTGWAKTQDPEPASSATIT
 DPQKANRFHRTLTLTLWLPAGYVPSPKHRSPLIANTLWGNMMLLATESLKNABELTPSGHPFWGITGGGLGM
 35 MVYQDPRENHPGFHMRSSGYSAGMIAGQTHFTSLKFSQTYTKLNERYAKNNVSSKNYSQGEMLFSLQEG
 FLLTKLVGLYSYGDHNCHEFYTQGENLTSQGTFRSQTMGGAVFDDLPMKPFGSTHILTAPFLGALGIYSS
 LSHFTEVGAYPRFSFKTPLINVLVPIGVKGSFHMNATHRPQAWTVELAYQPVLYRQEPGIAAQLLASKGI
 WFGSGSPSSRHMSYKISQQTQPLSWLTLHFQYHGFYSSSTFCNYLNGEIALRF

 >gi|3329342|gb|AE001360.1:c4464-1570,
 40 ATGAAAAAAGCGTTTTTCTTTTCTTATCGGAACTCCCTATCAGGACTAGCTAGAGAGGTTCTTTCTA
 GAATCTTTCTTATGCCCACTCAGTTCCAGATCCTACGAAAGAGTCGCTATCAAATAAAATTAGTTTGAC
 AGGAGACACTCACAATCTCACTAACTGCTATCTCGATAACCTACGCTACATACTGGCTATTCTACAAAAA
 ACTCCCAATGAAGGAGCTGCTGTCACAATAACAGATTACCTAAGCTTTTTTGATACAAAAAAGAGGTA
 45 TTTATTTTGCAAAAAATCTCACCCCTGAAAGTGGTGGTGGCGATTGGTTATGCGAGTCCCAATTCTCTAC
 CGTGGGAGATTCTGTGATACAATAGGTCTGTAATCTTTGAAAATAATACTTGTGTCAGACTATTTCATGG
 AGAAATCCTTATGCTGCTGATAAAATAAGAGAAGGCGGAGCCATTATGCTCAAAATCTTTACATAAATC
 ATAATCATGATGTGGTCGGATTATGAAGAACTTTTCTTATGTCCAAGGAGGAGCCATTAGTACCGCTAA
 TACCTTTGTTGTGAGCGAGAATCAGTCTTGTCTTTCTTATGGACAACATCTGTATTCAAATAATACA
 50 GCAGGAAAAGGTGGCGCTATCTATGCTGGAACGAGCAATTCTTTTGAGAGTAATAACTGCGATCTCTTCT
 TCATCAATAACGCCTGTTGTGTCAGGAGGAGCGATCTTCTCCCTATCTGTTCTCTAACAGGAAATCGTGG
 TAACATCGTTTTCTATAAACAATCGCTGCTTTAAAAATGTAGAAACAGCTTCTTCAGAAGCTTCTGATGGA
 GGAGCAATTAAAGTAACTACTCGCCTAGATGTTACAGGCAATCGTGGTAGGATCTTTTTTAGTGACAATA
 TCACAAAAAATTTATGGCGGAGCTATTTACGCTCCTGTAGTTACCTAGTGGATAATGGCCCTACCTACTT
 55 TATAACAATATCGCCAATAATAAGGGGGGCGCTATCTATATAGACGGAACAGTAACCTCAAAAATTTCT
 GCCGACCGCCATGCTATTATTTTAAATGAAAATATTGTGACTAATGTAACATAATGCAATGGTACCAGTA
 CGTCAGCTAATCCTCCTAGAGAAATGCAATAACAGTAGCAAGCTCCTCTGGTGAAATCTATTAGGAGC
 AGGGAGTAGCCAAAATTTAATTTTTATGATCCTATTGAAGTTAGCAATGCAGGGGTCTCTGTGTCCTTC
 AATAAGGAAGCTGTATCAAAACAGGCTGTGTAGTATTTTTCAGGAGCTACTGTTAATCTGCAGATTTTCATC
 AACGCAATTTACAACAAAAACACCTGCACCCCTTACTCTCAGTAATGGTTTTCTATGTATCGAAGATCA
 60 TGCTCAGCTTACAGTGAATCGATTACACAAACTGGGGGTGTTGTTTCTCTTGGGAATGGAGCAGTTCTG
 AGTTGCTATAAAATGGTACAGGAGATTCTGCTAGCAATGCCTCTATAACACTGAAGCATATTGGATTGA
 ATCTTTCTTCCATTCTGAAAAGTGGTGTGAGATTCTTTTATTGTTGGGTAGAGCCTCAAAAATAACAGCAA
 TAACTATACAGGATCTGCAGCTACCTTTTCAATTAAGTGTATGTAACACTCTCACTCATTGATGACTAC
 65 GGGAACTCTCCTTATGAATCCACAGATCTGACCCATGCTCTGTCTACACAGCCTATGCTATCTATTCTG
 AAGCTAGCGATAACAGCTACAATCAGAAAATATAGATTTTTCGGGACTAAATGTCCCTCATTATGGATG
 GCAAGGACTTTGGACTTGGGGCTGGGCAAAACTCAAGATCCAGAACAGCATCTTCAGCAACAATCACT

GATCCACAAAAAGCCAATAGATTTTCATAGAACCTTACTACTAACATGGCTTCCTGCCGGGTATGTTCTTA
 GAAAAAACACAGAAAGTCCCTCATAGCTAACACCTTATGGGGGAATATGCTGCTTGCAACAGAAAGCTT
 AAAAAATAGTGCAGAGCTGACACCTAGTGGTCATCCTTTCTGGGGAAATTACAGGAGGAGGACTAGGCATG
 ATGGTTTACCAAGATCCTCGAGAAAATCATCCTGGATTCCATATGCGCTCTTCCGGTACTCTGCGGGGA
 5 TGATAGCAGGCGAGACACACCTTCTCATTGAAATTCAGTCAGACCTACACAAACTCAATGAGCGTTA
 CGCAAAAAACAACGTATCTTCTAAAAATTACTCATGCCAAGGAGAAATGCTCTTCTCATTGCAAGAAGGT
 TTCTTGCTGACTAAATTAGTTGGGCTTTACAGCTATGGAGACCATAACTGTCAACATTCTATACTCAAG
 GAGAAAATCTAACATCTCAAGGGACGTTCCGCGAGTCAAACGATGGGAGGTGCTGTCTTTTTTGTATCTCCC
 10 TATGAAACCTTTGGATCAACGCATATACTGACAGCTCCCTTTTTAGGTGCTCTTGGTATTTATTCTAGC
 CTGTCTCATTACTGAGGTGGGAGCCTATCCGCGAAGCTTTTCTACAAAGACTCCTTTGATCAATGTCC
 TAGTCCCTATTGGAGTTAAAGGTAGCTTTATGAATGCTACCCACAGACCTCAAGCCTGGACTGTAGAATT
 GGCATACCAACCCGTTCTGTATAGACAAGAACCAGGGATCGCAGCCCAGCTCCTAGCCAGTAAGGGTATT
 TGGTTCGGTAGTGAAGCCCCCTCATCGCGTCATGCCATGTCTTATAAAATCTCACAGCAAACACAACCTT
 15 TGAGTTGGTTAACTCTCCATTTCAGTATCATGGATTCTACTCCTCTTCAACCTTCTGTAATTATCTCAA
 TGGGGAAATTGCTCTGCGATTCTAG

>gi|3329279|gb|AAC68408.1| Putative Outer Membrane Protein D [Chlamydia
 trachomatis]

MSSEKDIKSTCSKFSLSVVAAILASVSGLASCVDLHAGGQSVNELVYVGPQAVLLLDQIRDLFVGSKDSQ
 20 AEGQYRLIVGDPSSFQEKDADTLPGKVEQSTLFSVTNPVVFQVDQDQVSSQGLICSFTSSNLDSPRDG
 BSFLGIAFVGDDSSKAGITLTDVKASLSGAALYSTEDLIFEKIKGLEFASCSSLEQGGACAAQSILIHDC
 QQLQVHKHTTAVNAEGSSANDHLGFGGGAFFVTGSLSGEKSLYMPAGDMVVANCDGAISFEGNSANFANG
 GAIAASGVKLVFVANDKKTSPFIENRALSAGGAIASSDIAFQNCALVFKGNCAIGTEDKGSLLGGGAISSLG
 25 TVLLQGNHGTICDKNESASQGGAI FGKNCQISDNEGPVVFRDSTACLGGAIAAQEIVSIQNNQAGISFE
 GSKASFGGGIACGSFSSAGGASVLGTIDISKNLGAISFSRTLCTTSDLQOMEYQGGGALFGENISLSENA
 GVLTFKDNIVKTFASNGKILGGGAILATGKVEITMNSSEGISFTGNARAPQALPTQEEFPLFSKKEGRPLS
 SGVSGGAILLQREVAI LHNAAVVFEQNRQLQCSEEEATLLGCCGGGAVHGMDSITVGNSSVRFNGNYAMG
 QGVSGGALLSKTVQLAGNGSVDFSRNIASLGGGALQASEGNCELVDNGYVLFDRNDRGRVYGGAIISLRGD
 30 VVISGNKGRVEFKDNIATRLYVEETVEKVEVEPAPEQKDNNELSFLGRAEQSFITAAQALFASDGDGDL
 SPSSISSSEELAKRRECAGGAI FAKRVRI VDNQEAUVFSNNFSDIYGGAI FTGSLREEDKLDGQIPEVLI
 SGNAGDVVFSGNSSKRDEHLPHTGGGAICTQNLITISQNTGNVLFYNNVACSGGAVRIEDHGNVLLAEFGG
 DIVFKGNSSFRAQGSDAIYFAGKESHITALNATEGHAIVFHDALVFENLEERKSAEVLINSRENPGYTG
 SIRFLEAESKVPQCIHVQQGSLELLNGATLCSYGFQDAGAKLVLAAGAKLKILDSGTPVQQGHAIKPE
 35 AEIESSEPEGAHSLWIAKNAQTTPMVDIHTISVDLASFSSSQEGTVEAPQVIVPGGSYVRSSELNLE
 LVNTTGTGYENHALLKNEAKVPLMSFVASGEASAEISNLSVSDLQIHVVTPETIEDTYGHMGDWSEAKI
 QDGTLVISWNPTGYRLDPQKAGALVFNALWEEGAVLSALKNARFAHNLTQARMEFDYSTNVWGFAGGGFR
 TLSAENLVAIDGYKGAAGASAGVDIQLMEDFVLGVSGAFLGKMDSQKFDAEVSRKGVVGSVYTGFLAG
 SWFFKQYSLGETQNDMKTRYGVLGESSASWTSRQVLADALVEYRSLVGPVVRPTFYALHFNYPVEVSYAS
 40 MKFPFGTEQGREARSFEDASLTNITIPLMKFELAFIKGFSEVNSLGISYAWAAYRKVEGGAVQLLEAG
 FDWEGAPMDLPRQELRVALENTEWSSYFSTVLGLTAFCGGFTSTDSKLGYEANTGLRLIF

>gi|3329271|gb|AE001353.1:9710-14305,
 ATGAGTTCCGAGAAAGATATAAAAAGCACCTGTTCTAAGTTTCTTTGTCTGTAGTAGCAGCTATCCTTG
 CCTCTGTTAGCGGGTTAGCTAGTTGCGTAGATCTTCTATGCTGGAGGACAGTCTGTAAATGAGCTGGTATA
 45 TGTAGGCCCTCAAGCGGTTTATTGTTAGACCAAATTCGAGATCTATTGTTGGGTCTAAAGATAGTCAG
 GCTGAAGGACAGTATAGGTTAATTGTAGGAGATCCAAGTCTTTTCCAAGAGAAAGATGCGGATACTCTTC
 CCGGAAGGTAGAGCAAAGTACTTTGTTCTCAGTAACCAATCCCGTGGTTTTCCAAGGTGTGGACCAACA
 GGATCAAGTCTCTTCCCAAGGGTTAATTGTAGTATTTACGAGCAGCAACCTTGATTCTCCTCGTGACGGA
 GAATCTTTTTTAGGTAATTGCTTTTTGTTGGGGATAGTAGTAAGGCTGGAATCACATTAAGTACGCTGAAAG
 50 CTCTCTTGTCTGGAGCGCTTTATATTCTACAGAAGATCTTATCTTTGAAAAGATTAAGGGTGGATTGGA
 ATTTGCATCATGTTCTTCTCTAGAACAGGGGGAGCTTGTGAGCTCAAAGTATTTTGATTGATGATTGT
 CAAGGATTGCAGGTTAAACACTGTACTACAGCCGTGAATGCTGAGGGGTCTAGTGCGAATGATCATCTTG
 GATTGGAGGAGGCGCTTTCTTTGTACGGGTTCTCTTCTGGAGAGAAAAGTCTCTATATGCCTGCAGG
 AGATATGGTAGTTGCGAATTGTGATGGGCTATATCTTTGAAGGAAACAGCGCGAAGCTTTGCTAATGGA
 55 GGAGCGATTGCTGCCCTCTGGGAAAGTGCTTTTTGTGCGCTAATGATAAAAAGACTTCTTTTATAGAGAACC
 GAGCTTTGTCTGGAGGAGCGATTGCAGCCTCTCTGATATTGCCTTTCAAACCTGCGCAGAACTAGTTTT
 CAAAGGCAATTGTGCAATTGGAACAGAGGATAAAGGTTCTTTAGGTGGAGGGGCTATATCTTCTTAGGC
 ACCGTTCTTTTGAAGGGAATCACGGGATAACTTGTGATAAGAATGAGTCTGCTTCGCAAGGAGGCGCCA
 TTTTGGCAAAAATTGTGAGATTCTGACAACGAGGGGCCAGTGTTTTTTCAGAGATAGTACAGCTTGCTT
 60 AGGAGGAGGCGCTATTGCAGCTCAAGAAATTGTTTCTATTACAGAACATCAGGCTGGGATTCTCTCGAG
 GGAGGTAAGGCTAGTTTCGGAGGAGGTATTGCGTGTGGATCTTTTTCTCCGCGAGGTGGTGCTTCTGTTT
 TAGGGACCATTTGATATTTTGAAGAATTTAGGCGCGATTTCGTTCTCTCGTACTTTATGTACGACCTCAGA
 TTTAGGACAAATGGAGTACCAGGAGGAGGAGCTTATTTGGTGAAAAATTTCTCTTTCTGAGAATGCT
 65 GGTGTGCTCACCTTTAAAGACAACATTTGTGAAGACTTTTGTCTCGAATGGGAAAATTTCTGGGAGGAGGAG
 CGATTTTAGCTACTGGTAAGGTGGAATTTACTAATAATTCGAAGGAATTTCTTTTACAGGAAATGCGAG
 AGCTCCACAAGCTCTTCCAACCTCAAGAGGAGTTTCTTTTATTACAGCAAAAAGAAGGGCGACCACTCTCT
 TCAGGATATTCTGGGGGAGGAGCGATTTTAGGAAGAGAAGTAGCTATTCTCCACAACGCTGCAGTAGTAT

TTGAGCAAAATCGTTTGCAGTGCAGCGAAGAAGAAGCGACATTATTAGGTTGTTGTGGAGGAGGCGCTGT
 TCATGGGATGGATAGCACTTCGATTGTTGGCAACTCTTCAGTAAGATTGGTAATAATTACGCAATGGGA
 CAAGGAGTCTCAGGAGGAGCTCTTTTATCTAAAACAGTGCAGTTAGCTGGGAATGGAAGCGTCGATTTTT
 CTCGAAATATTGCTAGTTTGGGAGGAGGAGCTCTTCAAGCTTCTGAAGGAAATTGTGAGCTAGTTGATAA
 5 CGGCTATGTGCTATTACAGAGATAATCGAGGGAGGGTTTATGGGGGTGCTATTTCTTGCTTACGTGGAGAT
 GTAGTCATTTCTGGAAACAAGGGTAGAGTTGAATTTAAAGACAACATAGCAACACGTCCTTATGTGGAAG
 AAAGTGTAGAAAAGGTTGAAGAGGTAGAGCCAGCTCCTGAGCAAAAAGACAATAATGAGCTTTCTTTCTT
 AGGGAGAGCAGAACAGAGTTTTATTACTGCAGCTAATCAAGCTCTTTTCGCATCTGAAGATGGGGATTTA
 TCACCTGAGTCATCCATTTCTTCTGAAGAACTTCGAAAAGAAGAGAGTGTGCTGGAGGAGCTATTTTTG
 10 CAAAACGGGTTTCGATTGTAGATAACCAAGAGGCCGTTGTATTCTCGAATAACTTCTCTGATATTTATGG
 CGGCGCCATTTTACAGGTTCTCTTCGAGAAGAGGATAAGTTAGATGGGCAAATCCCTGAAGCTCTTGATC
 TCAGGCAATGCAGGGGATGTTGTTTTTCCGGAAATTCCTCGAAGCGTGATGAGCATCTTCTCATACAG
 GTGGGGGAGCCATTTGTACTCAAAATTTGACGATTTCTCAGAATACAGGGAATGTTCTGTTTTATAACAA
 CGTGGCCTGTTCCGGGAGGAGCTGTTTCGTATAGAGGATCATGGTAATGTTCTTTTAGAAGCTTTTGGAGGA
 15 GATATTGTTTTTAAAGGAAATCTTCTTTTCAGAGCACAAGGATCCGATGCTATCTATTTTGCAGGTAAG
 AATCGCATATTACAGCCCTGAATGCTACGGAAGGACATGCTATTGTTTTCCACGACGCATTAGTTTTTGA
 AAATCTAGAAGAAAGGAAATCTGCTGAAGTATTGTTAATCAATAGTCGAGAAAATCCAGTTTACACTGGA
 TCTATTGATTTTTAGAAGCAGAAAGTAAAGTTCTCAATGTATTTCATGTACAACAAGGAAGCCTTGAGT
 TGCTAAATGGAGCCACATTATGTAGTTATGGTTTTTAAACAAGATGCTGGAGCTAAGTTGGTATTGGCTGC
 20 TGGAGCTAACTGAAGATTTTAGATTTCAGGAACCTCTGTACAACAAGGGCATGCTATCAGTAAACCTGAA
 GCAGAAATCGAGTCATCTTCTGAACCAGAGGGTGACATTCTCTTGGATTGCGAAGAATGCTCAACAA
 CAGTTCCTATGGTTGATATCCATATTCTGTAGATTTAGCCTCCTTCTCTTCTAGTCAACAGGAGGG
 GACAGTAGAAGCTCCTCAGGTTATTGTTCTGGAGGAAGTTATGTTTCGATCTGGAGAGCTTAATTTGGAG
 TTAGTTAACCAACAGGTACTGGTTATGAAAATCATGCTTTATGAAGAATGAGGCTAAAGTTCCATTGA
 25 TGTCTTTTCGTTGCTTCTGGTGATGAAGCTTCAGCCGAAATCAGTAACTTGTTCGGTTCTGATTTACAGAT
 TCATGTAGTAATCCAGAGATTGAAGAAGACATACGGCCATATGGGAGATTGGTCTGAGGCTAAAATT
 CAAGATGGAACCTCTTGTCATTAGTTGGAATCCTACTGGATATCGATTAGATCCTCAAAGACAGGGGCTT
 TAGTATTTAATGCATTATGGGAAGAAGGGCTGTCTTGTCTGCTCTGAAAATGCACGCTTTGCTCATAA
 TCTCACTGCTCAGCGTATGGAATTCGATTATCTACAAATGTGTGGGGATTGCGCTTTGGTGGTTTCCGA
 30 ACTCTATCTGCAGAGAATCTGGTTGCTATTGATGGATACAAAGGAGCTTATGGTGGTGCTTCTGCTGGAG
 TCGATATTCAATTGATGGAAGATTTGTTCTAGGAGTTAGTGGAGCTGCTTTCTTAGGTAAATGGATAG
 TCAGAAGTTGATGCGGAGGTTTCTCGGAAGGGAGTTGTTGTTCTGTATATACAGGATTTTACCTGGA
 TCCTGGTTCTTCAAAGGACAATATAGCCTTGGAGAAACACAGAACGATATGAAAACGCGTTATGGAGTAC
 TAGGAGAGTTCGAGTGCTTCTTGGACATCTCGAGGAGTACTGGCAGATGCTTTAGTTGAATACCGAAGTTT
 35 AGTTGGTCTGTGAGACCTACTTTTTATGCTTTGCATTTCAATCCTTATGTGCAAGTATCTTATGCTTCT
 ATGAAATTCCTGGCTTTACAGAACAAGGAAGAGAAGCGGCTTCTTTGAAGACGCTTCCCTTACCAATA
 TCACCATTCCTTTAGGGATGAAGTTTGAATTGGCGTTTCATAAAAGGACAGTTTTCAGAGTGAACTCTTT
 GGAATAAGTTATGCATGGGAAGCTTATCGAAAAGTAGAAGGAGGCGCGGTGCAGCTTTTAGAAGCTGGG
 TTTGATTGGGAGGGAGCTCCAATGGATCTTCTAGACAGGAGCTGCGTGTGCTCTGAAAATAATACGG
 40 AATGGAGTTCTTACTTCAGCACAGTCTTAGGATTAACAGCTTTTGTGGAGGATTACTTCTACAGATAG
 TAACTAGGATATGAGGCAATACTGGATTGCGATTGATCTTTTAA

>gi|3329169|gb|AAC68308.1| Outer Membrane Protein Analog [Chlamydia trachomatis]

45 MSSKLVNLYRLTFLSFLGIASSTSLDAMPAGNPAPFPVIPGINIEQKNACSFDLNCSYDVLSALSGLNLKLCF
 CGDYIFSEEAQVKDVPVVTSTVITAGVGPSPDITSTTKTRNFDLVNCLNTNCVAVAFSLPDRSLSAIPLF
 DVSFEVKVGLKQYRLLPMNAYRDTSEPLNSESEVTDGMIEVQSNYGFVWDVSLKKVIWKDGVSVFVG
 ADYRHASCPIDYIIANSQANPEVFIADSDGKLNFKEWSVCVGLTITYVNDYVLPYLAFSIGSVSRQAPDDS
 FKKLEDRFTNLKFKVRKITSSHRGNICIGATNYVADNFFYNVEGRWGSQRAVNVSGGFQF
 50 >gi|3329166|gb|AE001342.1:c4638-3616,
 ATGAGTAGCAAGCTAGTGAATCTCCGTTTGACTTTCCTATCTTTTTTAGGGATCGCATCTACTTTCAT
 TAGACGCTATGCCTGCGGGGAATCCGGCGTTTCCAGTCAATCCCGGGGATTAATATTGAACAGAAAAATGC
 CTGTTCTTTTCGATTTATGTAATCTTATGATGTACTATCCGCACTGTCCGGTAACCTGAAGCTCTGCTTC
 TGCGGAGATTATATCTTTTCAGAAGAAGCTCAGGTAAAAGATGTCCCTGTCGTTACCTCTGTGACAACAG
 55 CTGGGGTTGGTCTTCTCCTGATATTACTTCGACAACCAAAACGCGAAATTTTCGATCTCGTGAAGTGTAA
 TCTCAATAACAACCTGTGTAGCTTTTCCCTTCTGATCGTTTCGTCGAGCGGATTCTCTGTTT
 GATGTGAGTTTTCGAAGTGAAGTAGGAGACTGAAACAATACTACCGCTTCCCATGAAAGTATCGAG
 ACTTCACCTCGGAACCTCTCAATTCTGAATCAGAAGTTACGGACGGGATGATTGAAGTACAGTCCAATTA
 CGGATTTGTTTGGGATGTTAGCTTGAAGAAAGTCAATGGAAGATGGCGTTTCTTTGTAGGCGTCCGT
 60 GCAGACTATCGCCATGCTTCTTGCCCTATTGACTACATCATTGCAAACAGTCAAGCTAATCCAGAAGTAT
 TCATCGCTGACTCGGATGGGAACTGAACCTCAAGGAGTGGAGTGTCTGCGTAGGCTCTTACTACCTATGT
 GAATGACTACGTTCTTCTTACTTAGCGTTTCTTATAGGGAGTGTCTTCGCAAGCTCCGGACGACAGC
 TTCAAAAATTAGAAGATCGCTTCACTAACCTCAAATTTAAAGTTCGTAAAATTACCAGCTCTCATCGTG
 65 GAAACATCTGCATCGAGCGCAAACTATGTGCGCGATAACTTCTTCTACAACGTAGAAGGAAGATGGGG
 AAGCCAGCGCGCTGTGAACGTCTCCGGAGGATTCCAATTTCTAA

- >gi|3328866|gb|AAC68034.1| Sulfite Reductase [Chlamydia trachomatis]
 MSLFSKFKAQWMLHSRELCSSTSDIGNTCSDPVFQVLCNPVRSEISYKVGDSLGVFPTNPISILVDSVLD
 ALQYGRSPVSRHADSPLPLHEFLTSYVDLDKIPKSLRPFPPGDLDDTWSLAEAILVYQPRIPFEEFIR
 5 SAMPLLPFRYSIASSPTCSHGKLELLVRCVSFQKTLRYGLCSAFLCKDLQEGESFRGFIQPTRHFTLE
 QKNFGKPLIMIGAGTGIAPYKGFQHQRIYHQDVGSNILLFFGERFEKSNFYRDFLQELIVSGKLQLFTAF
 SRDSESKLYVQNVIEQQKELIQEVYEQEAFFVCGKKILGTEVKRALEQILGPKAVRELIAQKRLVSDVY
 >gi|3328863|gb|AE001317:c2573-1521,
 ATGTCTTTATTTTCTAAATTCAAAGCTCAGTGGATGTTTTTACATTACAGTGAGCTTTGTTCTTCCACAT
 CGGATATTGGGAATACTTGTTCGGATCCTGTTTTTACAGTTTTATGTAATCCGGTTCGTTCTGAGATTTT
 10 CTATAAAGTTGGGGATTCTTTGGGGGTATTCCCAACAAATCCTTCCATATTAGTCGATTACAGTTCTAGAT
 GCTTTACAGTATGGCCCCAGGTCTCCTGTCTGATCTCGGCATGCAGATTCTGTTCTCCCTCTTCACGAAT
 TTCTTACTAGTTACGTAGACTTAGATAAAATCCAAAATCGTTAAGACCTTTTTTCCAGGGGATTTAGA
 CGATACCTGGTCTTTAGCTGAAGCTATTTTGGTTTACCAGCCGCGTATTCTTTTGAAGAGTTTATTCGG
 AGTGCATGCTCTTTATTGCCTCGATTTTATTCTATAGCTTCTTCTCCAACATGTTCTCATGGGAAGCTAG
 15 AGTTGCTCGTGCCTGTGTAGTTTCCAAGGTAAACGCAGCTGCGCTATGATTATGTTCCGGCTTTTTT
 ATGTAAGGACTTACAAGAGGGAGAGTCTTTTCGTGGGTTTATACAACCGACGCGGCATTTTACTTTGGAG
 CAGAAAAATTTTGGGAAACCTTAAATTATGATCGGAGCAGGGACAGGTATCGCTCCGTACAAAGGGTCT
 TACAACATCGAATATACCATCAGGACGTAGGCTCCAATATTCTATTCTTTGAGAGCGGTTTGGAGAAAG
 TAACTTCTATTACCGGGATTTTCTCCAGGAGCTGATCGTTTTCAGGAAAACTCCAGTTATTACAGCCCTTT
 20 TCCAGAGATTCCGAGTCTAAATTGTATGTTTCAAGATGTTATAGAGCAACAAAAAGAACTTATACAAGAAG
 TCTACGAACAAGAAGCTTTCTTTTTTGTGTTGTTGGGAAAAAATCCTTGGTACGGAAGTTAAACGTGCTTT
 AGAGCAGATATTAGTCTTAAGGCGGTACGAGAGCTGATTGCACAGAAGAGACTAGTTTACAGCTATAC
 TAA
- >gi|3328843|gb|AAC68011.1| Putative outer membrane protein C [Chlamydia trachomatis]
 MKFMSATAVFAAALSSVTEASSIQDQIKNTDCNVSKLGYSTSQAFTDMMLADNTEYRAADSVSFYDFSTS
 SRLPRKHLSSSSSEASPTTEGVSSSSSGETDEKTEBEELDNGGIYAREKLITISEQDLSNQSIELHDNSI
 30 FFGEGEVIFDHRVALKNGGAIYGEKEVVFENIKSLLEVNIAVEKGSVYAKERVSLENVTEATPSSNNG
 EQGGGGIYSEQDMLISDCNNVHFQGNAAAGATAVKQCLDEEMIVLLAECDVSLSEDTLTSTPETEQTESNG
 NQDGSSEETEDTQVSESPSTPSPDDVLGKGGGIYTEKSLTITGITGTIDFVSNIAATDSGAGVFTKENLSC
 NTNSLQFLKNSAGQHGGGAYVTQTMSTVNTTSESITPPLIGEVIFFSENTAKGHGGGICTNKLSSLNLK
 TVTLTKNSAKESGGAIFTDLASIPITDTPESSTPSSSSPASTPEVVASAKINRFFASTAKPAAPSLTEAE
 35 SDQTDQTETSDTNSDIDVSIENILNVAINQNTSAKKGAIYKKAKLSRINNLELSGNSSQDVGGGCLT
 ESVEFDAIGSLLSHYNSAAKEGGAIHSTKVTLSNLKSTFTFADNTVKAIVESTPEAPEEIPPEVEGESTA
 TEDPNSNTEGSSANTNLEGSQGDADTGTGDVNNESTQSDTGNAESEELQDSTQSNENETLPSNIDQ
 SNENTDESSDSTHEITDESVSSSSESGSTPDGGAASSGAPSGDQISANACLAKSYAASTDSSPVSN
 SSGSEEPVTSSSDSDVTASSDNPSSSSGDSAGDSEEPTEPEAGSTTETLTIGGAIYGETVKIENFSG
 40 QGIFSGNAKIDNTTEGSSSKSDVLGGAVYAKTLFNLDSGSSRRTVTFSGNTVSSQSTTGQVAGGAIYSPT
 VTIAFPVVFSSKNSATNNANNTTDTQKDTFGGAIGATSAVSLSGGAHFLENVADLGSAILVPGTQNTET
 VKLESGSYFFKKNALKRATYAPVVS IKAYTATFNQNSLEEGSAIYFTKEASIESLGSVLFTGNLVT
 TLTSTTEGTPATSGDVTKYGAIFGQIASSNGSQDNLPLKLIASGGNICFRNNEYRPTSSDTGTSTFC
 SIAGDVKLTMQAAGKGTISFFDAIRTSKKTGTQATAYDTLDINKSEDETNSAFTGTILFSSSELHENK
 45 SYIPQNVVLHSGSLVLKPNTELHVISFEQKEGSSLVMTPGSVLSNQTVADGALVINNMITDLSSEVENKI
 AEGNIFTPPELRIDTTTGGSGGTPSTDESQNSDDTEEQNNNDASNQGESANGSSSPAVAAHTSRTR
 NFAAAATATPTTPTATTTTNSQVILGGEIKLIDPNTGFFQNPALRSDDQISLLVLPDSSKMQAQKIVL
 TGDIAPOKGYTGTLTLPDQLQNGTISVLWKFDSYRQWAYVPRDNHFYANSILGSQMLMVTVKQGLLNDK
 50 MNLARFEEVSYNNLWISGLGTMLSQVGTPTSEEFYYSRGASVALDAKPAHDVIVGAAFSKMIGKTKSLK
 RENNYTHKGSEYSYQASVYGGKPFHFVINKKTEKSLPLLLQGVIISYGYIKHDTVTHYPTIRERNKGEWED
 LGWLTALRVSSVLRTPAQGDTKRITVYGELEYSSIRQKQFTETEYDPRYFDNCTYRNLAIPMGLAFEGEL
 SGNDILMYNRFVSAYMLSIRNSPTCKYQVLLSSGEGEIIICGPVTRNSARGEYSTQLYLGLWTLTLYGSYT
 IEADAHTLAHMMNCGARMTF
- >gi|3328842|gb|AE001315.1:120-5432,
 ATGAAATTTATGTCAGCTACTGCTGATTTTGTGTCAGCACTCTCCTCCGTTACTGAGCGGAGCTCGATCC
 55 AAGATCAAATAAAGAATACCGACTGCAATGTTAGCAAATTAGGATATTCAACTTCTCAAGCATTTACTGA
 TATGATGCTAGCAGACAACACAGAGTATCGAGCTGCTGATAGTGTTTCACTTCTATGACTTTTTCGACATCT
 TCCAGATTACCTAGAAAAACATCTTAGTAGTAGTAGTGAAGCTTCTCAACGACAGAAGGAGTGTCTTCAT
 CTTTCATCTGGAGAAACTGATGAGAAAAACAGAAGAACTAGACAATGGCGGAATCATTTATGCTAGAGA
 60 GAACTAACTATCTCAGAATCTCAGGACTCTCTCTAATCAAAGCATAGAACTCCATGACAATAGTATT
 TTCTTCGGAGAGGTGAAGTTATCTTTGATCAGAGAGTTGCCCTCAAAAACGGAGGAGCTATTTATGGAG
 AGAAAGAGGTAGTCTTTGAAAACATAAAATCTCTACTAGTAGAAGTAAATATCGCGGTGAGAAAGGGGG
 TAGCGTCTATGCAAAAAGAACGAGTATCTTTAGAAAATGTTACCGAAGCAACCTTCTCTCCAATGGTGGG
 65 GAACAAGGTGGTGGTGAATCTATTCAGAACAGGATATGTTAATCAGTGATTGCAACAATGTACATTTCC
 AAGGGAATGCTGCAGGAGCAACAGCAGTAAACAATGTCTGGATGAAGAAATGATCGTATTGCTCCGAGA
 ATGCGTTGATAGCTTATCCGAAGATACACTGGATAGCACTCCAGAAACGGAACAGACTGAGTCAAATGGA
 AATCAAGACGGTTCGTCTGAAACAGAAGATACACAAGTATCAGAATCACCAGAATCAACTCCTAGCCCCG

ACGATGTTTTAGGTAAAGGTGGTGGTATCTATACAGAAAAATCTTTGACCATCACTGGAATTACAGGGAC
 TATAGATTTTGTGAGTAACATAGCTACCGATTCTGGAGCAGGTGTATTCACTAAAGAAAACTTGTCTTGC
 ACCAACACGAATAGCCTACAGTTTTTGA AAAA ACTCGGCAGGTCAACATGGAGGAGGAGCCTACGTTACTC
 AAACCATGTCTGTTACTAATACTAGTGAAGTATACTACTCCCCCTCTCATAGGAGAAGTGATTTTT
 5 CTCTGAAAATACAGCTAAAGGGCAGGTGGTGGTATCTGCCTAACAACTTTCTTTATCTAATTTAAAA
 ACGGTGACTCTCACTAAAACTCTGCAAAGGAGTCTGGAGGAGCTATTTTTACAGATCTGGCGCTTATAC
 CAATAACAGATACCCAGAATCTTCTACCCCTCTTCTCTCGCCTGCAAGCACTCTGAAGTAGTTGC
 TTCTGTCTAAAATAAATCGATTCTTTGGCCTCTACGGCAAAACCGGCAGCCCCCTCTCTAACAGAGGCTGAG
 TCTGATCAAACGGATCAAACAGAACTTCTGATACTAATAGCGATATAGACGTGTCGATTGAGAACATTT
 10 TGAATGTCTGCTATCAATCAAAACACTTCTGCGAAAAAAGGAGGGGCTATTTACGGGAAAAAGCTAAACT
 TTCCCGTATTAACAATCTTGAACCTTTCAGGAATTTCATCCAGGATGTAGGAGGAGGTCTCTGTTTAACT
 GAAAGCGTAGAATTTGATGCAATTGGATCGCTCTTATCCCACTATAACTCTGCTGTCTAAAGAAGGTGGGG
 CTATTCAATTTCTAAAACGGTTACTCTATCTAACCCTCAAGTCTACCTTCACTTTTGCAGATAACACTGTAA
 AGCAATAGTAGAAAGCACTCTCTGAAGCTCCAGAAGAGATTCTCCAGTAGAAGGAGAAGAGTCTACAGCA
 15 ACAGAAGATCCAAATTCTAATACAGAAGGAAGTTCGGCTAACACTAACCTTGAAGGATCTCAAGGGGATA
 CTGCTGATACAGGGACTGGTGATGTTAACAAATGAGTCTCAAGACACATCAGATACTGGAAACGCTGAATC
 TGAAGAACAACACTACAAGATTCTACACAATCTAATGAAGAAAAATACCTTCCCAATAGTAATATTGATCAA
 TCTAACGAAAAACACAGACGAATCATCTGATAGCCACACTGAGGAAATAACTGACGAGAGTGTCTCATCGT
 CCTCTGAAAGTGGATCATCTACTCTCAAGATGGAGGAGCAGCTTCTTCAGGGGCTCCCTCAGGCTCATCA
 20 ATCTATCTCTGCAAACGCTTGTTTAGCTAAAAGCTATGTGCGAGTACTGATAGCTCCCCGCTATCTAAT
 TCTTCAGGTTTCAAGAGCCTGTCTCACTTCTTCTTCAGATTACAGACGTTACTGCATCTTCTGATAATCCAG
 ACTCTTCTCTATCTGGAGATAGCGCTGGAGACTCTGAAGAACCAGCTGAGCCAGAAGCTGGTTCTACAAC
 AGAAACTCTTACTTTAATAGGAGGAGGTGCTATCTATGAGAGAACTGTTAAGATTGAGAATCTCTGCGC
 CAAGGAATATTTTCTGGAAACAAAGCTATCGATAACACCACAGAAGGCTCTCTTCCAAATCTGACGCTCC
 25 TCGGAGGTGCGGTCTATGCTAAAACATTGTTAATCTCGATAGCGGGAGCTCTAGACGAATGTCACTCT
 CTCCGGGAATACTGTCTCTTCTCAATCTACAACAGGTACAGGTGCTGGAGGAGCTATCTACTCTCTACT
 GTAACCATGTCTACTCTGTAGTATTTCTAAAACCTCTGCAACAAACAAATGCTAATAACACTACAGATA
 CTCTAGAGAAAAGACACCTTTGGAGGAGCTATCGAGCTACTTCTGCTGTTTCTCTATCAGGAGGGGCTCA
 TTTCTTAGAAAACGTTGCTGACCTCGGATCTGCTATTGGGTTGGTGCCAGGCACACAAAATACAGAAACA
 30 GTGAAATAGAGTCTGGCTCCTACTACTTTGAAAAAATAAAGCTTTAAACAGAGCTACTATTACGCAC
 CTGTCTGTTTCCATTAAAGCCTATACTGCGACATTTAACCAAAACAGATCTCTAGAAGAAGGAGCGCGAT
 TTACTTTACAAAAGAAGCATCTATTGAGTCTTTAGGCTCTGTTCTCTTTCACAGGAACTTAGTAACCTTA
 ACGCTAAGCACAACACTACAGAAGGCACACCAGCCAACTCAGGAGATGTAAACAAAATATGGTGCTGTCTA
 TCTTTGGACAAAATAGCAAGCTCAAACGGATCTCAGACGGATAACCTTCCCTGAAACTCATTTGCTCTAGG
 35 AGGAAATATTTGTTTCCGAAACAATGAATACCGTCTCTACTTCTTCTGATACCGGAACCTCTACTTTCTGT
 AGTATTGCGGGAGATGTTAAATTAACCATGCAAGCTGCAAAAGGGAACAGATCAGTTTCTTTGATGCAA
 TCCGGACCTCTACTAAGAAAACAGGTACACAGGCAACTGCCTACGATACTCTCGATATTATAAATCTGA
 GGATTCAGAAAACGTGAACTCTGCGTTTACAGGAACGATTCTGTTCTCTCTGAATTACATGAAAAATAAA
 TCCTATATTCCACAAAACGTAGTTCTACACAGTGGATCTCTTGTATTGAAGCCAAATACCGAGCTTCTAG
 40 TTATTTCTTTTGGAGCAGAAAGAAGGCTCTTCTCTCGTTATGACACCTGGATCTGTTCTTTTGAACAGAC
 TGTGCTGATGGAGCTTTGGTCATAAATAACATGACCATTGATTTATCCAGCGTAGAGAAAAATGGTATT
 GCTGAAGGAAATATCTTTACTCTCTCCAGAATTGAGAATCATAGACACTACTACAGGTGGAGCGGTGGAA
 CCCCATCTACAGATAGTGAAGTAACAGATGATGATACCGAGGAGCAAAATAATAATGACGCCCTC
 GAATCAAGGAGAAAGCGCAATGGATCGTCTTCTCTCTGCACTAGCTGCTGCACACACATCTCGTACAAGA
 45 AACTTTGCGCTGCACTACAGCCACACCTACGACAACCAACGGCTACAACCTACAACAAGCAACCAAG
 TAATCTTAGGAGGAGAAATTAACCTCATCGATCTTAATGGGACCTTCTTCCAGAACCCTGCATTAAGATC
 CGACCAACAAATCTCTTGTAGTGTCTCTACAGACTCATCAAAAATGCAAGCTCAGAAAATAGTACTG
 ACGGGTGATATTGCTCTCTCAGAAAGGATATACAGAACACTCACTCTGGATCTGATCAACTACAAAATG
 GAACGATCTCAGTGTCTGGAATTTGACTCTTTATAGACAATGGGCTTATGTACCTAGAGACAATCATT
 50 CTATGCGAACTCGATTCTGGGATCTCAAATGTTAATGGTCACAGTCAAAACAAGGCTTGCTCAACGATAAA
 ATGAATCTAGCTCGCTTTGAGGAAGTTAGCTATAACAACCTGTGGATATCAGGACTAGGAACGATGCTAT
 CGCAAGTAGGAACACCTACTTCTGAAGAATTCATTATTACAGCAGAGGAGCTTCTGTTGCTTTAGATGC
 TAAACCAAGCCCATGATGTGATTGTTGGAGCTGCATTAGTAAGATGATCGGGAACAAAATCCTTGAAA
 AGAGAGAATAACTCACTCACAAAGGATCCGAATATTCTTACCAAGCATCGGTATACGGAGGCAAAACCAT
 55 TCCACTTTGTAATCAATAAAAAACGAAAAATCGCTACCGCTATTGTTACAAGGAGTCATCTCTTACGG
 ATATATCAAACATGATACAGTGACTCACTATCCAACGATCCGTGAACGAAACAAAGGAGAATGGGAAGAC
 TTAGGATGGCTGACAGCTCTCCGTGTCTCTCTGTCTTAAGAACTCTGCAACAAGGGGATACTAAACGTA
 TCACTGTTTACGGGAGAATTGGAATACTCCAGTATCCGTGCAAAACAATTACAGAAACAGAATACGATCC
 TCGTTACTTTCGACAACTGCACCTATAGAAACTTAGCAATTCCTATGGGGTTAGCAATTCGAAGGAGCTC
 60 TCTGGTAACGATATTTGATGTACAACAGATTCTCTGTAGCATACATGCTATCAATCTATCGAAATTTCTC
 CAACATGCAAAATACCAAGTGCTCTCTTTCAGGAGAGGGCGGAGAAATATTTGTGGAGTACCGACAAGAAA
 CTCAGCTCGCGGAGAATACAGCACGAGCTGTACCTGGGACCTTGTGGACTCTGTATGGATCCTACAG
 ATAGAAGCAGACGCACATACACTAGCTCATATGATGAAGTGGGTGCTCGTATGACATTTCTAA

65 >gi|3328815|gb|AAC67986.1| hypothetical protein [Chlamydia trachomatis]
 MMKPLRFYFFCAIYFTLLQAAFAKEPNSCPDCQNNWKEVTHTDQLPENIIHADDACYHSGYVQALIDMH

FLDSCCQVIVENQTAYLFSLPDDVTRNAIINLIKDLFFIHSVEICQASYQTCHHQGPHGKTSLEPQRSF
 CTKVCCKEAIWLPQNTILFSPVADPRQATNSAGIRFNDEVLGKRVGSATFGGDFIPLRLFDISRPHGDM
 DIGLQGAUVSVFDDLDHPEACMVNSDFFVAALCNFAVNKWSYRFLWLHSSHLGDEFILANQLPPKKRYNR
 SDEAVDFFASFRYTPQIRVYGIGYIISRDLTFPEDPLYFEGGIELRPFGLREDNLHAQPVFAMHFRFWE
 5 EHDFSIDQTYIVGMEWSKFQDVGKRVRAVLEYHQGFSHEGQFVREEDDYGFRLSYGF
 >gi|3328812|gb|AE001312.1:2790-4016,
 ATGATGAAACCTCTACGTTTCGGTTATTTCTTTGCGCAATCTATTTTACTTTGTTACAGGCAGCGTTTG
 CTAAGAACCGAATTCTTGTCCCGACTGCCAGAATAATTGGAAAGAAGTCACCCACACGGATCAACTCCC
 10 AGAAAACATCATTATCATGCTGATGATGCTTGTATCACTCTGGTTATGTACAGGCTCTCATTGATATGCAT
 TTCTTAGATAGCTGCTGCCAGGTCATCGTTGAAAACCAAACGCTTACTTATTTTCTCTTCTACAGATG
 ATGTTACGCGCAACGCCATTATCAACCTAATTAAAGACCTTCCATTCACTCCGTAGAAATCTGCCA
 AGCATCCTATCAAACCTGTCAATCAAGCCCTCATGGAAAGACTTCTCTTCCAGAACACGTTCTTTT
 TGTACAAAGGTCTGTGGAAAAGAAGCTATTGGTTACCACAGAATAACCATCCTATTTCTCGCCTCTGTAG
 15 CAGATCCTAGACAAGCAACTAATAGTGCAGGTATCCGTTTTAACGACGAAGTCTTAGGAAAACGTTGTTG
 CTCTGCTACCTTCGGTGGAGATTTTCTCTTACGATTATTTGATATCTCCCGATTCCATGGAGACATG
 GATATTGGTCTCCAAGGAGCTGTATTCTCTGTTTTCGACCTGGATCATCCAGAAGCTTGCATGGTCAACT
 CTGACTTTTTTGTGTCGCCGCTTTGTGCAACTTTGCGAGTGAACAAATGGAGCTACCGCTTCAGACTATGGCA
 TCTTTCTTCTCATCTTGGCGACGAATTTATTTGTTGCAACAGTTACCTCCTAAAAACGTTATAATCGA
 20 AGCGATGAAGCCGTCGATTCTTTGCTTCTTTTTCGTTTCACTCCACAGATCCGTGTTTATGGAGGTATTG
 GGTATATCATTAGTCGAGATTTAACATTCCTGAAGATCCTCTTTTACTTTGAAGGAGGTATCGAACTACG
 TCCTTTTCGATTACGGGAAGACAACCTTCATGCCCAACCCGCTTTTGTATGCATTTTTCGCTTTTGGGAA
 GAGCATGACTTTTCTATAGACCAAACCTATATAGGCATGGAGTGGTCCAAATTCAGGATGTAGGGA
 GAAAAGTGCAGCTGTATTGGAATACCACCAAGGTTTCTCCACGAAGGACAATTTGTCCGAGAAGAATG
 25 CGATTATTATGGCTTTTCGATTAAAGTTATGGCTTCTAG
 >gi|3328651|gb|AAC67834.1|Omp85 Analog [Chlamydia trachomatis]
 MLGIRKKTILQLAVLLLTFSRSSFCSTSEGRMVVESITITQGENTQNKRAIPKIKTKQGTLSQADFD
 EDLRTLKDFDRVEPIVEFRNGQAVISLILAKPVIREINISGNEAIPTHKILKTLELYKNDLFDRELFF
 30 KNFDALRLTYLKRGYDSQLSYSHNNEKEGFIIDISIEIKEGRHGRIKLTISGITRTEASDLGDIVLTK
 QYSTTTTSWFTGAGVYHPDMVEQDLFAITNYFQNKGYADAKVSKEVSTDAKGNITLLIVVDKGPLYTLGHV
 HIEGFTALSKRLLDKQLLVGPNLSLYCPDKIWTGAQKIRSAYARYGYVNTNVDVSFAHPTLPVYDVITYRV
 SEGSPYKIGLIKIKGNTHTKHDVILHETSLFPFGDTFDRKLLEGTTETRLRNTGYFKSVSVYTVRSQDLPLD
 SNDLYRDVFIIEVKETETGNLGLFLGFSIDHLFGGAIEAESNFDLFGARNFLKKGFKSLRGGEYLFLLKA
 35 NLGDKVTDYTVKWKPHFLNTPWILGVELDKSINKALSKDYSVDYTYGNISTTYILNDKLYGMYRGSQ
 TSLSLRKKTSSSNRPGPDLDNSNKGFSVSAAGLNVLDSIDNPRKPTMGIRSSLNFELSGLGTYQFTKLTA
 SGIYRLLTKKGVLVKRAEAKFIKPFGTTAQGIPIVSEFFLGGETTVRGYKPFIIIGPKFSPTEPQGGLS
 SLLLTEEFQYPLISQPCINAFVFLDSGFIGIEEYTIIRLKLDCSSAGFGLRFDMMNVPIMLGWGWPFPRPT
 EILNNEKIDVSQRFFALGGVF
 >gi|3328646|gb|AE001297.1:4000-6378,
 40 ATGCTTGGAATACGCAAAAAACGATTCTGCAACTCGCTGTTTTACTGTTGCTCACCTTTTCACGAAGTT
 CTTTCTGTTCAACTTCAGAAGGACGTATGGTCGTAGAGTCTATCACCATTACGACTCAAGGAGAGAATAC
 TCAAAATAAACGAGCTATTCTTAAATAAAAAACAAAGCAGGGGACGTTGTTCTCTCAAGCAGATTTTGAT
 GAAGATCTAAGAACACTTTTCGAAGATTTTGATCGAGTAGAGCCTATCGTAGAGTTTCGTAATGGACAAG
 45 CTGTGATCTCTCTGATTCTGACGGCAAAACCTGTTATCAGAGAGATCAATATTTTCAGGAAATGAAGCTAT
 CCCCACTCATAAAATTCGAAAACCTTAGAGCTTTATAAAAATGATCTTTTGTATCGGGAATTATTCTTT
 AAAAATTTTGATGCGCTAAGAACCTTTTATTGAAACGAGGGTACTACGATTCTCAACTCTCCTATTCTC
 ATAATCATAATGAGAAAGAGGGCTTTATCGATATTTCATCGAGATTAAAGAAGGACGTCACGGTCGCAT
 AAAAAAATTAACGATTTCGGGAATTACGCGAACAGAAGCATCAGACTTAGGTGACATTGTTTAACTAAA
 50 CAATACTCCACAACAACGAGCTGGTTCACTGGTGCCGGAGTGATCATCCGGACATGGTAGAGCAAGACT
 TATTGTCTATCACAATTAATTCCAAAATAAAGGATATGCTGATGCTAAAGTAAGCAAGAGGTCTCTAC
 AGATGCTAAAGGAACATTACTTTGCTTATCGTTGTAGACAAAGGACCTTTATACACATTAGGTACGTA
 CATATAGAAGGATTACAGCGTTATCCAAAAGACTGCTCGATAAACAACCTATTGGTTGGACCTAACTCCT
 55 TATATTGCCAGATAAAAATTTGGACTGGAGCACAAAAGATTTCGTAGCGCATACGCTAGATATGGCTACGT
 GAACACTAACGTTGATGTCTCCTTCTCAGCGCACCCCACTCTACCTGTTTACGATGTTACCTATCGAGTG
 AGTGAAGGATCTCCCTACAAAATCGGGTTAATTAAATCAAAGGGAACACTCATACTAAGCATGATGTGA
 TTTTGCATGAGACTAGTCTTTTCCCTGGAGACACTTTTGATAGATTAAACTGGAAGGTACAGAGACTCG
 TTTACGCAACACCGGCTACTTTAAAGTGTAAGTGCTATACGGTTTCGTTCCCAATTAGATCCTCTTGAT
 60 TCTAACGACTTTTATCGAGATGTTTATTGAAGTCAAAGAGACTGAAACAGGAAATCTTGGGCTATTCT
 TAGGATTACGCTCCATTGACCATTTATTGAGGGGCGAGAAATTGCAGAAAGCAACTTTGATTTATTG
 AGCCCGAAACTTTCTCAAAAAGGATTCAAATCTTTAAGAGGTGGTGGAGAATACCTCTTCTAAAGCT
 AATTAGGAGATAAGGTACCGATTACACTGTTAAATGGACGAAACCACTTCTTAAATACCCCTTGA
 65 TCTTGGAGTAGAATTAGATAAATCAATTAATAAGCTTTATCAAAAGACTACTCTGTGGATACCTATGG
 AGGGAATATCAGTACCACCTACATTCTTAACGATAAGTTAAATATGGGATGTATTACCGTGTATGCA
 ACAAGCTTAAGTTTGCAGCAAAAAACGTCAGCTCTAATAGACCTGGACCAGATTAGATAGTAATAAAG
 GATTTGTTTCCGAGCGGGACTCAATGTTCTTATGATTCTATTGATAATCCTAGAAAACCTACTATGGG
 AATCCGAGCTCCTTAAACTTTGAATTATCTGTTTAGGCGGAACCTTACCAATTTACTAACTAACAGCT

AGTGGTTCTATCTATCGCTTATTAACATAAAAAAGGTGTTTTGAAAGTCCGTGCAGAAAGCTAAGTTTATCA
AACCTTTTCGGAACAACAACCTGCACAAGGCATTCTGTGCAGCGAACGGTTCTTCTTAGGAGGTGAAACCAC
TGTTTCGCGGTACAAACCTTTTATTATTGGACCGAAATTTCTCCTACTGAACCACAAGGAGGCTTGTCT
TCCCTACTATTAACAGAAGAAATTTCAATATCCTTTGATTTCTCAACCTTGCATTAAATGCCCTTTGTATTTC
5 TAGATTCGCGATTCAATTGGGATAGAAGAGTACACTATTTCGCTGAAAGACCTTTGCAGTAGCGCCGGATT
TGGTCTACGCTTTTGATATGATGAATAATGTGCCAATTATGCTAGGCTGGGGTTGGCCGTTCCGCCCAACA
GAAATCCTCAATAATGAAAAATTGATGTATCTCAAAGATTCTTTTTGCCTTGGGAGGAGTATTCTAG

>gi|3328587|gb|AAC67774.1| CMP-2-keto-3-deoxyoctulosonic acid synthetase
[Chlamydia trachomatis]
10 MFAFLTSKKVGLPSRWGSSRFPGKPLAKILKTLVQRSYENALSSQSLDCVVVATDDQRIFDHVVEFGG
LCVMTSTSCANGTERVEEVSRHFPQAEIVVNIQGDPECLSPVIDGLVSTLENNPAADMVTSVTETDTP
EAILTDHKVKCVFDKNGKALYFSRSAIPHNFKHPTPIYHLHIGVYAFRKAFLSEYVKIPSSLSLAEDLEQ
LRVLEIGRSIYVHVQNATGPSVDYPEDITKVEQYLLCLSKASF

>gi|3328586|gb|AE001292.1:216-980,
15 GTGTTTTCGCTTTTAAACCAGCAAAAAGTCGGCATTCTCCCTCTAGATGGGGAAGCTCCCGCTTCCCCG
GAAAACCTCTAGCAAAAATCTAGGGAAAACCTTGTTCAAAGATCCTATGAAAATGCCTTAAGCAGTCA
ATCTCTAGATTGCGTTGTTGTGGCAACAGATGATCAACGAATTTTGACCATGTCGTTGAATTTGGGGG
CTCTGTGTCATGACTAGCACATCTTGCCTAACGGAAGTACGAGTAGAAGAGGTTGTGTCTCGACATT
20 TTCTCAAGCAGAGATTGTTGTGAACATCCAAGGAGACGAGCCTGTTTATCTCTACCGTCAATAGATGG
GCTTGTGAGCAGCTAGAGAACAATCCTGCTGCAGATATGGTCACATCTGTTACAGAAACAACAGACCCC
GAAGCGATATTGACAGATCACAAGTGAAGTGTGTTTTTCGATAAGAATGGCAAAGCTCTTTACTTTAGCA
GAAGCGCTATTCTCACAACCTTTAAACACCCCAACGCCTATTATCTGCATATTTGGTGTGTTTATGTTAG
AAAAGCTTTTCTAAGTGAATATGTTAAATTCCTCCTTCTCGTTAAGCCTAGCCGAAGATCTTGAACAA
25 TTACGAGTATTAGAAATAGGTCGTTCTATCTACGTTTCATGTCGTTCAGAATGCAACGGGCCCTTCTGTTG
ATTATCCCGAAGATATAACCAAAGTGGAGCAGTATTTATTATGTCTTTCAAAGCATCTTTTGA

>gi|3329039|gb|AAC68197.1| Thio:disulfide Interchange Protein [Chlamydia
trachomatis]
30 MIRQWYGFLLCLFSYTSFCFVEENSGRATPTVELVSESEQAVEGEVLRIGVLIAIPEGEHYWKNPGKL
GMPLRISWDLPSGCRLLLEHWPTEIFEEDGVVYFGYKSTMVVADIRVSKEIETRPLEIKAQVEWLSG
ASCLPGSSSRVLVIPIDQGPLIPNSKETFTFSRALAAQPRPLDAAIKISYQPDGLDVFPVPAKADRATQA
WFIAENTRDFAYAQEVPLEQATTYIWKLPHEGNMMPKIGLSGILIFKDDAGKVVASVQVEENQVEQLSA
LSWRFLSILLMAFIGGILLNIMPCVLPILTLKVFSLIKSAADHSSSVIGGIGFTLGAIVSFWGLAFCAF
35 LLKVLGQNIWGWFQLEPMFVAVLIIVFFLALSSLGVFEMGIIICLSLKKLQEEGGASVRKNQIWGAF
NGMLTTLVTTPCTGPFGLSVFGLVMAVSFVKQLAIFTAIGLGMASPYLLFASFPMKLAAILPKPGPMMSTF
KQLTGFMILLATATWLIWIFGVETSATAVTILLVGLWLAAGVAILGRWGLTVSPRNQRLIASVVFIFCIL
SSLVITSIGVRYFDENVPPAHSSDWQSFPEKLADLREKGIPVFNFTAKWCLTCQLNKPILLHANMQAFA
AKGVVLTLEADWTKKDPKITEELARLGRASVPSYVYPAGNKAPLILPERLSQSALEEMVFSQ

>gi|3329034|gb|AE001330.1:c6695-4617,
40 ATGATTTCGGCAATGGTATGGATTTTTCTTTGCTTGTCTGCTTACGCTATACGCTTGTGTTGGTGTAGAAG
AAAATAGTGGAAGAGCTACGCTACAGTAGAAGCTTGTAGTGAAAGCGAACAAGCTGTTGAAGGAGAAGT
GCTTCGTATCGGAGTATTGATTGCTATTCCAGAAGGAGAGCATATCTACTGGAAAAATCCAGGGAAGCTT
GGAATGCCTTTGCGCATTTCTTGGGATTTGCCATCAGGATGTAGGTTGCTGGAGGAACATTGGCCGACTC
45 CAGAGATTTTCGAAGAGGATGGGGTTGTTTATTTGCTTATAAACATTCTACAATGGTGGTTGCGGATAT
TCGCGTTTCTAAAGAGATAGAAACCGCTCCATTGGAGATAAAAGCGCAAGTTGAATGGTTGTCTTGGCGT
GCATCTTGTCTCCAGGTTCTTCGTCAGGTTCTTGTGATTCTCTATAGATCAGGGGCCGTTAATTCCTA
ATAGTAAAGAGACATTCACTTTTTCCCGTGCCTTAGCGGCTAACCTCGACCTTTGGATGCTGCCATAAA
GATTTCTTATCAGCTGATGGCTTAGATGTTTTTGTGCCAGCAGGGAAGCGGATCGGGCAACCCAGGCA
50 TGGTTTCATTGCTGAAAACACGCGAGATTTTGTCTATGCTCAAGAGGTTCTCTTGGCAAGCGACTACGT
ACATATGGAAGTTGAAACATCCTGAAGGAAATATGCCAAGGGTATTGGGTTGTGCGGGATTCTTATATT
CAAGGATGATGCAGGGAAGTAGTCGCTTCGATCAAGTAGAAGAGAATCAAGTCGAACAGCTTTCGGCA
TTGAGCTGGAGGTTTCTCTCTATTCTTCTTATGGCTTTCATTGGTGAATCTTATTAACATCATGCCCC
GTGTATTGCCTCTGATTACTTTGAAAGTATTTAGTTTAATTAAATCGGCGGCAGATCACCATTCTTCTC
55 TGTGATTGGAGGATTGGGTTTACTTTAGGGGCTATTGTAAGCTTTTGGGGACTCGCTTTTGTGCGTTT
TTGTTAAAGGTTTAGGGCAAAATATTGGATGGGGATTCCAGCTTCAAGAACCATGTTTGTGCGGTTT
TAATTATTGCTCTTCTTCTTATTGCTCTGAGTTTCGTTAGGCGTTTGGAGATGGGAATAATTTGCTGAG
CCTAGGGAAAAAATTGCAAGAAGAGGGAGGGGCATCGGTAAGGAAGAATCAGATCTGGGGAGCTTTTTC
AATGGGATGTTGACTACCTGGTTACAACCTCTGCACTGGGCCCTTTCTTGGCTCTGTATTGGATTAG
60 TTATGGCAGTGCTTTTGTTAAGCAGCTGGCAATTTTACTGCTATAGGATTAGGAATGGCAAGTCCCTA
TCTATTATTGCTTCTTTCCGAAGATGCTAGCCATTTTACCTAAACCTGGTCTTGGATGAGTACGTTT
AAACAGTTGACTGGGTTTATGTTGCTTGGCTACGCAACTTGGCTTATCTGGATTTTGGGGTAGAGACGA
GTGCAACCGCTGTAACATTTCTTGTAGGATTGTGGTTGGCTGCTGTAGGTGCATGGATTCTAGGGAG
ATGGGGAACCTTGTATCTCCGCGTAATCAGCGGCTTCTTGTCTCCGTTGTATTCAATTTCTGTATTTA
65 AGTTCCTTAGTGATTACCTCTATAGGTGTCCCTTATTTTGTAGAGAAGTCCCTCTGACATAGCTCTG
ATTGGCAATCTTTTCTCCCGAAAAGCTAGCTGATTACGCGAAAAAGGATTCCAGTTTTTGTAAATTT

CACTGCAAAGTGGTGTTTAACTGTCACCTCAATAAGCCTCTTCTTCATGCCAATATGCAAGCTTTTGCT
GCTAAGGGCGTAGTTACTTTAGAACGAGATTGGACGAAAAAGATCCAAAAATTACAGAAGAACTCGCTC
GTTTAGGCCGAGCCAGTGTACCTTCTTATGTGTATTACCTGCGGGGAACAAAGCTCCGCTTATTCTTCC
AGAAAGATTATCGCAATCTGCTTTGGAAGAGATGGTTTTTTCTCAGTAG

5

>gi|3329000|gb|AAC68161.1| Yop proteins translocation lipoprotein J
[Chlamydia trachomatis]
MFRYTLRSRLFFILALFFCSACDSRSMITHGLSGRDANEIVVLLVSKGVAAQKVPQAASSTGGSGEQLWD
ISVPAAQITEALAILNQAGLPRMKGTSLLDLFAKQGLVPSEMQEKIRYQEGLEQMATITIRKMDGIVDAS
VQISFSPPEEDQRPLTASVYIKHRGVLDNPNISIMVSKIIRLVASAVPGLCPENVSVVSDRASYSIDITING
PWGLSDEMNYVSVWGIILAKHSLTKFRLVFLYFLILLFLLSCGLLWVIWKTHLTLISALGGTKGFFDPAPY
SQLSFTQNKPPAPKETPGAEGAEQAQTASEQPSKENAEKQEENNEDA

10

>gi|3328999|gb|AE001327.1:84-1064,
ATGTTTCGTTATACTCTTTCTCGATCCTTATTTTTCATTTTGGCTCTTTCTTCTGCTCGGCTTGTGATA
GTCGTTCCATGATTACACACGGCTTGTGACGACGTGATGCTAATGAAATCGTAGTGCTTCTAGTCAGTAA
AGGGGTGCTGCACAGAAAGTCCCAAGCAGCGTCTCAACAGGAGGATCTGGAGAACAACTCTGGGAT
ATTTGCGTTCCTGCAGCACAAATTACAGAGGCTCTAGCTATTCTGAACCAAGCTGGGCTTCCAAGAATGA
AAGGAACAGCCTTCTTGATCTATTGCTAAACAAGGGCTGGTCCCTTCTGAAATGCAAGAAAAAATCCG
CTACCAAGAAGGTCTTTTCAAGACAAATGGCTACGACCATAGAAAGATGGACGGTATCGTCGATCGGAGC
GTACAGATTTCCTTTTCTCTGAAGAAGAAGTCAACGGCCGCTAACAGCCTCTGTATATATCAACACA
GAGGGTATTAGACAACCTAACAGTATTATGGTGTCTAAGATTAAACGTTTAGTTGCGAGTGTCTGTCCC
AGGACTATGTCCCGAGAACCTTTCCGTAGTCAGTGACCGAGCTTCTTATAGTGACATTACTATTAAATGGC
CCTTGGGGACTCTCCGATGAAATGAATTATGTTTCTGTATGGGGGATCATTCTAGCTAAGCATTCCCTTA
CTAAATCCCGCCTTGTTTTCTATTCTTAATCTCCTTCTCTCATTCTTTCTGTGGGCTACTCTGGGT
CATTGGGAAAACACACACTGATTTCTGCTCTGGGTGGAACAAAAGGATTCTTTGATCCTGCTCCTTAC
TCACAGCTCTCTTCTCACTCAGAATAAGCCAGCTCCAAAAGAACTCCTGGAGCAGCAGAAGGTGCAGAAG
CGCAAACCGCTTCGGAACACCCCTCTAAAGAAAACGCAGAAAAACAAGAAGAATAACGAGGACGCTTA
A

15

20

25

30

>gi|3328905|gb|AAC68071.1| hypothetical protein [Chlamydia trachomatis]
MEKRGVIVHILVCLLTIFGTFSLPAFGAHLAEQFYMDRFVFSQYPMETMEIHAERKKRVQFDVTG
SFPKLESVVYKGSFGLLRSKIKECEPELSSVNLSTSCRMDLDFRGEWKKNASIIYIRNEQEPITIMLPKD
IGVVVYTVQVDMNSKVVAEGLIKRGRGFWKKTFRNSLVGESPVTLTFHVETRNNGVIFLR

35

>gi|3328891|gb|AE001320.1:c11104-10502,
ATGGAGAAGAGAGCGTTATTGTGCATATACTAGTTTGTGTTGACAATCTTCGGAACGTTCAAGTTTAC
CCGCTTTCCGGCGCGCATTTTCTCGCGGAAGAAGAGCAGTTTATATGGATCGGTTTGTCTCTGGGCA
GTATCCAGATATGGAACTATGGAAATCCATGCAGAAAGAAAAAACGTGTACAATTTGATGTGACGGGA
AGCTTCCCTAAGTTGGAGAGCGTGGTTTATAAGGGATCTTTTGGATTGCTGCGTTTCAAAAATAAGGGAG
AGTGTCAGAACTGTCTTCTGTAAATCTTTCTGTACCTCTGCGAGAAATGGATTTAGATTTTTCGAGGGGA
GTGGAAAGAAGATGCGTCTATTATATTCTGAATGAGCAAGAGCCAATTACAATTATGTTGCTTAAAGAC
ATTGCTGTAGTTGCTTATACGAGGTTGATATGAATAGTAAAGTAGTTGCAGAGGGATCACTAATCAAGA
GAGGAAGAGGTTTTTGAAGAAAACCTTTTCGGAATCTTTGGTAGGAGAATCCCTGTGACGCTAACTTT
TCATGTAGAGACTCGTAATGGAGGAGTTATTTTCTCCGTTAG

45

>gi|3328884|gb|AAC68051.1| Phosphatidate Cytidylyltransferase [Chlamydia
trachomatis]

50

MFDSHDNSIFQSDLCQRLVVHSILLTFLVILLCTSLYPSSAFIVGLLSSACAALGTYEMGAMVRIKFPFS
FTRYALGSAIFIALTCLTARCKMCFPEHIDLLPWFLFFWTIRLVFKSRHYKLGPIGSTGLALFCMLYV
SVPIRLFLHILYGFVHTDTPFVGIIWAIFLIATTKSSDIFGYFFGKAFGKKRIAPVISPNKTVVGFIAGC
CGSILVSLLFYSHLPKAFADQIAVPWILIALGTVLGVSGFFGDIESTFKRDAQIKNSSDLESIGGMLDV
LDSILLSTPIVYAILLITQNRFLG

55

>gi|3328881|gb|AE001319.1:1804-2721,
ATGTTGATTCGGATCATAATTCATTTTCAAAGCGATTTGTGTCAGCGTCTGGTCTGCTCCACTCGATT
TTCTTACTTTCTTGTGATCTTCTCTGTACATCTTATATCCAGCTCAGCCTTTATGTAGGGCTTCT
TTCTCCGCTTGGCAGCTCTAGGAACATATGAGATGGGGGCTATGGTTAGAATCAAGTTTCCATTTTCT
TTCACACGCTATAGTGATAGGATCCGCTATTTTCTGCTCTGACCTGTCTTACAGCTCGTTGTGAAAA
TGTGTTTTCCAGAGCATATAGACCTACTTCTTGGTCTTTCTCTTCTTTTGGACGATTGCTTAGTATT
TAAAAGTCGCCATTATAAACTTGGTCCCATAGGCTCAACTGGGCTCGCGTTGTTTGTATGCTTTATGTA
TCAGTCCCTATCCGCTTGTTCCTCCACATTTGTATGGGTTTGTGCATACCGATACTCCATTTGTAGGAA
TTTGGTGGGCGATTTTCTTATCGCTACAACAAAAGCTCTGATATTTTGGTTACTTCTTTGGAAAAAGC
TTTTGGGAAAAACGCATTGCACCAAGTCATTAGCCGAACAAAACAGTAGTAGGCTTCATTGCTGGTTGC
TGTGGATCTATCTGGTTAGCCTTCTTTCTACTCCCATCTTCTTAAAGCCTTTGCTGATCAGATTGCGG
TGCCTTGGATCCTCATTGCTTTAGGTACTGTGTTGGGCGTTAGTGGATTCTTTGGAGACATTATCGAATC
TACGTTCAAACGGGATGCACAGATCAAGAACAGCAGTGATCTGGAGTCTATCGGAGGAATGCTAGATGTG

65

CTAGACTCCTTGCTTCTTTTCGACTCCTATCGTTTACGCTATCCTCCTTATCACTCAAAATAGGACATTTT
TAGGATGA

- 5 >gi|3328855|gb|AAC68022.1| hypothetical protein [Chlamydia trachomatis]
MRRSVCYVTPSVARAGQISTWRFYSSANFLPEGTLLKFDLGIDGRPIDWEIPSTDLSQPCNTIYLET
EDIVAAKAVYAPGGYIPTFEFTLPCDVEAGDTFSIILGSSPNFPQEDSSGNGAQLFTQRRKPFSLYVDPS
GKGSFEDPDIPTMDIRGNVLKNIRIPAPSYVIKNRFDITVRFEDFENLTNFSPEETHIELSYEHLREN
10 LNWQLFIPETGFVILPNLYFNEPGIYRIQLRNQATKEVFTSAPIKCFEETSSHLLWGLLHGSESRVDSEG
NIESCLRYFRDDCALNFFATSSFEIQDGLTPETIKTINQTVADFNEEDRFIALSGAQLSEEPGEGIREV
LLMKEPKSPGKHKECKLFPLSKLYKQSTSHELISIPSFTASKKFGYNFNNFHFEFERVVEIYNAGWCSE
TEAEGNPFPIKGSIDSENPEGTVLSALKRNLRFVAGGLDDRNLYNHFFDSDQQQYSPGLTAVICNKYS
RDSLLEALYQRCYATTGQRIIVNFQITSAPMGSELSTAIKPLVINRHISGYVAGTAKIASIEIIRNED
15 ILHTFHPDGNNFYEYDDLSFPAQVTLKDPQNGAPFAFYLRVTQENGAMAWSSPIWIDLN
>gi|3328850|gb|AE001316.1:4105-5970,
ATGCGCAGATCTGTTTGTGTACTCTTCCAGTTGCTAGGGCTGGTCAAATTTCTACCTGGCGTTTTCG
AATATTTCTTCAGCTAATTTTCTCCGAAGGCACATTGCTAAAATTTGACCTGGGAATAGACGGACGCC
TATAGACTGGGAGATTCTTCTTACAGATCTTCTCAACCATGTAATAACAATTTATTAGAAACGCCCTTCC
GAGGATATTGTGGCTGCAAAAGCTGTGTATGCTCCCGAGGCTATATCCCTACTTTTCAATTTACTCTCC
20 CTTGTGATGTGGAAGCTGGGGACACTTTCTCTATTATTCTTGGCTCCTCTCCCACTTCCCTCAAGAGGA
CTCTTCAGGTAATGGTGCTCAATTATTTACTCAACGCCGTAAACCTTTCTCTCTTTATGTTGACCCATCA
GGGAAAGGATCTTTTGAAGATCCCGATATCTTCAATGGATATCAGAGGAAATGTATTAATAAATATCC
GGATTTTGTCTCTTCTTATGTGATCAAAAACAAACGCTTTGATATTACAGTGCCTTCGAAGATGAATT
TGGGAACCTTAACCAATTTCTCCCAAGAGACCCATATCGAGCTTTCTGACGAACATCTTCGCGAAAAC
25 CTCAATTGCAATGTTTCATCCCTGAAACAGGCTTTGTGATCCTTCCAAACCTGTATTTCAATGAACCAG
GTATTTATCGTATTCAACTACGCAATCAAGCAACAAAGAGGCTTTTACATCAGCGCTATCAAATGTTT
TGACGAAACCTCTCTCATCTTTGTGGGGCTTCTACATGGAGAATCTGAACGTGTGACTCTGAAGGT
AATATCGAGTCTTGCTTGCCTTATTTCTGTGATGACTGCGCGTTAAACCTTTTGTCAACATCTCTTCTG
AAATTCAGATGGCCTGACCCAGAAACCATTAATAACCATTAACCAACCGTTGCTGATTTTAATGAAGA
30 AGATCGTTTCATTGCCTTATCCGGAGCACAGTACCTTTCTGAAGAGCCTGGCGAGGGAATTCGTGAAGTA
TTGCTGATGAAGGAACCCAAATCCCGAGGAAACATAAAGAAATGCAAACTATTTCTTTTATCTAAGCTAT
ATAAGCAATCAACTAGTCATGAGTTAATCTCAATCCCGAGCTTCACTGCTTCAAAGAAATTTGGATACAA
TTTTAATAATTTCCATCTGAAATTTGAAAGAGTTGTTGAAATTTATAATGCCTGGGGATGCTCTGAAAGA
ACTGAAGCTGAAGGAAACCTTTCCCTATTAAAGGTTCTATCGACTCAGAAATCCAGAGGGAACGTGTC
35 TATCTGCTTTAAAGAGAAACCTGCGTTTGGATTCGTAGCCGCTGGTCTTGATGATAGAAATCTATACAA
TCACTTTTGTGATTCGATCAACAGCAATACTCCCTGGATTAAACAGCTGTGATCTGCAATAAATATTCT
CGGGATTCTTACTCGAGGCAATTATACCAACGACAATGCTATGCTACAACCGGCCAAAGAATTATCGTGA
ATTTCCAGATTACATCTGCTCCTATGGGCTCCGAACCTCCACAGCCATTAAACAGGGCTCGTGATCAA
TAGACATATTTCCGGATATGTAGCAGGAACGCCAAGATTGCGTCGATCGAAATCATCCGCAATGAGGAT
40 ATTTCTCATACCTTCCACCCAGATGGAATAACTTTGAGTAGAGTACGACGATCTCTCTCTTTTGCAC
AAGTCACTCTAAAGATCTCAAATGGAGCTCTTTTGTCTTTTACTACTTACGAGTCACTCAAGAGAA
TGGAGCTATGGCTTGGAGCTCTCCTATTGGATAGATCTTAACATA
- 45 >gi|3328772|gb|AAC67946.1| hypothetical protein [Chlamydia trachomatis]
MKRFFPLFIGVLLAHTLPSEGLSHQAVQKKISYLSHFKGTIGIMDVEDGVLIHDDRLQANKAYVENR
TDCGIKIVAHGNVMVNYRGKILICDYLEYEDTDSCLLTNGRCSLYPWFIGGSTITISPSSIIHKGYIS
TSEGPQKHICLSGDYLYSSDSVLSMGPSRLSICNTPVLLLPQISIMPMEIPKPPITFRGGSGFLGSYL
GVSYSPISSKXHCSTTLFLDGFVKHIGLGYNMRFSQENPSNAINIKSYAHRLAIDSSGAKDRYRLHGD
50 FTFSKERAHLAGFHLSDSWETVVDIFPNFSLKNTGPTEVSLSWRDNNLFGKMTSSVKVNSFQNVKQEL
PQAILHHRPVRIRRSRIFLENRLAEGFLDFHSSNIPGSNFSWRFSFAHKVYRGLVLPITGLTFLPSLST
AIYYTRMLSPNAAHCQLSGSLSFDRVALQKEYRHARHIVEPFCFLKTRPVLSSDEPHIFSICKDAFHS
INLLHVGLSKVLNKHSTPSHLKLWTTYIFDEPHAKDTFPKTACWFSPLPLTQNTLSLDAEWIWKSRWD
HLNVIWEWILNDNLGLTLEFLHRSKYGFICKAKDNYTLVSRSLDTLLASPLSDRRNLITGKLFVRPHPH
55 WNYNLNLRYGWHRPDPSYLEYQMLGHKIFEHWQLFSVYEKREADKRCFFYLKLDKRRQKXHRHPFG
>gi|3328766|gb|AE001308.1:6085-8178,
GTGAAACGATTTTCCCACTTTTATTGGAGTGCTGCTCGCGCACACTTTGCGGTCAGAAGGTCTTTCTC
ATCAACAAGCTGTCCAAAAAAATTTCTTATCTGAGCCATTTTAAAGGCATTACAGGAATTATGGATGT
TGAGGATGGGGTATTACATATCCATGATGATCTACGCTTCAAGCCAATAAAGCCTATGTTGAAAATCGC
60 ACGGATGTGGGATCAAATCGTTGCTCATGGCAACGTTATGGTCAATTATCGCGGGAAAATTTAATCT
GTGATTATCTTGAGTACTATGAAGATACAGATTCTTGTTTACTCACCATGGCCGCTGTTCTGTTATACCC
ATGTTTCAATTGGAGGATCCACTATAACGATCTCACCATCTTCTATTATCATTCATAAAGGGTATATCTCG
ACTTCTGAAGGTCTCCAGAAACATATTTGTTTATCCGGAGATTATTTAAATACTCTTCAGACAGCGTAT
TATCTATGGGACCTCACGTCTTCTATCTGTAATACGCCTGTGTTATTGCTTCTCAAATCTCCATTAT
65 GCCTATGGAGATTCTAAGCCTCCGATTACTTTTCGAGGTGGGAGTGGAGGATTTCTGGGATCCTACTTA
GGTGTAGTTATTTCCCTATATCTAAAAAGCATTGTTCTACGACTTTGTTCTTGGATGGTTTTTTTAAAC

ATGGAATAGGTCTCGGCTATAACATGCGCTTTTCTCTCAGGAAAATCCAAGCAATGCCATAAATATTAA
 AAGCTATTACGCACATCGATTAGCTATTGATTTCATCAGGAGCAAAAGATCGCTATCGATTACATGGAGAC
 TTCACCTTTTCCAAAGAACGAGCCCATCTTGCTGGTGAATTCCATTTAAGTGATAGCTGGGAAACAGTTG
 TGGATATCTTCCCAAATACTTCTCTTTAAAAAATACAGGCCCTACAGAAGTTAGCCTATCATGGCGCGA
 5 TAACAATTTATTTGGGAAAATGACTTCTCTGTCAAAGTCAACTCCTTTCAAATGTTAAACAAGAATTG
 CCTCAAGCAATTCTTCATCACCGACCACTATCAGGCGCTCTCGCATTTTCTCCTAGAGAATCGCTTAG
 AAGCTGGTTTTTTAGATTTTCATTTCAGTAGTAATATTCCAGGCTCTAAGCTTCTCATCATGGAGGTTCTC
 ATCCGCTCACAAAGTCTACCGTGGGCTTGTTCTTCTATAGGAACGTTAACCCCTTCGCTATCTGGAAC
 GCTATCTACTATAACCGCATGCTCTCCCCAATGCAGCCCATTTGTCAATTATCTGGATCGCTATCTTTTG
 10 ATTATCGCGTTGCTTTTACAAAAAGAATATCGGCATGCAAGACATATTGTAGAGCCTTTTGTCTCCTTTT
 AAAAACCACTCGTCTGTATTATCTCTGATGAGCCTCATATTTTCTCGATTAAAGATGCTTTTCACTCT
 ATCAACCTTCTACATGTAGGATTGGAGTCAAAAGTCTTAAACAAACATTCCACTCCTTCGCATCTGAAAC
 TATGGACGACCTATATCTTTGATGAACCTCAGCCTAAGGACACTTCCCTAAACTGCTTGCTGGTTCTC
 TCTTCTCTTACACTCCAAATACTTTATCTTAGATGCGGAATGGATTTGGAAAAAAGCCGATGGGAT
 15 CATCTCAATGTAATCTGGGAATGGATTTGAATGATAATCTCGGTCTTACTTTAGAATTTTTACATAGAA
 GTAAGTATGGCTTTTATTAAAGTGCCTAAAGATACTACACTCGATGTAAGCCGATCTTTAGACACATT
 ACTAGCCTCTCTCTTTCCGATCGAAGAAATTTGATTACTGGCAAACTTTTTGTTCGTCCACATCCTCAT
 TGGAATTATAATCTTAATCTTCGTTATGGATGGCATCGTCCAGACTCTCCATCTATTTAGAATACCAGA
 20 TGATTCTGGGTATATAAATCTTTGAGCACTGGCAGCTATTCTCTGTCTACGAAAAACGTGAAGCTGATAA
 GCGCTGCTTCTTTTATCTAAAATTAGATAAACGAAACAGAAACACCGCCATCTTTTGGATAA

>gi|3329347|gb|AAC68470.1| Putative Outer Membrane Protein H [Chlamydia
 25 trachomatis]
 MPFSLRSTSFCLACLSYSYGFASSPQVLTNPVTTTPFKGDDVYLNGDCAFVNVAAGAENGSIISANGDN
 LTTITGQNHTLSFTDSQGPVLQNYAFISAGETLTLKDFSSLMFSKNVSCGEKGMISGKTVSISGAGEVIFW
 DNSVGYSPLSIVPASTPTPPAPAPAPAPASSLSPTVSDARKGSIFSIVETSLEISGVKKGVMPDNAGNFG
 TVFRGNSNNNAGSGGSGSATTPSFTVKNCCKGVSFTDNVASCAGGVVYKGTVLFDKNEGGIFFRGNTAYD
 30 DLGILAATSRDQNTETGGGGGVICSPDDSVKFEGNKGSI VFDYNFAKGRGGSILTKEFSLVADDSVVFSN
 NTAEGGGAIYAPTIDISTNGGSI LFERNRAEGBAICVSEASSGSTGNLTLSASDGDIVFSGNMTSDRP
 GERSAARILSDGTTVSLNASGLSKLI FYDPVVQNNASAAGASTPSPSSSMPGAVTINQSGNSVIFTAES
 LTPSEKLQVLNSTSNFPGALT VSGGELVVTEGATLTGTITATSGRVTLGSGASLSAVAGANNNYICTV
 SKLGIDLESFLT PNYKTA ILGADGTVT VNSGSTLDLVMESAEVYDNPLFVGS LTIPFVTLSSSASNGV
 35 TKNSVTINDADAAHYGYQGSWSADWTKPPLAPDAKGMVPNTNNTLYLTWRPASNYGEYRLDPQRKGELV
 PNSLWVAGSALRTFTNGLKEHYVSRDVGFASLHALGDYILNYTQDDRDFLARYGGFQATAASHYENG
 IFGVAFGQLYGQTKSRMYSKDAGNMTMLSCFGRSYVDIKGTETVMYWETAYGYSVHRMHTQYFNDKTQK
 FDHSKCHWHNNNNYAFVGAENHFLEYCIPTRQFARDYELTGFMRFEMAGGWSSSTRETGSLTRYFARGSG
 HNMSLPIGIVAHAVSHVRRSPPSKLTLMNGYRPDIWRVTPHCNMEIIANGVKTPIQGSPLARHAFFLEVH
 40 DTLYIHFFGRAYMNYSLDARRRQTAHFVSMGLNRI F
 >gi|3329342|gb|AB001360.1:10808-13858,
 ATGCCTTTTCTTTGAGATCTACATCATTTTGTGTTTTTTAGCTTGTTTGTGTTCTTATTCGTATGGAATTCG
 CGAGCTCTCCTCAAGTGTTAACACCTAATGTAACCACTCCTTTTAAGGGGACGATGTTTACTTGAATGG
 AGACTGCGCTTTTGTCAATGTCTATGCAGGGGACAGAACGGCTCAATTATCTCAGCTAATGGCGACAAT
 45 TTAACGATTACCGGACAAAACCATACATTATCATTTTACAGATTCTCAAGGGCCAGTTCTTCAAAATTATG
 CCTTCATTTACAGCAGGAGAGACACTTACTCTGAAAGATTTTTCAGATTGATGTTCTCGAAAAATGTTTC
 TTGCGGAGAAAAGGAATGATCTCAGGGAAAACCTGAGTATTTCCGGAGCAGGCGAAGTGATTTTTTGG
 GATAACTCTGTGGGGTATTCTCCTTTGTCTATTGTGCCAGCATCGACTCCAACCTCCTCCAGCACAGCAC
 CAGCTCCTGCTGCTTCAAGCTCTTTATCTCCAACAGTTAGTGATGCTCGGAAAGGGTCTATTTTTCTGT
 50 AGAGACTAGTTTGGAGATCTCAGGCGTCAAAAAGGGGTGATGTTGATAATAATGCCGGGAATTTTGGGA
 ACAGTTTTTTCGAGGTAATAGTAATAAATGCTGGTAGTGGGGGTAGTGGGTCTGCTACAACACCAAGTT
 TTACAGTTAAAAACTGTAAAGGGAAAGTTTCTTTTACAGATAACGTAGCCTCCTGTGGAGGCGGAGTAGT
 CTACAAAGGAAGTGTGCTTTTCAAAGACAATGAAGGAGGCATATTCTTCCGAGGGAACACAGCATACGAT
 GATTTAGGGATTCTTGCTGCTACTAGTCGGGATCAGAATACGGAGACAGGAGGCGGTGGAGGAGTTATTT
 55 GCTCTCCAGATGATTCTGTAAAGTTTGAAGGCAATAAAGGTTCTATTGTTTTTGATTACAACCTTTGCAAA
 AGGCAGAGGCGGAAGCATCCTAACGAAAGAATTCTCTCTTGTAGCAGATGATTCCGGTTGTCTTTAGTAAC
 AATACAGCAGAAAAAGGCGGTGGAGCTATTTATCTCTCTTCTTACTATCGATATAAGCAGCAATGGAGGATCGA
 TTCTATTTGAAAGAAACCGAGCTGCAGAAGGAGGCGCCATCTGCGTGAGTGAAGCAAGCTCTGGTTCAAC
 TGGAAATCTTACTTTAAGCGCTTCTGATGGGGATATTGTTTTTTCTGGGAATATGACGAGTGATCGTCTCT
 60 GGAGAGCGCAGCGCAGCAAGAATCTTAAGTGATGGAACGACTGTTTCTTTAAATGCTTCCGGACTATCGA
 AGCTGATCTTTTATGATCCTGTAGTACAAAATAATTCAAGCAGCGGTGCATCGACACCATCACCATCTTC
 TTCTTCTATGCTGCTGTCACGATTAATCAGTCCGGTAATGGATCTGTGATTTTTACC GGCGAGTCA
 TTGACTCCTTCAGAAAAACTTCAAGTTCTTAACCTCTACTTCTAAGTTCCAGGAGCTCTGACTGTGTGAG
 GAGGGGAGTTGGTTGTGACGGAAGGAGCTACCTTAACCTACTGGGACCATTACAGCCACCTCTGGACGAGT
 65 GACTTTAGGATCCGGAGCTTCTGTGCTGCGGTGTCAGGTGCTGCAATAATAATTATACCTGTACAGTA
 TCTAAGTTGGGAGATTGATTTAGAATCCTTTTTTAACCTCTAAGTATAAGACGGCCATACCTGGGTGCGGATG

GAACAGTTACTGTTAACAGCGGCTCTACTTTAGACCTAGTGATGGAGAGTGAGGCAGAGGTATATGATAA
 TCCGCTTTTGTGGGATCGCTGACAATTCCTTTTGTACTCTATCTTCTAGTAGTGCTAGTAACGGAGTT
 ACAAATAATCTGTCACTATTATGATGCAGACCTGCGCAGCTATGGGTATCAAGGCTCTTGGTCTGCAG
 ATTGGACGAAACCGCCTCTGGCTCTGATGCTAAGGGGATGGTACCTCCTAATACCAATAACACTCTGTA
 5 TCTGACATGGAGACCTGCTTCGAATTACGGTGAATATCGACTGGATCCTCAGAGAAAGGGAGAAGTATGTA
 CCCAATCTCTTTGGGTAGCGGGATCTGCATTAGAAGCTTTACTAATGGTTTGAAAGAACACTATGTTT
 CTAGAGATGTTGGATTTGTAGCATCTCTGCATGCTCTCGGGGATTATATTTTGAATTATACGCAAGATGA
 TCGGGATGGCTTTTGTAGCTAGATATGGGGGATTCAGGCGACCGCAGCCTCCCATTATGAAAATGGGTCA
 ATATTTGGAGTGGCTTTTGGACAACTCTATGGTCAGACAAAGAGCAGAATGTATTACTCTAAAGATGCTG
 10 GGAACATGACGATGTTGTCTGTTTTCGGAAGAAGTTACGTAGATATTAAGGAACAGAACTGTTATGTA
 TTGGGAGACGGCTTATGGCTATTTCTGTGCACAGAATGCATACGCAGTATTTTAAAGACAAAACGCAGAAAG
 TTCGATCATTCGAAATGTCTTGGCACAACAATAACTATTATGCGTTTGTGGGTGCCGAGCATAATTTCT
 TAGAGTACTGCAATTCCTACTCGTCAGTTCTAGAGATTATGAGCTTACAGGGTTTATGCGTTTGTGAAAT
 GGCCGGAGGATGGTCCAGTTCTACACGAGAACTGGCTCCCTAACTAGATATTTTCGCTCGCGGGTCAGGG
 15 CATAATATGTCGCTTCCAATAGGAATTGTAGCTCATGCAGTTTCTCATGTGCGAAGATCTCCTCCTTCTA
 AACTGACACTAAATATGGGATATAGACAGACATTTGGCGTGTCACTCCACATTGCAATATGGAATATAT
 TGCTAACGGAGTGAAGACACCTATACAAGGATCTCCGCTGGCACGGCATGCCCTTCTTCTAGAAAGTGCAT
 GATACCTTGTATATTCATCATTTTGAAGAGCCTATATGAACCTATTGCTGGATGCTCGTCTGACAAA
 CGGCACATTTTGTATCCATGGGCTTGAATAGAATCTTTTAA
 20
 >gi|3328874|gb|AAC68042.1| 60kDa Cysteine-Rich OMP [Chlamydia trachomatis]
 MRIGDPMNKLIRRAVTIFAVTSVASLFASGVLETSMAESLSTNVISLADTKAKDNTSHKSKKARKNHSKE
 TPVDRKEVAPVHESKATGPKQDSCFGRMYTVKVNDDRNVETQAVPEYATVGSPPYIEITATGKRDCVDV
 IITQQLPCBAEFVRSDPATPTADGKLWKIDRLQGGEKSKITVWVKPLKEGCGFTAATVCAACPEIRSVT
 25 KCGQPAICVKQEGPENACLRCPVVKINIVNQGTATARNVVVENPVPDGYAHSSGQRLVFTFLGDMQPG
 HRTITVEFCPLKRGRTNIATVSYCGGHKNTASVTTVINPCVQVSIAGADWSYVCKPVEYVISVNP
 LVLRLDVVEDTLSPGVTVLEAAGAQISCNKVVWTVKELNPGESLQYKVLVRAQTPGQFTNNVVVKS
 CSDC GTCTSCABATTYWKGVAAHMCVVDTCDPVCVGVNTVYRICVTVNRGSAEDTNVSLMLKFSKELQPV
 SFG PTKGTTITGNVTIVFDSLRLGSKETVEFVSVTLKAVSAGDARGEAILSSDTLTPVPSDTENTHIY
 30
 >gi|3328863|gb|AE001317.1:c11039-9378,
 ATGCGAATAGGAGATCCTATGAACAACTCATCAGACGAGCAGTGACGATCTTCGCGGTGACTAGTGTGG
 CGAGTTTATTTGCTAGCGGGGTGTTAGAGACCTCTATGGCAGAGTCTCTCTCTACAAACGTTATTAGCTT
 AGCTGACACCAAGCGAAAGACAACTTCTCATAAAGCAAAAAGCAAGAAAAACACAGCAAGAGAG
 35 ACTCCCGTAGACCGTAAAGAGGTTGCTCCGGTTCATGAGTCTAAAGCTACAGGACCTAAACAGGATCTT
 GCTTTGGCAGAATGTATACAGTCAAAGTTAATGATGATCGCAATGTTGAAATCACACAAGCTGTTCTGTA
 ATATGCTACGGTAGGATCTCCCTATCTATGAAATTACTGCTACAGGTAAGGGATTGTGTGATGTT
 ATCATTACTCAGCAATTACCATGTGAAGCAGAGTTCGTACGCAGTGATCCAGCGACAACCTCTACTGCTG
 ATGTTAGCTAGTTTGGAAAATTGACCGCTTAGGACAAGGCGAAAAGAGTAAATTAAGTATGTTGGGTAA
 40 ACCTCTAAAGAAGGTTGCTGCTTTACAGCTGCAACAGTATGCGCTTGTCAGAGATCCGTTCCGTTTACA
 AAATGTGGACAACCTGCTATCTGTGTTAAACAAGAAGGCCAGAGAATGCTTGTGTTGCGTTGCGGATAG
 TTTACAAAATTAATATAGTGAACCAAGGAACAGCAACAGCTCGTAACGTTGTTGTTGAAAATCCTGTTCC
 AGATGGTTACGCTCATTCTCTGACAGCGTGTACTGACGTTTACTCTTGAGATATGCAACCTGGAGAG
 CACAGACAATTACTGTAGAGTTTGTCCGCTTAAACGTGGTGTGCTACCAATATAGCAACGGTTTCTT
 45 ACTGTGGAGGACATAAAAATACAGCAAGCGTAACAACTGTGATCAACGAGCCTTGCGTACAAGTAAGTAT
 TGCAGGAGCAGATTGGTCTTATGTTTGAAGCCTGTAGAATATGTGATCTCCGTTTCCAATCTCGAGAT
 CTTGTGTTGCGAGATGTGTCGTTGAAGACACTCTTCTCCCGGAGTCACAGTTCTTGAAGCTGCAGGAG
 CTCAAAATTTCTTGTAAATAAAGTAGTTTGGACTGTGAAGAAGTGAATCCTGGAGAGTCTCTACAGTATAA
 50 AGTTCTAGTAAGAGCACAACTCTGGACAATTACAAATAATGTTGTTGTAAGAGCTGCTCTGACTGT
 GGTACTTGTACTTCTTGCGCAGAAGCGACAACCTTACTGGAAAGGAGTTGCTGCTACTCATATGTGCGTAG
 TAGATACTTGTGACCCTGTTTGTGTAGGAGAAAATACTGTTTACCGTATTGTGTGTCACCAACAGAGGTT
 TGCAGAAGATACAAATGTTTCTTTAATGCTTAAATCTCTAAAGAAGTGAACCTGTATCCTTCTCTGGA
 CCAACTAAAGGAACGATTACAGGCAATACAGTAGTATTCGATTGTTTACCTAGATTAGGTTCTAAAGAAA
 55 CTGTAGAGTTTCTGTAAACATTGAAAGCAGTATCAGCTGGAGATGCTCGTGGGAAGCGATTCTTCTTCT
 CGATACATTGACTGTTCCAGTTTCTGATACAGAGAAACACACATCTATTAA
 60
 >gi|3328841|gb|AAC68010.1| Putative outer membrane protein B [Chlamydia
 trachomatis]
 MKWLSATAVFAAVLPSVSGFCFPEPKELNFSRVGTSSSTTFTETVGEAGAEYIVSGNASFTKFTNIPTTD
 60 TTTPTNSNSSSSNGETASVSESDSTTTTPDPKGGGAFYNAHSGVLSFMTRSGTEGSLTLEIKITGEGG
 AIFSQGEELLFTDLTGLTIQNNLSQLSGGAIFGESTISLGGITKATFSSNSAEVPAPVKKPTEPKAQTASE
 TSGSSSSSSGNDVSSPSSSRAEPAAANLQSHFICATATPAAQTDTESTPSHKPGSGGAIYAKGDLTIAD
 SQEVLFSINKATKDGGAIKAEKDVSEFENITSLKVQTNNGAEEKGGAIYAKGDLISQSSKQSLFNSNYSKQG
 GGALYVEGDINFQDLEIRIKYNKAGTFETKKITLPAQASAGNADAWASSSPQSGSGATTVSNLSDSSS
 65 GSDSDTSETVPATAKGGGLYTDKNLSITNITGIIBIANNKATDVGGGAYVKGLTLCENSHRLQFLKNSSD
 KQGGGIYGEDNITLNLTKTLFQENTAKEEGGLFIKGTDKALMTGLDSFCLINNTSEKHGGGAFVTK

BISQTYTSDVETIPGITPVHGETVITGNKSTGGNGGGVCTKRLALSNLQSIISIGNSAAENGGGAHTCPD
SFPTADTAEQPAAASAATSTPESAPVVSTALSTPSSSTVSSLTLLAASSQASPATSNKETQDPNADTDL
IDYVVDTTISKNTAKKGGGIYAKKAKMSRIDQLNISENSATEIGGGICCKESLELDAVLSVSTENLVGK
EGGGLHAKTVNINLKSFGFSNNKANSSSTGVATTASAPAAAAASLQAAAAVPSSPATPTYSGVVGGA
5 IYGEKVTFSCSGCTCFQSGNQAIIDNNPSQSSSLNVQGGAIYAKTSLSIGSSDAGTSYIFSGNSVSTGKSQT
TGQIAGGAIYSPTVTLNCPATFSNNTASMATPKTSSSEDGSSGNSIKDTIGGAIAGTATLSGVSRFSGNT
ADLGAAGITLANANTPSATSGSQNSITEKITLENGSFIFERNQANKRGAIYSPSVSIKGNNTIFNQNTST
HDGSAIYFTKDATIESLGSVLFTGNNVTATQASSATSGQNTNTANYGAAIFGDPGTTQSSQTDAILTLLA
SSGNITFSNNSLQNNQGDTPASKFCSIAGYVKLSLQAAKGKTIISFFDCVHTSTKKIGSTQNVYETLDINK
10 EENSNPYTGTIVFSSSELHENKSYIPQNAIHLNGTLVLKEKTELHVVSFEQKEGSKLIMKPGAVLSNQINIA
NGALVINGLTLIDLSMGTPOAGEIFSPPELRIVATTSSASGGSGVSSSIPTNPKRISAAAPSGSAATTPT
MSENKVFLTGDLTLIDPNGNFYQNPMLGSDLDVPLIKLPTNTSDVQVYDLTSLGDLFPQKGYMGWTWLD
NPQTGKLQARWTFDTRRWVYIPRDNHFYANSILGSGNSMIIVKQGLINNMLNNARFDDIAYNNFWVSGV
GTFLAQQGTPLSEFYSYSRGTSVAIDAKPRQDFILGAAFSKMVGKTKAIKKMHNYFHKGSEYSYQASVY
15 GKKFLYFLNKLQHGWLALPFLIQGVVSYGHIKHDTTTTLYPSIHERNKGDWEDLGWLADLRISMDLKEPSKD
SSKRITVYGELEYSSIRQKQFTEIDYDPRHFDDCAYRNLSLPVGCAGEGAIMNCNIIIMYNKLALAYMPSI
YRNNPVCKYRVLSSNEAGQVICGVPTRTSARABYSTQLYLGPFWTLTYGNYTIDVGMYTLSQMTSCGARM
F
>gi|3328833|gb|AE001314.1:9601-14856,
20 ATGAAATGGCTGTCTAGCTACTGCGGTGTTTGTCTGCTGTTCTCCCTCAGTTTCAGGGTTTTGCTTCCCAG
AACCTAAAGAATTAATTTCTCTCGCGTAGGAACCTTCTTCCTCTACCACTTTTACTGAAACAGTTGGAGA
AGCTGGGGCAGAAATATATCTCTCTGTTAAGCATCTTTTACAAAATTTACCAACATTTCTACTACCGAT
ACAACAACCTCCACGAACCTCAAACTCCTCTAGCTCTAACGAGAGACTGCTTCCGTTTCTGAGGATAGTG
25 ACTCTACAACAACGACTCCTGATCTTAAAGGTGGCGGCGCCTTTTATAACGCGCACTCCGGAGTTTATC
CTTTATGACACGATCAGGAACAGAGGTTCTTAACTCTGTCTGAGATAAAAATAACTGGTGAAGGCGGT
GCTATCTTCTCTCAAGGAGAGCTGCTATTTACAGATCTGACAGGTCTAACCATCCAAAATAACTTATCCC
AGCTATCCGGAGGAGCGATTTTGGAGAATCTACAATCTCCCTATCAGGGATTACTAAAGCGACTTTCTC
CTCCAACCTCTGCAGAAAGTTCTCTGCTCTGTTAAGAAACCTACAGAACCTAAAGCTCAAACAGCAAGCGAA
30 ACGTCGGGTCTTAGTAGTTCTAGCGGAAATGATTGCGGTGCTTCCCCAGTTCCAGTAGAGCTGAACCCG
CAGCAGCTAATCTTCAAAGTCACTTTATTTGTGCTACAGCTACTCCTGCTGCTCAAACCGATACAGAAAC
ATCAACTCCCTCTCATAAGCCAGGATCTGGGGGAGCTATCTATGCTAAAGGCGACCTTACTATCGCAGAC
TCTCAAGAGGTACTATTCTCAATAAATAAGCTCACTAAAGATGGAGGAGCGATCTTTGCTGAGAAAGATG
TTTCTTTTCGAGAATATTACATCATTAAAGTACAAACTAACGGTGTGAAGAAAAGGGAGGAGCTATCTA
35 TGCTAAAGGTGACCTCTCAATTCAATCTTCTAAACAGAGTCTTTTAAATTCTAACTACAGTAAACAGGT
GGTGGGCTCTATATGTTGAAGGAGATATAAAGTCTTCAAGATCTTGAAGAAATTCGCATTAAAGTACAATA
AAGCTGGAACGTTTCAAAACAAAAAATCACTTTACCAAAGCTCAAGCATCTGCAGGAAATCGAGATGC
TTGGGCTCTTCTCTCTCAATCTGTTCTGGAGCACTACAGTCTCCAACCTCAGGAGACTCTAGCTCT
40 GGCTCAGACTCGGATACCTCAGAAACAGTTCCAGCCACAGCTAAAGGCGGTGGGCTTTATCTGATAAGA
ATCTTTGATTACTAATCATCAGGAATATCGAAATGCAAAATAACAAAGCGACAGATGTTGAGGTTGG
TGCTTACGTAAAAGGAACCTTACTTGTGAAAACCTCTCACCGTCTACAATTTTGAAGAACTCTTCCGAT
AAACAAGGTGGAGGAATCTACGGAGAGACAACATCACCTATCTAATTTGACAGGGAAGACTCTATTCC
AAGAGAATACTGCCAAAGAGGGCGGTGGACTCTTCAAAAAGGTACAGATAAAGCTCTTACAATGAC
45 AGGACTGGATAGTTTCTGTTAATTAAACACATCAGAAAAACATGGTGGTGGAGCCTTTGTACCAAA
GAAATCTCTCAGACTTACACCTCTGATGTGGAACAATTCAGGAATCACGCTGTACATGGTGAAACAG
TCATTACTGGCAATAAATCTACAGGAGGTAATGGTGGAGGCGGTGTGTACAAAACGTCTTGCCTTATCTAA
CCTTCAAAGCATTTCTATATCCGGGAATTTCTGCAGCTGAAAATGGTGGTGGAGCCACACATGCCAGAT
50 AGCTTCCCAACGGCGGATCTGCAGAACAGCCCGCAGCAGCTTCTGCCGCGACGTCTACTCCCGAGTCTG
CCCCAGTGGTCTCAACTGCTCTAAGCACACCTTCACTTCTACCCTCTCTTCAATTAACCTTACTAGCAGC
CTCTTCAACAGCCTCTCTGCAACCTCTAATAAGGAACTCAAGATCTTAATGCTGATACAGACTTATTTG
ATCGATTATGTAGTTGATACGACTATCAGCAAAAACACTGCTAAGAAAGGCGGTGGAATCTATGCTAAAA
AAGCCAAGATGTCCCGCATAGACCAACTGAATATCTCTGAGAACTCCGCTACAGAGATAGGTGGAGGTAT
55 CTGCTGTAAAGAACTTTAGAACTAGATGCCCTAGTCTCCTTATCTGTAACAGAGAACCTTGTGGGAAA
GAAGGTGGAGGCTTACATGCTAAACTGTAAATATTTCTAATCTGAAATCAGGCTTCTCTTCTCGAACA
ACAAAGCAAACCTCTCATCCACAGGAGTCGCAACACAGCTTTCAGCACCTGCTGCAGCTGCTTCCCT
ACAAGCAGCCGACGAGCCGTACCATCATCTCCAGCAACACCAACTTATTCAGGTGTAGTAGGAGGAGCT
ATCTATGGAGAAAAGGTTACATTCTCTCAATGTAGCGGGACTTGTCAAGTCTCTTGGGAACCAAGCTATCG
60 ATAACAATCCCTCCCAATCATCGTTGAACGTACAAGGAGGAGCCATCTATGCCAAAACCTCTTTGTCTAT
TGGATCTTCCGATGCTGGAACCTCTATATTTCTCGGGGAACAGTGTCTCCACTGGGAAATCTCAAACA
ACAGGGCAAATAGCGGGAGGAGCGATCTACTCCCTACTGTTACATTTGAATTTGCTTGCACATCTCTA
ACAATACAGCCTCTATGGCTACACCAAAGACTTCTTCTGAAGATGGATCCTCAGGAAATCTATTAAGA
TACCATTGGAGGAGCCATTGCAGGACAGCCATTACCTTATCTGGAGTCTCTCGATTTTCAGGGAATACG
65 GCTGATTTAGGAGCTGCAATAGGAACCTAGCTAATGCAATACACCCAGTGCAACTAGCGGATCTCAAA
ATAGCATTACAGAAAAAATTACTTTAGAAAAACGGTCTTTTATTTTGAAGAAACCAAGCTAATAAACG
TGGAGCGATTTACTCTCCTAGCGTTTCCATTAAAGGGAATAATATTAACCTTCAATCAAATAACATCACT
CATGATGGAAGTGCTATCTACTTTACAAAAGATGCTACGATTGAGTCTTTAGGATCTGTTCTTTTACAG
GAAATAACGTTACAGCTACACAAGCTAGTTCTGCAACATCTGGACAAAATACAAATCTGCCAATATGG

GGCAGCCATCTTTGGAGATCCAGGAACCACTCAATCGTCTCAAACAGATGCCATTTTAACCCCTTCTTGCT
 TCTTCTGGAAACATTACTTTTAGCAACAACAGTTTACAGAATAACCAAGGTGATACCTCCGCTAGCAAGT
 TTTGTAGTATTGCAGGATACGTCAAACCTCTCTTACAAGCCGCTAAAGGGAAGACTATTAGCTTTTTCGA
 TTGTGTGCACACCTCTACCAAAAAAATAGGTTCAACACAAAACGTTTATGAACTTTAGATATTAATAAA
 5 GAAGAGAACAGTAATCCATATACAGGAACATTGTGTTCTCTTCTGAATTACATGAAAACAAATCTTACA
 TCCCACAGAATGCAATCCTTCACAACGGAACTTAGTTCTTAAAGAGAAAACAGAACTCCACGTAGTCTC
 TTTTGAGCAGAAAGAAGGTCTAAATTAATTATGAAACCCGGAGCTGTGTTATCTAACCAAAACATAGCT
 AACGGAGCTCTAGTTATCAATGGGTTAACGATTGATCTTTCCAGTATGGGGACTCCTCAAGCAGGGGAAA
 TCTTCTCTCTCCAGAATTACGTATCGTTGCCACGACCTCTAGTGTCATCCGGAGGAAGCGGGGTACGACG
 10 TAGTATACCAACAAATCCTAAAAGGATTTCTGCAGCAGCGCCTTCAGGTTCTGCCGCAACTACTCCAAC
 ATGAGCGAGAACAAGTTTTCCTAACAGGAGACCTTACTTTAATAGATCCTAATGGAACTTTTACCAAA
 ACCCTATGTTAGGAAGCGATCTAGATGTACCACTAATTAAGCTTCCGACTAACACAAGTGACGTCCAAGT
 CTATGATTTAACTTTATCTGGGGATCTTTTCCCTCAGAAAGGTTACATGGGAACCTGGACATTAGATTCT
 AATCCACAAAACAGGGAACTTCAAGCCAGATGGACATTGATACCTATCGTCTGGGTATACATACCTA
 15 GGGATAATCATTTTTATGCGAACTCTATCTTAGGCTCCAAAACCTCAATGATTGTTGTGAAGCAAGGGCT
 TATCAACAACATGTTGAATAATGCGCGCTTCGATGATATCGCTTACAATAACTTCTGGGTTTCAGGAGTA
 GGAACCTTCTTAGCTCAACAAGGAACCTCCTTTCCGAAGAATTACAGTTACTACAGCCGCGGAACCTTCAG
 TTGCCATCGATGCCAAACCTAGACAAGATTTTATCCTAGGAGCTGCATTTAGTAAGATGGTGGGGAAGAA
 CAAAGCCATCAAAAAATGCATAATTACTTCCATAAGGGCTCTGAGTACTCTTACCAAGCTTCTGTCTAT
 20 GGAGGTAAATTCCTGTATTCTTGCTCAATAAGCAACATGGTTGGGCACTTCTTTCTAATACAAGGAG
 TCGTGTCTATGGACATATTAACATGATACAACAACACTTTACCCTTCTATCCATGAAAGAAATAAAGG
 AGATTGGGAAGATTTAGGATGGTTAGCGGATCTTCGTATCTCTATGGATCTTAAAGAACCTTCTAAAGAT
 TCTTCTAAACGGATCACTGTCTATGGGGAACCTTGAGTATTCAGCATTTCGCCAGAAACAGTTACAGAAA
 TCGATTACGATCCAAGACACTTCGATGATTGTGCTTACAGAAATCTGTCTGCTTCTGTGGGATCGCTGT
 25 CGAAGGAGCTATCATGAACTGTAATATTCTTATGTATAATAAGCTTGCATTAGCCTACATGCCTTCTATC
 TACAGAAATAATCTGTCTGTAAATATCGGGTATTGTCTTCAATGAAGCTGGTCAAGTTATCTGCGGAG
 TGCCAACTAGAACCTCTGCTAGAGCAGAATACAGTACTCACTATATCTTGGTCCCTTCTGGACTCTCTA
 CGAAACTATACTATCGATGTAGGCATGTATACGCTATCGCAAATGACTAGCTGCGGTGCTCGCATGATC
 TTCTAA
 30

>gi|3328840|gb|AAC68009.1| Putative outer membrane protein A [Chlamydia
 trachomatis]
 35 MNRVIEIHAYDQRLSQSPNTNFLVHHPYLTLIPKFLLGALIVYAPYSFAEMELAI SHGKQKDRDTFT
 MISSCPEGTNYIINRKLILSDFLSNKVSSGGAFRLNLAGKISFLGKNSSASIHFKHININGFGAGVFSSES
 SIEFTDLRKLVAFGSESTGGIFTAKEDISFKNNHHIAFRNNTKNGGVIQLQGDMMKGSVSVFVDQRGAII
 FTNNQAVTSSSMKHSGRGGAISGDFAGSRILFLNNQITFEGNSAVHGGAIYKNGLVEFLNAGPLAFK
 ENTITANGGAIYTSNFKANQQTSPILFSQNHANKKGAIYAQYVNLQNQDTIRFEKNTAKEGGGAI TSS
 40 QCSITAHNTIIFSDNAAGDLGGGAILLEGKKPSLTLLIAHSGNIAFSGNTMLHITKKASLDHRNSILIKEA
 PYKIQLAANKNHSIHFFDPVMALSASSSPIQINAPEYETPFSPKGMIVFSGANLLDDAREDVANRTSIF
 NQPVHLYNGTSLIENGALHIVQSFQKQTGGRISLSPGSSALALYTMNSFFHGNISSKEPLEINGLSFGVDIS
 PSNLQAEIRAGNAPLRLSGSPSIHDPEGLFYENRDTAASPYQMEILLTSDKIVDISKFTTDSLVTNKQSG
 FQGAWHFSWQPNNTINNTKQKILRASWLPTGEYVLESNRVGRAPVNSLWSTFLLLQTAHNLGDHLCNNRS
 45 LIPTSYFVGLIGGTGAEMSTHSSEESFISRLGATGTSIIRLTPSLTSLGGGSHMFGDSFVADLPEHITS
 EGIVQNVGLTHVWGPLTVNSTLCAALDHAMVRI CSKDHDTYKWDTFGMRGTLGASYTFLEYDQTMRFV
 SFANIEATNILQRAFTETGYNPRFSFKTLNLNIAIPIGIYEFCLGNSSFALLGKGSIGYSRDIKRENPS
 TLAHLAMNDFAWTTNGCSVPTSAHTLANQLILRYKACSLYITAYTINREGKNSLSLSCGGYVGF
 >gi|3328833|gb|AE001314.1:6535-9462,
 50 ATGAATCGAGTTATAGAAATCCATGCTCACTACGATCAAAGACAACCTTCTCAATCTCCAAATACAACT
 TCTTAGTACATCATCCTTATCTTACTCTTATCCCAAGTTTCTACTAGGAGCTCTAATCGTCTATGCTCC
 TTATTCGTTTGCAGAAATGGAATTAGCTATTTCTGGACATAAACAAGGTAAAGATCGAGATACCTTTTACC
 ATGATCTCTTCTGTCTCTGAAGGCATAATTACATCATCAATCGCAAACCTCATACTCAGTGATTTCTCGT
 TACTAAATAAAGTTTCATCAGGGGAGCCTTTTCGGAATCTAGCAGGGAAAATTTCTTCTTAGGAAAAAA
 55 TTCTTCTGCGTCCATTCAATTTAAACACATTAATATCAATGGTTTTGGAGCCGGAGTCTTTTCTGAATCC
 TCTATTGAATTTACTGATTTACGAAAACCTGTTGCTTTTGGATCTGAAAGCACAGGAGGAATTTTACTG
 CGAAAGAGGACATCTCTTTTAAAAACAACCACCACATTGCCTTCCGCAATAATATCACCAAGGGGAATGG
 TGGCGTTATCCAGCTCCAAGGAGATATGAAGGAAGCGTATCCTTTGTAGATCAACGTGGAGCTATCATC
 TTTACCAATAACCAAGCTGTAACCTCTTTCATCAATGAAACATAGTGGTGGAGGAGCAATTAGCGGTG
 60 ACTTCGCAGGATCCAGAATCTTTTCTTAATAACCAACAAATTACTTTCGAAGGCAATAGCGCTGTGCA
 TGGAGGTGCTATCTACAATAAGATGGCCTTGTGAGTCTTAGGAAATGCAGGACCTTGTGCTTTTAA
 GAGAACACAAACATAGCTAACGGGGGAGCTATATACACAAGTAATTTCAAAGCGAATCAACAAACATCCC
 CCATTCTATTCTCTCAAAATCATGCGAATAAGAAAGGCGGAGCGATTACGCGCAATATGTGAACCTTAGA
 65 ACAGAATCAAGATACTATTGCTTTGAAAAAAATACCGCTAAAGAAGCGGTGGAGCCATCACCTCTTCT
 CAATGCTCAATTACTGCTCATAATACCATCATTTTTTCCGATAATGCTGCCGGAGATCTGGAGGAGGAG
 CAATTCTCTAGAAGGGAAAAACCTTCTCTAACCTTGATTGCTCATAGTGGTAATATGCAATTTAGCGG

CAATACCATGCTTCATATCACCAAAAAAGCTTCCCTAGATCGACACAATTCTATCTTAATCAAAGAAGCT
 CCCTATAAAATCCAACCTTGACGCGAACAAAAACCATTTCTATTCATTTCTTTGATCCTGTCATGGCATTGT
 CAGCATCATCTTCCCTTATACAAATCAATGCTCCTGAGTATGAACTCCCTTCTTCTCACCTAAGGGTAT
 5 GATCGTTTTCTCGGGTGCAGTCTTTTAGATGATGCTAGGGAAGATGTTGCAAATAGAACATCGATTTTT
 AACCAACCCGTTTCATCTATATAATGGCACCCCTATCTATCGAAAAATGGAGCCCATCTGATTGTCAAAGCT
 TCAAACAGACCGGAGGACGTATCAGTTTATCTCCAGGATCCTCCTTGGCTCTATACAGATGAACCTCGTT
 CTTCCATGGCAACATATCCAGCAAAGAACCCCTAGAAATTAATGGTTTAAAGCTTTGGAGTAGATATCTCT
 CCTTCTAATCTTCAAGCAGAGATCCGTGCGGCAACGCTCCTTTACGATTATCCGGATCCCCATCTATCC
 10 ATGATCCTGAAGGATTATCTACGAAAAATCGCGATACTGCAGCATCACCATAACCAATGGAAATCTTGCT
 CACCTCTGATAAAAATTGTAGATATCTCAAATTTACTACTGATTCTCTAGTTACGAACAAACAATCAGGA
 TTCCAAGGAGCCTGGCATTTTAGCTGGCAGCCAAATACTATAAACAATACTAAACAAAAAATATTAAAGAG
 CTTCTTGGCTCCCAACAGGAGAATATGTCTTGAATCCAATCGAGTGGGGCGTGCCGTTTCTAATTCCTT
 ATGGAGCACATTTTTTACTTTTACAGACAGCCTCTCATAACTTAGGCGATCATCTATGTAATAATCGATCT
 CTTATCTCTACTTCTACTTTCGGAGTTTAAATGGAGGAACCTGGAGCAGAAATGCTTACCCACTCCTCAG
 15 AAGAAGAAGCTTTTATATCTCGTTTAGGAGCTACAGGAACCTCTATCATAAGCTTAACCTCCCTCCCTGAC
 ACTCTCTGGAGGAGGCTCACATATGTTTCGGAGATTCGTTTCGTTGCAGACTTACCAGAACACATCACTTCA
 GAAGGAATTGTTTCAAGATGTCGGTTTAAACCCATGTCTGGGGACCCCTTACTGTCAATTCTACATTATGTG
 CAGCCTTAGATCACAAACGCGATGGTCCGCATATGCTCCAAAAAGATCACACCTATGGGAAATGGGATAC
 ATTCGGTATGCGAGGAACATTAGGAGCCTCTTATACATTCCTAGAATATGATCAAACTATGCGCGTATTC
 20 TCATTCCGCAACATCGAAGCCACAAATATCTTCAAAAGAGCTTTTACTGAAACAGGCTATAACCCAAGAA
 GTTTTTTCCAAGACAAAACCTTCTAAACATCGCCATCCCATAGGGATTGGTTATGAATCTGCTTAGGGAA
 TAGCTCTTTTGTCTCTACTAGGTAAGGGATCCATCGGTTACTCTCGAGATATTAAACGAGAAACCCATCC
 ACTCTTGTCTCACCTGGCTATGAATGATTTTGTCTGGACTACCAATGGCTGTTTCAAGTTCCAACCTCTGCAC
 ACACATTGGCAAATCAATTGATTCTTCGCTATAAAGCATGTTTCCTTATACATCACGGCATATACTATCAA
 25 CCGTGAAGGGAAGAACCTCTCCAATAGCTTATCCTGCGGAGGCTATGTTGGCTTCTAA

>gi|3328763|gb|AAC67938.1| O-Sialoglycoprotein Endopeptidase family
 [Chlamydia trachomatis]
 30 MYKYFIVDTSGSPFLAYVDVLEVWSLPTGPDQGVVLFNFI NSLDLPFQIGIVSVGPGGFSATRVGV
 AFAQGLSLAKNVPLVGYSSLEGYLSLQEEELALLPLGKKGIVALNSELSLDGFLLLDTTSTPGILLSY
 SEALEYCLDKGCHVISPDPTTFVLEFSSRISVRKVVPICDIRKYVVSQFVLSQNLPLCLDYRSISSFF
 >gi|3328757|gb|AE001307.1:c6730-6098,
 GTGTACAAATATTTTATTGTAGACACTTCCGGTTCTCAGCCGTTTTTGGCCTATGTCGATTGTCGAGATG
 35 TTTTGAAGTATGGTCTTTGCCTACAGGGCCAGATCAAGGAGTTGTGTTAAATTTTCAACAGCCT
 GGATTTGCCTTTTCCAAAGCTTATGGAGTCTCTGTGGTCCCTGGGGGATTTCGCAACTAGAGTGGGAGTT
 GCTTTTGTCTCAAGGGCTCTCTCTGGCTAAAAATGTCCCTTTAGTTGGCTATAGCTCTTTAGAAGGATATC
 TTTCTTTGGGTCAAGAAGAGGAGGCTTTGCTTTTGCCTTAGGGAAAAAGGTTGGGATTGTAGCTTTAAA
 CTGAGAGCTTTCTCTTGATGGTTTCTGCTTACAGATACTACTTCTACTCCGGGAATTTTATGTCTTAT
 40 TCTGAAGCTCTAGAGTATTGTTTAGATAAGGGATGTTGTGATGATCTCTCCGGATCCAACGTATTTTCG
 TAGAACTATTTTCTTCGCGTATTTCGGTAAGGAAGGTGGTTCTTGTATCGATCGAATCGTAAGTACGT
 TGTTCGAGTTTGTCTGTCTCAAAATCTTCCGTTGTGTTAGATTACCGGAGCATCTTCTCTTTTTT
 TAG
 45 >gi|6578102|gb|AAC67897.2| ATP Synthase Subunit K [Chlamydia trachomatis]
 MIDVSVVGPVLAMALAMIGSAVCGMAGVASHAVMSRIDEGHGKIIGLSAMPSSQSIYGLIFMLLLNDIAI
 KDGKVS AVSGIVMGIAVGSALLLSAFMQGKCCVSAIQAYARSSAIYGKSFASIGIVESFALFAFV FALL
 F
 >gi|3328718|gb|AE001303.1:c956-531,
 50 ATGATAGATGTATCAGTAGTGGGGCCTGTATTGGCTATGGCTTTGGCAATGATTGGTAGCGCTGTTGGAT
 GTGGAATGGCTGGAGTCTGCTTCTCACGAGTGATGCTCGAATCGATGAAGGACACGGGAAGATTATTGG
 TCTGTCTGCTATGCCCTCATCACAAATCCATTTACGGGTTGATTTTCATGTTACTGCTGAATGATGCAATT
 AAGGATGGAAGTCTCTGCAAGTCAAGTGGTATCGTAATGGGTATAGCTGTAGGATCTGCGTTATTGCTTT
 CTGCTTTTATGCAAGGGAAGTGTCTGTGAGTGCTATCAAGCCTATGCGCGTTCTCTGCAATATATGG
 55 TAAATCAATTGCTTCGATTGGGATTGTTGAGTCTTTTGCCTTATTGCTTTTTCGCTATTGTTA
 TTCTAA

>gi|3329252|gb|AAC68382.1| S14 Ribosomal Protein [Chlamydia trachomatis]
 60 MAKSAVAREVKRRKLVEANFQKRAELRKLAKSLSVSEERERAREALNKMRRDTSRSLHNRCLLTGRP
 RGYLRKFALSRICFRQMASMGDIPGVVKASW
 >gi|3522908|gb|AE001351.1:2436-2741,
 ATGGCGAAGAACTCAGCAGTAGCTAGAGAAGTTAAACGTCGAAAGTTAGTAGAAGCTAATTTTCAAGA
 GAGCAGAGCTTCGAAAACCTTGCGAAGAGTTTATCTGTTAGCGAGGAAGAAAGAGAGCTCGGGAAGC
 65 TCTCAATAAAATGAGAAGAGATACTTCTCCTTCTCGTTTACATAATAGATGCCTATTAACAGGCCGTCCT
 CGTGGATACCTTAGAAAAGTTTGTCTCTCAAGAATTGTTTTAGACAAATGGCTTCTATGGGAGATATCC

CAGGCGTTGTGAAAGCAAGTTGGTAG

- >gi|3329133|gb|AAC68276.1| Major Outer Membrane Protein [Chlamydia trachomatis]
- 5 MKKLLKSVLVAALSSASSLQALPVGNPAEPSLMIDGILWEGFGGDPDCPCATWCDASMRVGYGDFVF
DRVLKTDVKNKEFQMGAKPTTDTGNNSAAPSTLTARENPAYGRHMQDAEMFTNAACMALNIWDRFDVFC
ATSGYLKGNASAFNLVGLFGDNENQKTVKAESVPMNSFDQSVVELYTDFTFAWSVGARAALWECGCATLG
ASFQYAQSKPKVEELNVLCNAAEFTINKPKGYVGKEFFPLDLTAGTDAATGTKDASIDYHEWQASLALS
10 LNMFTPYIGVKSRSASFDADTIRIAQPKSATAIFDFTTLNPTIAGAGDVKTGAEGQLGDTMQIVSLQLNK
MKSRKSCGIAVGTITVDADKYAVTVETRLIDERAHVNAQFRF
- >gi|3329126|gb|AE001338.1:c6759-5578,
ATGAAAAAATCTTGAATCGGTATTAGTATTTGCCGCTTTGAGTTCTGCTTCTCTTGAAGCTCTGC
CTGTGGGGAACTCTGCTGAACCAAGCCTTATGATCGACGGAATTCTGTGGGAAGGTTTCGGCGGAGATCC
TTGCGATCCTTGCGCCACTTGGTGTGACGCTATCAGCATGCGTGTGGTTACTACGGAGACTTTGTTTTT
15 GACCGTGTTTTGAAGAACTGATGTGAATAAAGAAATTCAGATGGGTGCCAAGCCTACAACCTGATACAGGCA
ATAGTGCAGCTCCATCCACTCTTACAGCAAGAGAGAATCCTGCTTACGGCCGACATATGCAGGATGCTGA
GATGTTTACAAATGCCGCTTGCATGGCATTGAATATTTGGGATCGTTTGTATGTATTCTGTACATTAGGA
GCCACCACTGGATATCTTAAAGGAACTCTGCTTCTTTCAATTTAGTTGGATTGTTGGAGATAAGTAAA
ATCAAAAAACGGTCAAAGCGGAGTCTGTACCAAATATGAGCTTTGATCAATCTGTTGTTGAGTTGTATAC
20 AGATACTACTTTTGGTGGAGCGTCCGCGCTCCGCGCAGCTTTGTGGGAATGTGGATGTGCAACTTTAGGA
GCTTCACTCAATATGCTCAATCTAAACCTAAAGTAGAAGAATTAACCGTTCTCTGCAATGCAGCAGAGT
TTACTATTAAATAAACCTAAAGGGTATGTAGGTAAGGAGTTTCTCTTGTATCTTACAGCAGGAACAGATGC
TGCGACAGGAATAAGGATGCCTCTATTGATTACCATGAATGGCAAGCAAGTTTAGCTCTCTTACAGA
CTGAATATGTTCACTCCCTACATTGGAGTTAAATGGTCTCGAGCAAGCTTTGATGCCGATACGATTTCGTA
25 TAGCCAGCCAAAATCAGCTACAGCTATTTTTGTACTACCACGCTTAACCCAACTATTGCTGGAGCTGG
CGATGTGAAAATCTTGCAGTATTGCAGTAGGAACAACCTATTGTGGATGCAGACAAATACGCAGTTA
ATGAAATCTAGAAAATCTTGCAGTATTGCAGTAGGAACAACCTATTGTGGATGCAGACAAATACGCAGTTA
CAGTTGAGACTCGCTTGATCGATGAGAGAGCAGCTCACGTAAATGCACAATTCGCTTCTAA
- 30 >gi|3328987|gb|AAC68150.1| hypothetical protein [Chlamydia trachomatis]
MLKMFVNLNLSVFFSLLLSACGYTVLSPHYVEKKFSLSEGIYVCPIEGDSLGLVSSLSYELEKRLHTRS
QGTSSGYVLKVSFLNETDENIGFAYTPQKPDEKPKVHFIVSNEGRLLSAKVQLIKNRTQEILVEKCLRK
SVTFDFQPDILGTANAHQLALGQFEMHNEAIKSASRILYSQLAETIVQQVYYDLF
- 35 >gi|3328980|gb|AE001325.1:10880-11464,
ATGCTGAAAATGTTTTGGTTGAATAGCCTCGTTTTCTTCTCGTTACTACTATCAGCCTGCGGCTATACAG
TGCTCTCCCCCACTATGTAGAAAAGAAATTTCTCGCTTTCCGAAGGCATCTATGTCTGCCCTATCGAAGG
AGATTCACTAGGAGATCTCGTATCTCTCTTTCTTACGAATTAGAAAAGCGAGGACTCCACACACGACTCT
CAAGGAACCTCTTCTGTTATGTACTCAAAGTCTCTCTTTTCAATGAGACTGATGAAAATATTGGATTTCG
40 CATACACTCCCCAAAACCTGATGAAAACCTGTAAACACTTCATTGTCTCTAATGAAGGGCGCTTAGC
GTTATCAGCAAAAAGTCCAACTAATCAAAAACCGCACACAAGAAATATTAGTGAGAAATGCCTGAGAAAA
TCGGTTACTTTTGAATTTTCAACCTGACCTCGGAACCGCAATGCTCATCAGCTAGCTCTCGGACAATTTG
AAATGCATAATGAAGCAATAAAAAGCGCTTCTCGTATATTGTATTTCGCAATTAGCAGAGACTATTGTACA
45 ACAGGTATACTATGACCTTTTCTGA
- >gi|3328972|gb|AAC68136.1| Apolipoprotein N-Acetyltransferase [Chlamydia trachomatis]
- 50 MFKLVSYIILSWVLVCLAQPDVSVVASVVCICGYSLLWAGLFALVEQLSWKKVWCIAFIWTWTVEGAHF
SWMLEDLVVGTSIYFVWGILLSYLATLFASFSLVWCCRKQYRGALVWLPVWVAIEAIRYYGLLSGVS
FDFIGWPLTATAYGRQFGSFFGWAGQSFLVIAANICCFVCLLKHSFSKGLWLTLCAFPYLLGGAHYEYL
KKHFSDESVLRVAIVQPGYSPPHMHAGRTASAIWRGLVSLCQTIQTPVDVIVFPEVSVFGLHRQAYTLHE
NQPVLLESLLPNKSWGEFFTNLDWIQAIAERYQCTVIMGMERWENKGGILHLYNAECVSREGEITSYDKR
ILVPGGEYIPGGKIGFSLCQTFPFEPALPFQRLPGEFSGVVNITERIKAGISICYEETFGYAIRPYKRQQ
55 ADILVNLNDNGWYPRSRPLVHFYHGMRLRNQELGIPCIACRTGVSAAVDSLGRIVGILPWESRTCPVST
GVLQVSVPLYSYHTVYARLGDAPLLLIIVCSVIGALAYFYRKKKETPPQTF
- >gi|3328966|gb|AE001324.1:c6152-4524,
GTGTTTAACTTGTGTCATACATCATCTTTCTTGGGTGCTGGTCTGTTTGGCTCAGCCGGATGTAAGTG
TTGTAGCTTCTGTTGTAGTTGTATTGCGGTTACAGCTTACTTTGGGCTGGGCTTTTTGCTTTAGTAGA
60 GCAATTATCTTGGAGAAAGTTTGGTGCATCGCTTTTATTGACTGGACTGTGCAAGGCGCTCATTTC
CTTGGATGCTTGAAGATCTTTATGTAGGGACAAGCATCTATTTTGGTTGGGGTATACTGCTTTCTTATC
TCGCCACCTATTGCTAGTTTTCTTGTGTTGGTGTGTTGGTGTGTCGCAAGCAATATAGGGGAGCTCT
TGTTTGGCTTCCAGGGGTTTGGGTGGCGATAGAAGCAATACGCTATTATGGGTTGCTTTCAGGAGTTTCT
TTTGATTTTATTGGCTGGCCTCTTACAGCGACAGCCTATGGCCGGCAATTCCGGCAGCTTTTTTGGATGGG
65 CTGGACAAAGCTTTCTAGTTATTGCTGCCAATATATGCTGTTTTGCAAGTATGTTTATTAACACTCTTT
TTCCAAAGGTTTGTGTTGACGTTGTGCGCTTCCCTTATCTGTTAGGCGGAGCGCATTACGAATACCTA

AAGAAGCATTTTTCGACTCTGAAGTGCTTCGAGTTGCCATCGTGCAGCCTGGATATAGTCTCATATGC
ATGCAGGGAGGACGGCTAGTGCATTTTGGAGAGGTTTGGTTTCTTTGTGCCAGACTATTCAAACCTCCTGT
AGATGTGATCGTTTCCCAGAAAGTAAGTGTTCCTTTTGGCTTACATAGACAAGCCTATACTCTTCATGAA
AATCAGCCTGTATTAGAAAGTTTGTCTCCTAACAAATCTTGGGGCGAGTTTTCACAAATTTGGATTGGA
5 TCCAAGCGATAGCTGAACGTTATCAATGCACCGTTATCATGGGAATGGAACGATGGGAAAAAAGGGGG
AATACTGCATTTGTATAATGCTGCTGAATGCGTATCGCGAGAAGGGGAAATAACTAGCTATGATAAGCGG
ATTCTTGTTCCTGGAGGTGAGTACATCCCTGGAGGGAAAAATAGGTTTTCCTTGTGTCAAACCTTTTTCC
CAGAATTTGCTCTTCCCTTTCAACGTTTGGCAGGAGAGTTTCTGGAGTTGTGAATATAACAGAGCGAAT
AAAAGCTGGGATCTCTATTGTTTATGAGGAGACATTTGGGTATGCAATTCGCCCTTACAAAAGGCAACAA
10 GCCGATATTTTAGTAAATCTTACTAATGACCGTTGGTATCCGCGTTCAAGGCTGCCTCTAGTACATTTT
ATCATGGCATGTTACGTAATCAAGAGTTGGGTATACCTTGTATTGCGCGCTGTGCGCAGGAGTTTCTGCG
TGCAGTGGATTCTTTGGGTAGAATTGTGCGGCATACTTCCCTGGGAATCGAGAACTTGGCCAGTTTCTACA
GGAGTACTCCAAGTTTCCGTCCTCTTTACAGTTATCATACTGTATATGCAAGGCTGGGTGATGCTCCTC
TGTTACTGATTGCAGTTTGTTCGGTTATCGGAGCGATTGCCTATTTTATAGGAAAAAGAGACCCC
15 ACCACAAACATTTTTTTGA

>gi|3328612|gb|AAC67797.1| Fructose-6-P Phosphotransferase [Chlamydia
trachomatis]
20 MSSNKHASLCQKTPSLCRELQKAPALLLTEDIRFKALLNERIDSVAELFPCTYNPSYKYFISKSDLSAET
SPLKVGVMLSGGPAPGGHNVILGLLHSIKKLHPNSQLLGFIRNGEGLLNNTVEITDEFIEEFNRSGGFN
CIGTGRNIIITEENKARCLQTANELDLGLVIGGDGSENTATAILAEYFAKHQAKTVLVGVPKTIDGLQ
HLFLDLTFGFDATKIFYSSIIISNISRDALSCGHYHFIKLMGRSSSHITLECALQTHPNIALIGEETAEK
SISLETLIHIDICETIADRAAMGKYHGVILIPGVEIFPIEQSLVKBIESIPEQENLYQALSLSSQQLLC
25 QFPEDICHQLLYNRDAHGNVYVSKISVDKLLIHLVRQHLETHFRQVPFNAISHFLGYEGRSPTPTFDNV
YSYNLGYGAGVLVFNRCNGYLSTIEGLTSPIEKWRLRALPIVRMLTTKQKDSKHYPLIKRLVDIASPV
FNKFSLYRKIWALEDYSYRVGPLQIHSPEDAHSDFFPLILFLNHNNEWQKRCISICLEIPDQDY
>gi|3328609|gb|AE001294.1:2452-4113,
ATGTCGTCGAATAAACATGCTTCTCTTTGTCAAAGACGCCTTCTTTGTGTGCGGAGCTTCAAAAAGCTC
30 CTGCTCTTCTATTAAACAGAAGACATAAGGTTTAAAGCTCTTCTTAATGAACGCATGACTCTGTTGCAGA
ACTATTTCCATGCACTTATACTCTCCCTACTACAAATTTATTTGCAAGTCCGATCTTTCGCTGAGACC
TCTCCCTTAAAGTGGGCGTTATGCTTTCTGGAGGCCAGCTCCTGGTGCGCAATGTCATCTTAGGAT
TGCTACACAGTATTAAAAAGCTCCATCCGAATAGTCAGCTTTTAGGATTTATTCGCAATGGAGAAGGACT
TCTCAATAATAACTGTAGAAATCACAGATGAATTCATTGAAGAGTTTCGTAACCTCTGGAGGCTTTAAT
35 TGCATAGGAACAGGTCGCACTAATATCATAACCGAAGAAAAATAAGCGCGCTGTTACAAACAGCAAATG
AACTCGATTTAGATGGATTAGTGATTATTGGAGGCGATGGTTCCAATACAGCCACGGCGATTCTTGCTGA
ATATTTTGCTAAGCATCAAGCAAAAACGGTATTAGTTGGTGTTCCTCCAAACTATTGATGGAGATTGCGAG
CACCTATTTTAGACCTCACATTTGGGTTTGATACTGCTACTAAATTTTATTCATCCATCATCAGCAACA
TTTCTAGAGACGCATTATCGTGTAAGGCCACTATCATTATTATAAATAATGGGCCGGTCTTCTTCTCA
40 TATCACGCTAGAATGCGCACTACAGACTCACCCAAATATTGCTCTTATAGGCCGAAGAGATTGCAGAAAAA
AGCATCTCCTTAGAAACATTAATCCATGATATTGTGAAACAATAGCAGATCGAGCTGCTATGGGGAAAT
ACCATGGCGTTATTCTCATCCCTGAAGGAGTCAATTGAGTTTATTCTGAAATACAGTCTCTGTTAAAGA
AATTGAATCCATTCCAGAGCAGGAGAATCTTACCAAGCTTTATCCTTATCTTCTCAGCACTTTTATGC
CAATTTCCGGAAGATATTGCCATCAGCTCTTGATATAATAGAGATGCTCATGGCAACGCTATGTATCAA
45 AAATTAGTGTGATAAACTTCTGATTCTAGTTCTGTCACATTTAGAAACACATTTTAGACAAGTTCC
CTTCAATGCAATCTCCATTTTATAGTTATGAAGGCGTTTCAAGAACTCTTACACATTTTGATAATGTG
TATAGCTATAACTTAGGATATGGTGTGCGGTTCTCGTTTAAACCGCTGTAATGGGTATTATCCACGA
TCGAAGGTCTAACTAGCCCTATTGAAAAATGGCGATTGCGCGCTTTACCCATTGTTTGAATGTTGACGAC
CAAGCAGGGGAAAGACAGTAAACATTATCCTCTGATAAAAAAAGATTGGTAGATATTGCTAGTCTCTGTT
50 TTTAATAAGTTCTCACTGTATCGGAAAACTGGGCTTTAGAAGACTCCTATCGCTTTGTAGGGCCATTAC
AAATACATTCTCCGAGGATGCTCATTCTGATGATTTTCTCTCTTAATTTTGTATTTTGAATCATAATGA
ATGGCAAAAACGCTGTTCTATTGTTTAGAAATCCCCGATCAGGATTATTAA

55 >gi|3328517|gb|AAC67709.1| hypothetical protein [Chlamydia trachomatis]
MICCDKVLSSVQSMVIDKCSVTKCLQTAKQAAVLALSLFAVFASGSLSILSAAVLFSGTAAVLPYLLIL
TTALLGFVCAVIVLLRNL SAVVQSCKKRSPEEIEGAARPSDQESGGRLSEESASPQASPTSSTFGLESA
LRSIGDSVSGAFDDINKDNRSRSHSF
60 >gi|3328516|gb|AE001286.1:75-578,
ATGATCTGCTGTGACAAAGTCTTGTGAGCGTACAATCAATGCCTGTTATAGATAAATGCTCTGTAACGA
AATGCTTACAAACGGCTAAGCAAGCAGCTGTTCTTGGCTTGTCTTTGTTTGGCGGTGTTGCTTCAGGAAG
TTTATCCATATTATCAGCGGCGGTACTGTTTAGTGGCACTGCTGCTGTTCTTCCATATCTGCTGATATTA
ACAACAGCTCTTCTAGGATTTGTTTGTGCTGTTATGTGCTTTTAAGAAATTTATCAGCAGTTGTTTCA
65 GTTGTA AAAAGAGATCACCTGAAGAAATGAAGGGGCTGCTCGTCCCTCTGATCAGCAGGAATCAGGAGG
ACGTTTGTCCGAGGAGAGCGCTTACCACAAGCATCTCTACTTCGTCTACTTTTGGTCTTGAATCCGCT

TTGCGCTCAATAGGAGATA

>gi|3328482|gb|AAC67677.1| L28 Ribosomal Protein [Chlamydia trachomatis]
 MSKKCALTGRKPRRGYSYAIRGISKKKKIGLKVGTGRTRFFPNMMTKRLWSTEENRFLKLKISAAALR
 5 LVDKLGLDQVVARAKSKGF
 >gi|3328480|gb|AE001283.1:c2251-1982,
 ATGTCGAAAAAATGTGCGCTTACAGGAAGAAAGCCTCGTCGCGTTATAGCTATGCTATCCGAGGGATT
 CTAAGAAAGAAAAAGGGATCGGTTTGAAGTTACAGGAAGAACAAACGTCGATTCTTCCCTAATATGAT
 10 GACTAAGAGACTATGGTCTACTGAGGAAAAATCGCTTCTCAAACCTCAAATTTCTGCAGCAGCTTTACGC
 CTTGTTGATAAACTAGGGTTAGATCAGGTTGTTGCTAGAGCTAAAAGCAAGGGTTTTTAG

>gi|3328436|gb|AAC67635.1| SS DNA Binding Protein [Chlamydia trachomatis]
 MLFGYLVGFLAADPEERMTSGGKRVVLRLLGVKSRVGSKDETVWCRCNIWNNRYDKMLPYLKKGSSVIVA
 15 GELSLESYVGRDGPQASISVSVDTLKFNSGSSRPDARGSDGQRANDNVSIGFDGESLDTDSALDKEV
 YAGFGEDQQYASEDVFP
 >gi|3328434|gb|AE001279.1:1060-1533,
 ATGTTGTTTCGGATATTTGGTAGGATTTCTAGCTGCCGATCCTGAAGAAAGAATGACATCCGGAGGTAAAC
 GGGTTGTTGTTTTACGTTTGGGTGTAAATCTCGTGTAGGATCTAAAGATGAAACAGTGTGGTGCAGATG
 20 CAATATCTGGAACAACCGTTATGATAAGATGCTTCTTATTTGAAGAAAGGTTCTTCAGTCATTGTTGCT
 GGAGAGCTTTCTTTAGAAAGCTATGTAGGTAGAGACGGTTCTCCACAAGCTTCTATTTCTGTAAGCGTAG
 ATACATTAAAATTTAATTCGGATCTTCTCGTCTGATGCTAGAGGTTTCAGATGAAGGTCGTGAGAGAGC
 TAATGATAATGCTCTATTTGGATTTGATGGAGAAAGTTTAGATACAGACTCTGCGCTTGATAAGGAAGTC
 25 TATGCAGGGTTTGGAGAAGACCAACAGTATGCTAGTGAAGATGTTCTTTTTTAG

>gi|3328411|gb|AAC67611.1| hypothetical protein [Chlamydia trachomatis]
 MKKQEKMHQPONLLKVFIFFLAFFISYPSAEHSPLOSSIQEKILTARPGDYAVLSRGSQKFFFLIRQSSS
 EATWVEMSEFASLTQOEKLVQSSWKNFHLQSSKKVYLLRISKNPMLIFVLKNAQWMLSEKDPLPF
 30 FVKILRLPLSPAPSHLIKYGKERTPWSRPTSLNGELITLPSSAWISVWPKDSSPLSEKNILYFSNNER
 LAFFLWTSIDTPTGTVIKTIEMGHQAASSYPALPNF
 >gi|3522886|gb|AE001277.1:c6191-5448,
 ATGAAAAAGCAAGAAAAATGCACCCTCAAAACCTTCTTAAAGTTTTTATTTTTTTCTTGGCATTTTTTCA
 TATCCTATCCCTCGGCTGAAGCCCATCTCCTCTCCAATCATCAATCCAAGAAAAAATCTAACTGCCCG
 35 CCCCCGAGACTATGCCGCTTAAGCCGAGGATCTCAAAAATTTTTCTTTTAAATTCGCCAAAGTTCTTCG
 GAAGCGACTTGGGTGCAATGTCTGAATTTGCTTCCCTAACACAGCAAGAAAAAATAGTAGAACAGT
 CTTCCTGGAAGAATGCCCTCCATCAACTCCAATCTTCAAAAAAGTGTAAGTTGTTACGAATTTCAAAAA
 TCCTCTTATGATTTTTGTTCTCAAAAATGCCAATGCCTCTCTCAGAAAAAGATCCTTTGCCTTTT
 40 TTTGTAATAATCCTTCGACTCCCTTTATCTCCAGCCCTCTCACTTAATTAATACAAAGGGAAGAAC
 GCACCCCTGGTCTCCGCAACATCTTTGAATGGAGAAGTCTAACCCTTCTTCCAGTGCTTGGATTTT
 TGTTTGGCCAAAAGATTCTTCTCTCTATCAGAAAAAATATTCTCATATATTTTTCTAACAATGAACGT
 TTAGCGTTTCTCTATGGACTAGTATTGATACTCCTACAGGGACAGTGATTATTAAGACTATTGAAATGC
 GGCACCAAGCCGCTCCTCTATCCAGCTCTTCCCAATTTCTAG

45 **crpA, CHLTR 15 kD cysteine-rich protein (Chlamydia trachomatis serovar D (D/UW-3/Cx))**

DNA sequence
 50 AATATGAGCACTGTACCCGTTGTTCAAGGAGCTGGATCTTCCAATTCGGCACAGGATATTTCCACTAGA
 CCAATTAACACTGAAAGAGCGTATATCGAATCTTCTATCTTCCACTGCATTTAAGGTGGGATTAGTGGTG
 ATAGGACTACTTTTAGTGATTGCTACTTTGATATTCCTAGTTTCGGCAGCTTCGTTTGTAAATGCCATC
 TATCTAGTAGCTATTTCTGCTATTTTGGGATGCGTGAATATCTGCGTAGGAATTTTATCCATGGAAGGA
 CACTGTTCTCCGAGAGATGGATCTTATGTAAGAAGGTATTAAAGACTTCAGAAGATATCATCGATGAT
 55 GGGCAGATAAACAACCTCTAATAAAGTGTCTTACTGATGAGAGGTTGAATGCCATAGGTGGGTAGTGGAA
 TCTCTATCTAGAAGAAATAGTCTGGTGGATCAGACCAATGA

translated amino acid sequence
 NMS TVPVVQAGS SNSAQDISTR PLTLKERISN LLSSTAFKVG
 60 LVVIGLLLVI ATLIFLVSA SFINAIYLV IPAILGCVNI CVGILSMEGH
 CSPERWILCK KVLKTSEDI DDGQINNSNK VFTDERLNAI GGVVESLSRR
 NSLVDQTQ*

65 **OmcA, CHLTR 9 kD cystein-rich outer membrane complex lipoprotein (Chlamydia trachomatis serovar D (D/UW-3/Cx))**
DNA sequence

SUBSTITUTE SHEET (RULE 26)

5 GGGCTAGTTTCTTTTATTGTTAAAAAGAATTGCTTTTATCGATAAAAGAACTTCAAGAGCCCTTTTCTAGAAAGGAGTCT
 GGAAGTTATGAAAAAACTGCTTTACTCGCTGCTTTATGTAGTGTGTTCCTTAAGTAGTTGTGTCGTATCGTTGACT
 TTTGCTTCGAAGATCCATGCGCACCTATCCAATGTTACCTTGTGAATCTAAGAAGAAAGACGTAGACGGTGGTTGCAAC
 TCTTGTAAACGGGTATGTCCAGCTTGCAAACCTTGCGGAGGGGATACGCACCAAGATGCTAAACATGGCCCTCAAGCTAG
 AGGAATTCCAGTTGACGGCAAATGCAGACAATAG

10 Translated amino acid sequence

15 GL VSFIVKRIAF IDKRNFKSPF
 LERSLEVMMKK TALLAALCSV VLSGCCRV DCCFEDPCAP IQCSPCESKK
 KDVDGGCNSC NGYVPACKPC GGDTHQDAKH GPQARGIPVD GKCRQ*

20 cutE, apolipoprotein N-acyltransferase (*Chlamydia trachomatis* serovar D (D/UW-3/Cx))

DNA sequence

25 GCTAGTAAGGGAGCCCTTTAGTGTTTAACTTGTGTCATACATCCTTTCTTGGGTGCTGGTCTGTTTGGCTCAGCC
 GGATGTAAAGTGTGTAGCTTCTGTTGTAGTTGTATTGCGGTTACAGCTTACTTTGGGCTGGGCTTTTTCCTTAGTAG
 AGCAATTATCTTGGAAAGAAAGTTTGGTGCATCGCTTTTATTTGGACTTGGACTGTGCAAGGCGCTCATTTCTCTGGATG
 CTGGAAGATCTTTATGTAGGGACAAGCATCTATTTTGTGTTGGGATACTGCTTTCTTATCTCGCCACCCTATTTGCTAG
 TTTTCTTGTTTGGTTGTGTGGTGTGTCGCAAGCAATATAGGGGAGCTCTTGTTTGGCTTCCAGGGGTTTGGGTGGCGA
 TAGAAGCAATACGCTATTATGGGTGCTTTCAGGAGTTCTTTTGATTTTATTGGCTGGCCTCTTACAGCGACAGCCTAT
 GGCCGGCAATTCGGCAGCTTTTGGATGGGCTGGCAAAAGCTTCTAGTTATGTCTGCCAATATATGCTGTTTTCAGT
 30 ATGTTTATTTAAACACTCTTTTCCAAAGGTTGTGGTTGACGTTGTGCGCGTTCCTTATCTGTTAGGCGGAGCGCATT
 ACGAATACCTAAAGAAGCATTTTCCGACTCTGAAGTCTTCGAGTTGCCATCGTGCAGCCTGGATATAGTCCTCATATG
 CATGCAGGGAGGACGGCTAGTGCTATTTGGAGAGGTTTGGTTCTTTGTGCCAGACTATTCAAACCTCTGTAGATGTGAT
 CGTTTTCCCAAGAGTAAGTGTTCTTTTGGCTTACATAGACAAGCCTATACTCTTCATGAAAATCAGCCTGTATTAGAAA
 GTTTGCTTCTAACAAATCTTGGGGCGAGTTTTCACAAATTTGGATTGGATCCAAGCGATAGCTGAACGTTATCAATGC
 35 ACCGTTATCATGGGAATGGAACGATGGGAAAATAAAGGGGAATACTGCATTGTATAATGCTGCTGAATGCGTATCGCG
 AGAAGGGGAAATAACTAGCTATGATAAGCGGATTCTGTTCCTGGAGGTGAGTACATCCCTGGAGGGAAAAATAGGTTTTT
 CCTTGTGTCAAACCTTTTCCAGAAATTTGCTCTTCCCTTTCAACGTTTGCCAGGAGAGTTTCTGGAGTTGTGAATATA
 ACAGAGCGAAATAAAGCTGGGATCTCTATTGTTATGAGGAGACATTGGGTATGCAATTCGCCCTTACAAAAGGCAACA
 AGCCGATATTTAGTAAATCTTACTAATGACGGTTGGTATCCGCGTTCAAGGCTGCCCTAGTACATTTTATCATGGCA
 40 TGTTACGTAATCAAGAGTTGGGTATACCTTGTATTGCGCGCTGTGCGACAGGAGTTTCTGCTGCACTGGATTCTTTGGGT
 AGAATTGTGCGCATACTTCCCTGGGAATCGGAACTTGCCAGTTTCTACAGGAGTACTCCAAGTTTCCGTCCTCTTTA
 CAGTTATCATCTGTATATGCAAGGCTGGGTGATGCTCCTCTGTTACTGATTGCAGTTTGTTCGGTTATCGGAGCGATTG
 CCTATTTTATAGGAAAAAGAAAGAGACCCACCACAAACATTTTTTTGA

45 Translated amino acid sequence

50 APLVFKLVSY ILSWVLVCL AQPDSVSVAS VVSCICGYSL LWAGLFALVE
 QLSWKVWCCI AFITWTWTV EG AHFSWML EDL YVGTSYFVW GILLSYLATL
 FASFSCLVWV CCRKQYRGAL VWLPGVWVAI EAIRYYGLS GVSFDFIGWP
 LTATAYGRQF GSFFGWAGQS FLVIAANICC FAVCLLKHSF SKGLWLTLC
 FPYLLGGAHY EYLKHFSDS EVLRVAIVQP GYSPHMHAGR TASAIWRGLV
 55 SLCQTIQTPV DIVVFPEVSV PFGLHRQAYT LHENQPVLES LLPNKS WGEF
 FTNLDWIAI AERYQCTVIM GMERWENKGG ILHLYNAAEC VSREGEITSY
 DKRILVPGGE YIPGGKIGFS LCQTFPEFA LPFQRLPGEF SGVNVITERI
 KAGISICYEE TFGYAIRPYK RQQADILVNL TNDGWYPRSR LPLVHFYHGM
 LRNQLGIPC IRACRTGVSA AVDSLGRIVG ILPWESRTCP VSTGVLQVSV
 60 PLYSYHTVYA RLGDAPILLI AVCSVIGALA YFYRKKKETP PQTF*

pal, peptidoglycan-associated lipoprotein (*Chlamydia trachomatis* serovar D (D/UW-3/Cx))

65 DNA sequence

70 G AAAATTGTTA TAGGATCAGG
 AGAGAAACGT TTCCCATGCT GGGGAGCATT TCCTTCACAA CATATAAGA
 AAACCTCATG AGAAAGACTA TTTTAAAGC GTTTAATTTA TTATTCTCCC
 TTCTTTTCT TTCTTCATGC TCTTATCCTT CGAGAGATTG GGAATGCCAT
 GGTTCGCACT CCGCAAGACC TCGTAAATCC TCTTTGGAT TCGTACCTTT
 CTACTCCGAT GAAGAAATTC AACAGCTTT TGTGAAGAT TTTGATTCCA
 AAGAAAGACA GCTGTACAAA ACGAGCGCAC AGAGTACCTC TTTCCGAAAT
 ATCACTTTTC CTACAGATAG TTATTCTATT AAAGGAGAGG ATAACCTCAC
 GATTCTTGCA AGCTTAGTTC GTCATTGCA TAAATCTCCT AAAGCTACGC

TATATATAGA GGGCCATACA GATGAACGTG GAGCTGCAGC TTATAACCTA
 GCTTTAGGAG CTCGTCGTGC GAATGCTGTA AAACAATACC TCATCAAACA
 GGGAAATCGCT GCAGACCGCT TATCACTAT TTCTTACGGA AAAGAACATC
 5 CTGTTATCC AGGCCATAAT GAATTAGCTT GGCAACAAAA TCGTCGTACT
 GAATTTAAGA TCCATGCTCG CTA

Translated amino acid sequence

10 RETFPMGLSI SFTTYKENLM RKTIFKAFNL LFSLLFLSSC SYPCRDWECH
 GCD SARPRKS SFGFVPFYSD EEIQAFVED FDSKEEQLYK TSAQSTSFRN
 ITFATDSYSI KGEDNLILA SLVRHLHKSP KATLYTEGHT DERGAAAYNL
 15 ALGARRANAV KQYLIKQGIA ADRLFTISYG KEHPVHPGHN ELAWQQRNRRT
 EFKIHAR*

The following *Chlamydia trachomatis* outer membrane proteins (full sequences
 20 above) are disclosed for the first time as being useful in a *C. trachomatis* vaccine. A
 vaccine comprising one or more of these proteins (or native or functional analogues
 thereof) is a further aspect of this invention (particularly in the context of being
 presented on the surface of a bleb).

25 Amino acid sequences:

>gi|6578118|gb|AAC68456.2| predicted Protease containing IRBP and DHR domains [Chlamydia trachomatis]
 >gi|6578109|gb|AAC68227.2| CHLPN 76kDa Homolog [Chlamydia trachomatis]
 >gi|3328866|gb|AAC68034.1| Sulfite Reductase [Chlamydia trachomatis]
 30 >gi|3328815|gb|AAC67986.1| hypothetical protein [Chlamydia trachomatis]
 >gi|3328587|gb|AAC67774.1| CMP-2-keto-3-deoxyoctulosonic acid synthetase [Chlamydia trachomatis]
 >gi|3329039|gb|AAC68197.1| Thio:disulfide Interchange Protein [Chlamydia trachomatis]
 >gi|3329000|gb|AAC68161.1| Yop proteins translocation lipoprotein J [Chlamydia trachomatis]
 >gi|3328905|gb|AAC68071.1| hypothetical protein [Chlamydia trachomatis]
 35 >gi|3328884|gb|AAC68051.1| Phosphatidate Cytidyltransferase [Chlamydia trachomatis]
 >gi|3328855|gb|AAC68022.1| hypothetical protein [Chlamydia trachomatis]
 >gi|3328772|gb|AAC67946.1| hypothetical protein [Chlamydia trachomatis]
 >gi|3328763|gb|AAC67938.1| O-Sialoglycoprotein Endopeptidase family [Chlamydia trachomatis]
 >gi|6578102|gb|AAC67897.2| ATP Synthase Subunit K [Chlamydia trachomatis]
 40 >gi|3329252|gb|AAC68382.1| S14 Ribosomal Protein [Chlamydia trachomatis]
 >gi|3328987|gb|AAC68150.1| hypothetical protein [Chlamydia trachomatis]
 >gi|3328972|gb|AAC68136.1| Apolipoprotein N-Acetyltransferase [Chlamydia trachomatis]
 >gi|3328612|gb|AAC67797.1| Fructose-6-P Phosphotransferase [Chlamydia trachomatis]
 >gi|3328517|gb|AAC67709.1| hypothetical protein [Chlamydia trachomatis]
 45 >gi|3328482|gb|AAC67677.1| L28 Ribosomal Protein [Chlamydia trachomatis]
 >gi|3328436|gb|AAC67635.1| SS DNA Binding Protein [Chlamydia trachomatis]
 >gi|3328411|gb|AAC67611.1| hypothetical protein [Chlamydia trachomatis]

50 Again, when such blebs are present in a vaccine formulation they may be more
 protective against *Chlamydia trachomatis* infection than the use of the protein in
 isolation.

Particularly beneficial pairs of *Chlamydia trachomatis* antigens are further preferred embodiments of this invention. Thus in a further aspect a Gram-negative bleb (preferably from gonococcus) is provided presenting on its surface both the PorB and PmpG outer membrane proteins from *Chlamydia trachomatis*. Furthermore, a
5 Gram-negative bleb (preferably from gonococcus) is provided presenting on its surface both the PorB and MOMP (from one or more serovars) outer membrane proteins from *Chlamydia trachomatis*. Lastly, a Gram-negative bleb (preferably from gonococcus) is provided presenting on its surface both the PmpG and MOMP (from one or more serovars) outer membrane proteins from *Chlamydia trachomatis*.

10 By MOMP (or OMP1 or OMP I) from one or more (1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more) serovars it is preferred that one or more should be selected from a list serovars consisting of: B, Ba, D, Da, E, L1, L2, L2a, F, G, K, L3, A, C, H, I, Ia, & J; more preferably from a list consisting of D, E, F, G, K, H, I, & J. Most preferably one or more MOMPs should at least comprise MOMP from serovar D or E (most
15 preferably D). A further preferred strategy is the selection of one or more MOMP from each of the following 3 serogroups: B-serogroup (consisting of serovars B, Ba, D, Da, E, L1, L2 and L2a, and preferably selected from serovars D, Da, & E); F-G-serogroup (consisting of serovars F and G); and C-serogroup (consisting of servars A, C, H, I, Ia, J, K, and L3, and preferably selected from serovars H, I, Ia, J and K).

20 Most preferably the genes for the *Chlamydia trachomatis* antigens should be inserted at the PorA locus of *Neisseria* (preferably gonococcus).

Such a preparation formulated as a vaccine may give enhanced protection to a host against *Chlamydia trachomatis* than when a single antigen is administered.

Preferably the bleb has been derived from a strain (preferably gonococcus)
25 which has been modified to upregulate one or more protective outer membrane antigens (as described below).

Preferably the bleb has been derived from a strain (preferably gonococcus) which has been modified to downregulate one or more immunodominant variable or non-protective outer membrane antigens (as described below).

30 Preferably the blebs are derived from a strain (preferably gonococcus) which has a detoxified lipid A portion of bacterial LPS, due to the strain having been engineered to reduce or switch off expression of one or more genes which cause LPS

to be toxic (preferably selected from the following genes, or homologues thereof htrB, msbB and lpxK; see section below).

Preferably the blebs are derived from a strain (preferably gonococcus) which has a detoxified lipid A portion of bacterial LPS, due to the strain having been engineered to express at a higher level of one or more genes producing a gene product that is capable of detoxifying LPS (preferably selected from the following genes, or homologues thereof: pmrA, pmrB, pmrE and pmrF; see section below).

Vaccine compositions comprising the bleb of the invention and a pharmaceutically suitable excipient or carrier is also envisaged. Preferably the vaccine additionally comprises a mucosal adjuvant. Mucosal adjuvants are well known in the art (see Vaccine Design "The subunit and adjuvant approach" (eds Powell M.F. & Newman M.J.) (1995) Plenum Press New York). A preferred mucosal adjuvant is LT2 (or LTII, which can be split into LTIIa and LTIIb – see Martin et al. Infection and Immunity, 2000, 68:281-287). Preferably such vaccines should be formulated and administered as described below in "vaccine formulations".

The content of blebs per dose in the vaccine will typically be in the range 1-100µg, preferably 5-50µg, most typically in the range 5 - 25µg.

Optimal amounts of components for a particular vaccine can be ascertained by standard studies involving observation of appropriate immune responses in subjects. Following an initial vaccination, subjects may receive one or several booster immunisations adequately spaced.

A method of preventing *Chlamydia trachomatis* infection in a host is also provided comprising the steps of administering an effective amount of the above vaccine to a host in need thereof. Preferably the vaccine is mucosally administered via either a intranasal, oral, intradermal or intravaginal route.

Chlamydia pneumoniae antigens integrated into a Gram negative bacterial bleb

In a further aspect, the invention provides a Gram-negative bleb presenting on its surface a protective antigen from *Chlamydia pneumoniae*. *Neisseria meningitidis*, *Moraxella catharralis*, and *Haemophilus influenzae* are preferred species for the

production of said bleb. A bacterial strain capable of producing such a bleb is a further aspect of the invention. Such protective antigens are preferably one or more of those listed below:

5 1) Cell Envelope: Membrane Proteins, Lipoproteins and Porins

	Gene:	Protein Function:
10	yaeT	OMP85 homolog
	60IM	60 kD inner membrane protein
	lgt	prolipoprotein diacylglycerol transferase
	crpA	CHLTR 15 kD cysteine-rich protein
15	omcB	60 kD cysteine-rich outer membrane complex protein
	omcA	9 kD cysteine-rich outer membrane complex lipoprotein
	cutE	apolipoprotein N-acetyltransferase
	ompA	major outer membrane protein
	pal	peptidoglycan-associated lipoprotein
20	porB	outer membrane protein analog

2) Coding Genes (Not in *C. trachomatis*)

25	Gene:	Protein Function:
	yqfF	conserved hypothetical inner membrane protein
	yxjG	hypothetical protein
	guaA	GMP synthase
	guaB	inosine 5'-monophosphate dehydrogenase
30	argR	similarity to arginine repressor
	CPn0232	similarity to 5'-methylthioadenosine nucleosidase
	CPn0251	conserved hypothetical protein
	CPn0278	conserved outer membrane lipoprotein protein/a>
	CPn0279	possible ABC transporter permease
35	yxjG	hypothetical protein
	yqeV	hypothetical protein
	CPn0486	hypothetical proline permease
	CPn0505	3-methyladenine DNA glycosylase
	CPn0562	CHLPS 43 kDa protein
40	CPn0585	similarity to CHLPS IncA
	yvyD	conserved hypothetical protein
	CPn0608	uridine 5'-monophosphate synthase
	CPn0735	uridine kinase
	CPn0907	CutA-like periplasmic divalent cation tolerance protein
45	CPn0927	CHLPS 43 kDa protein
	CPn0928	CHLPS 43 kDa protein
	CPn0929	CHLPS 43 kDa protein
	CPn0980	similar to <i>S. cerevisiae</i> 52.9 kDa protein
	bioA	adenosylmethionine-8-amino-7-oxononanoate aminotransferase
50	bioD	dethiobiotin synthetase
	bioB	biotin synthase
	CPn1045	conserved hypothetical membrane protein
	CPn1046	tryptophan hydroxylase

55

3) *Chlamydia*-Specific Proteins

Gene:	Protein Function:
-------	-------------------

	pmp_1	polymorphic outer membrane protein
	pmp_2	polymorphic outer membrane protein
	pmp_3	polymorphic outer membrane protein
5	pmp_3	polymorphic outer membrane protein
	pmp_4	polymorphic outer membrane protein
	pmp_4	polymorphic outer membrane protein
	pmp_5	polymorphic outer membrane protein
	pmp_5	polymorphic outer membrane protein
10	CPn0133	CHLPS hypothetical protein
	CPn0186	similarity to IncA
	incB	inclusion membrane protein B
	incC	inclusion membrane protein C
	CPn0332	CHLTR T2 protein
	ltuB	LtuB protein
15	pmp_6	polymorphic outer membrane protein
	pmp_7	polymorphic outer membrane protein
	pmp_8	polymorphic outer membrane protein
	pmp_9	polymorphic outer membrane protein
20	pmp_10	polymorphic outer membrane protein
	pmp_10	polymorphic outer membrane protein
	pmp_11	polymorphic outer membrane protein
	pmp_12	polymorphic outer membrane protein
	pmp_13	polymorphic outer membrane protein
25	pmp_14	polymorphic outer membrane protein
	pmp_15	polymorphic outer membrane protein
	pmp_16	polymorphic outer membrane protein
	pmp_17	polymorphic outer membrane protein
	pmp_17	polymorphic outer membrane protein
30	pmp_17	polymorphic outer membrane protein
	pmp_18	polymorphic outer membrane protein
	pmp_19	polymorphic outer membrane protein
	pmp_20	polymorphic outer membrane protein
	euo	CHLPS Euo protein
35	CPn0562	CHLPS 43 kDa protein homolog
	CPn0585	similar to CHLPS inclusion membrane protein A
	CPn0728	CHLPN 76 kDa protein homolog
	CPn0729	CHLPN 76 kDa protein homolog
	gp6D	CHLTR plasmid protein
40	CPn0927	CHLPS 43 kDa protein homolog
	CPn0928	CHLPS 43 kDa protein homolog
	CPn0929	CHLPS 43 kDa protein homolog
	pmp_21	polymorphic outer membrane protein
	ltuA	LtuA protein
45		

(Full sequence information has been published at the Chlamydia Genome Project web site: <http://chlamydia-www.berkeley.edu:4231/index.html>).

50

Additional Chlamydia genes, and encoded proteins, suitable for expression in a Gram-negative bacteria for OMV vaccine preparation:

Chlamydia pneumoniae 98kD putative outer membrane protein gene.	WO200026237
	-A2
Patent Inventors <i>DUNN PL</i>	
<i>OOMEN RP</i>	
<i>MURDIN AD</i>	
Chlamydia POMP91B precursor gene.	WO200026239
	-A2
Patent Inventors <i>DUNN PL</i>	
<i>OOMEN RP</i>	
<i>MURDIN AD</i>	

Chlamydia antigen CPN100634 full length coding sequence.	WO200032794 -A2
Patent Inventors <i>OOMEN RP</i> <i>WANG J</i> <i>MURDIN AD</i>	
Chlamydia antigen CPN100634 gene open reading frame.	WO200032794 -A2
Patent Inventors <i>OOMEN RP</i> <i>WANG J</i> <i>MURDIN AD</i>	
Chlamydia antigen CPN100635 full length coding sequence.	WO200032794 -A2
Patent Inventors <i>OOMEN RP</i> <i>WANG J</i> <i>MURDIN AD</i>	
Chlamydia antigen CPN100635 gene open reading frame.	WO200032794 -A2
Patent Inventors <i>OOMEN RP</i> <i>WANG J</i> <i>MURDIN AD</i>	
Chlamydia antigen CPN100638 full length coding sequence.	WO200032794 -A2
Patent Inventors <i>OOMEN RP</i> <i>WANG J</i> <i>MURDIN AD</i>	
Chlamydia antigen CPN100638 gene open reading frame.	WO200032794 -A2
Patent Inventors <i>OOMEN RP</i> <i>WANG J</i> <i>MURDIN AD</i>	
Chlamydia antigen CPN100639 full length coding sequence.	WO200032794 -A2
Patent Inventors <i>OOMEN RP</i> <i>WANG J</i> <i>MURDIN AD</i>	
Chlamydia antigen CPN100639 gene open reading frame.	WO200032794 -A2
Patent Inventors <i>OOMEN RP</i> <i>WANG J</i> <i>MURDIN AD</i>	
Chlamydia antigen CPN100708 full length coding sequence.	WO200032794 -A2
Patent Inventors <i>OOMEN RP</i> <i>WANG J</i> <i>MURDIN AD</i>	
Chlamydia antigen CPN100708 gene open reading frame.	WO200032794 -A2
Patent Inventors <i>OOMEN RP</i> <i>WANG J</i> <i>MURDIN AD</i>	
<i>C. pneumoniae</i> ATP/ADP translocase coding sequence.	WO200039157 -A1
Patent Inventors <i>DUNN P</i> <i>OOMEN RP</i> <i>WANG J</i> <i>MURDIN AD</i>	
Chlamydia pneumoniae 98 kDa outer membrane protein CPN100640 gene.	WO200032784 -A1
Patent Inventors <i>DUNN P</i>	

<i>OOMEN RP</i> <i>WANG J</i> <i>MURDIN AD</i>	
Chlamydia pneumoniae 98 kDa outer membrane protein coding region.	WO200032784 -A1
Patent Inventors <i>DUNN P</i> <i>OOMEN RP</i> <i>WANG J</i> <i>MURDIN AD</i>	
DNA encoding a 9 kDa cysteine-rich membrane protein.	WO200053764 -A1
Patent Inventors <i>DUNN P</i> <i>OOMEN RP</i> <i>WANG J</i> <i>MURDIN AD</i>	
DNA encoding a 60 kDa cysteine-rich membrane protein.	WO200055326 -A1
Patent Inventors <i>DUNN P</i> <i>OOMEN RP</i> <i>WANG J</i> <i>MURDIN AD</i>	
A 9 kDa cysteine-rich membrane protein.	WO200053764 -A1
Patent Inventors <i>DUNN P</i> <i>OOMEN RP</i> <i>WANG J</i> <i>MURDIN AD</i>	
A 60 kDa cysteine-rich membrane protein of Chlamydia pneumoniae.	WO200055326 -A1
Patent Inventors <i>DUNN P</i> <i>OOMEN RP</i> <i>WANG J</i> <i>MURDIN AD</i>	
C. pneumoniae mip (outer membrane protein).	WO200006741 -A1
Patent Inventors <i>DUNN PL</i> <i>OOMEN RP</i> <i>MURDIN AD</i>	
C. pneumoniae mip (outer membrane protein) truncated protein.	WO200006741 -A1
Patent Inventors <i>DUNN PL</i> <i>OOMEN RP</i> <i>MURDIN AD</i>	
C. pneumoniae omp protein sequence.	WO200006743 -A2
Patent Inventors <i>DUNN PL</i> <i>OOMEN RP</i> <i>MURDIN AD</i>	
C. pneumoniae omp protein truncated sequence.	WO200006743 -A2
Patent Inventors <i>DUNN PL</i> <i>OOMEN RP</i> <i>MURDIN AD</i>	
Amino acid sequence of the CPN100111 polypeptide.	WO200011183 -A2
Patent Inventors <i>OOMEN RP</i> <i>MURDIN AD</i>	
Amino acid sequence of the CPN100224 polypeptide.	WO200011183 -A2

Patent Inventors <i>OOMEN RP</i> <i>MURDIN AD</i> Amino acid sequence of the CPN100230 polypeptide.	WO200011183 -A2
Patent Inventors <i>OOMEN RP</i> <i>MURDIN AD</i> Amino acid sequence of the CPN100231 polypeptide.	WO200011183 -A2
Patent Inventors <i>OOMEN RP</i> <i>MURDIN AD</i> Amino acid sequence of the CPN100232 polypeptide.	WO200011183 -A2
Patent Inventors <i>OOMEN RP</i> <i>MURDIN AD</i> Amino acid sequence of the CPN100233 polypeptide.	WO200011183 -A2
Patent Inventors <i>OOMEN RP</i> <i>MURDIN AD</i> Amino acid sequence of the CPN100394 polypeptide.	WO200011183 -A2
Patent Inventors <i>OOMEN RP</i> <i>MURDIN AD</i> Amino acid sequence of the CPN100395 polypeptide.	WO200011183 -A2
Patent Inventors <i>OOMEN RP</i> <i>MURDIN AD</i> Amino acid sequence of the POMP91A protein of <i>Chlamydia pneumoniae</i> .	WO200011180 -A1
Patent Inventors <i>DUNN PL</i> <i>OOMEN RP</i> <i>MURDIN AD</i> <i>Chlamydia pneumoniae</i> antigen CPN100202 protein sequence.	WO200006739 -A2
Patent Inventors <i>OOMEN RP</i> <i>MURDIN AD</i> <i>Chlamydia pneumoniae</i> antigen CPN100149 protein SEQ ID NO:2.	WO200006740 -A1
Patent Inventors <i>OOMEN RP</i> <i>MURDIN AD</i> <i>Chlamydia pneumoniae</i> antigen CPN100605 protein SEQ ID NO:2.	WO200006742 -A2
Patent Inventors <i>OOMEN RP</i> <i>MURDIN AD</i> <i>Chlamydia</i> antigen CPN100634.	WO200032794 -A2
Patent Inventors <i>OOMEN RP</i> <i>WANG J</i> <i>MURDIN AD</i> <i>Chlamydia</i> antigen CPN100635.	WO200032794 -A2
Patent Inventors <i>OOMEN RP</i> <i>WANG J</i> <i>MURDIN AD</i> Mature <i>Chlamydia</i> antigen CPN100635.	WO200032794 -A2
Patent Inventors <i>OOMEN RP</i> <i>WANG J</i> <i>MURDIN AD</i> <i>Chlamydia</i> antigen CPN100638.	WO200032794

Patent Inventors <i>OOMEN RP</i> <i>WANG J</i> <i>MURDIN AD</i>	-A2
Chlamydia antigen CPN100639.	WO200032794 -A2
Patent Inventors <i>OOMEN RP</i> <i>WANG J</i> <i>MURDIN AD</i>	
Chlamydia antigen CPN100708.	WO200032794 -A2
Patent Inventors <i>OOMEN RP</i> <i>WANG J</i> <i>MURDIN AD</i>	
C. pneumoniae ATP/ADP translocase protein sequence.	WO200039157 -A1
Patent Inventors <i>DUNN P</i> <i>OOMEN RP</i> <i>WANG J</i> <i>MURDIN AD</i>	
Chlamydia pneumoniae 98kD putative outer membrane protein.	WO200026237 -A2
Patent Inventors <i>DUNN PL</i> <i>OOMEN RP</i> <i>MURDIN AD</i>	
Chlamydia POMP91B precursor protein.	WO200026239 -A2
Patent Inventors <i>DUNN PL</i> <i>OOMEN RP</i> <i>MURDIN AD</i>	
Chlamydia pneumoniae 98 kDa outer membrane protein CPN100640.	WO200032784 -A1
Patent Inventors <i>DUNN P</i> <i>OOMEN RP</i> <i>WANG J</i> <i>MURDIN AD</i>	
Chlamydia pneumoniae processed 98 kDa outer membrane protein CPN100640.	WO200032784 -A1
Patent Inventors <i>DUNN P</i> <i>OOMEN RP</i> <i>WANG J</i> <i>MURDIN AD</i>	
C. pneumoniae mip (outer membrane protein) encoding DNA.	WO200006741 -A1
Patent Inventors <i>DUNN PL</i> <i>OOMEN RP</i> <i>MURDIN AD</i>	
C. pneumoniae omp protein encoding DNA.	WO200006743 -A2
Patent Inventors <i>DUNN PL</i> <i>OOMEN RP</i> <i>MURDIN AD</i>	
DNA encoding the CPN100111 polypeptide.	WO200011183 -A2
Patent Inventors <i>OOMEN RP</i> <i>MURDIN AD</i>	
DNA encoding the CPN100224 polypeptide.	WO200011183 -A2
Patent Inventors <i>OOMEN RP</i>	

<i>MURDIN AD</i> DNA encoding the CPN100230 polypeptide.	WO200011183 -A2
Patent Inventors <i>OOMEN RP</i> <i>MURDIN AD</i> DNA encoding the CPN100231 polypeptide.	WO200011183 -A2
Patent Inventors <i>OOMEN RP</i> <i>MURDIN AD</i> DNA encoding the CPN100232 polypeptide.	WO200011183 -A2
Patent Inventors <i>OOMEN RP</i> <i>MURDIN AD</i> DNA encoding the CPN100233 polypeptide.	WO200011183 -A2
Patent Inventors <i>OOMEN RP</i> <i>MURDIN AD</i> DNA encoding the CPN100394 polypeptide.	WO200011183 -A2
Patent Inventors <i>OOMEN RP</i> <i>MURDIN AD</i> DNA encoding the CPN100395 polypeptide.	WO200011183 -A2
Patent Inventors <i>OOMEN RP</i> <i>MURDIN AD</i> Nucleotide sequence of the POMP91A gene of <i>Chlamydia pneumoniae</i> .	WO200011180 -A1
Patent Inventors <i>DUNN PL</i> <i>OOMEN RP</i> <i>MURDIN AD</i> Chlamydia pneumoniae antigen CPN100202 nucleotide sequence.	WO200006739 -A2
Patent Inventors <i>OOMEN RP</i> <i>MURDIN AD</i> Chlamydia pneumoniae antigen CPN100149 protein encoding DNA SEQ ID NO:1.	WO200006740 -A1
Patent Inventors <i>OOMEN RP</i> <i>MURDIN AD</i> Chlamydia pneumoniae antigen CPN100605 protein encoding DNA SEQ ID NO:1.	WO200006742 -A2
Patent Inventors <i>OOMEN RP</i> <i>MURDIN AD</i>	

When such blebs are present in a vaccine formulation they may be more protective against *Chlamydia pneumoniae* infection than the use of the protein/antigen
5 in isolation.

Particularly beneficial pairs of *Chlamydia pneumoniae* antigens have also been found. Thus in a further aspect a Gram-negative bleb (preferably from meningococcus) is provided presenting on its surface both the PorB and MOMP outer membrane proteins from *Chlamydia pneumoniae*. Furthermore, a Gram-negative bleb
10 (preferably from meningococcus) is provided presenting on its surface both MOMP

and one or more Pmp outer membrane proteins from *Chlamydia pneumoniae*. A Gram-negative bleb (preferably from meningococcus) is additionally provided presenting on its surface both the PorB and one or more Pmp outer membrane proteins from *Chlamydia pneumoniae*. A Gram-negative bleb (preferably from meningococcus) is also provided presenting on its surface both the PorB and Npt1 proteins from *Chlamydia pneumoniae*. A Gram-negative bleb (preferably from meningococcus) is additionally provided presenting on its surface both the Npt1 and one or more Pmp proteins from *Chlamydia pneumoniae*. Lastly, a Gram-negative bleb (preferably from meningococcus) is provided presenting on its surface both the Npt1 and MOMP proteins from *Chlamydia pneumoniae*. Bacterial strains from which these blebs are derived are further aspects of this invention.

Such preparations formulated as a vaccine can give enhanced protection to a host against *Chlamydia* than when a single antigen is administered.

Preferably the bleb has been derived from a strain which has been modified to upregulate one or more protective outer membrane antigens (see below; for instance for meningococcal protective outer membrane antigens see section "Neisserial bleb preparations" for those antigens that should preferably be upregulated).

Preferably the bleb has been derived from a strain which has been modified to downregulate one or more immunodominant variable or non-protective outer membrane antigens (as described below; for instance for meningococcal variable/non-protective outer membrane antigens see section "Neisserial bleb preparations" for those antigens that should preferably be downregulated).

Preferably the blebs are derived from a strain which has a detoxified lipid A portion of bacterial LPS, due to the strain having been engineered to reduce or switch off expression of one or more genes which cause LPS to be toxic (preferably selected from the following genes, or homologues thereof *htrB*, *msbB* and *lpxK*; see section below).

Preferably the blebs are derived from a strain which has a detoxified lipid A portion of bacterial LPS, due to the strain having been engineered to express at a higher level of one or more genes producing a gene product that is capable of detoxifying LPS (preferably selected from the following genes, or homologues thereof: *pmrA*, *pmrB*, *pmrE* and *pmrF*; see section below).

Vaccine compositions comprising the bleb of the invention and a pharmaceutically suitable excipient or carrier are also envisaged. Preferably the vaccine additionally comprising a mucosal adjuvant. Mucosal adjuvants are well known in the art (see Vaccine Design "The subunit and adjuvant approach" (eds Powell M.F. & Newman M.J.) (1995) Plenum Press New York). A preferred mucosal adjuvant is LT2 (or LTII, which can be split into LTIIa and LTIIb – see Martin et al. Infection and Immunity, 2000, 68:281-287). Preferably such vaccines should be formulated and administered as described below in "Vaccine formulations".

The content of blebs per dose in the vaccine will typically be in the range 1-100µg, preferably 5-50µg, most typically in the range 5 - 25µg.

Optimal amounts of components for a particular vaccine can be ascertained by standard studies involving observation of appropriate immune responses in subjects. Following an initial vaccination, subjects may receive one or several booster immunisations adequately spaced.

The efficacy of a *C. pneumoniae* vaccine can be evaluated in a mouse model of infection such as the one described by Murdin et al., 2000, J. Infect. Dis. 181 (suppl 3):S5444-51. The protection elicited by a vaccine formulation can be assessed by reduction of the bacterial load in the lung after a challenge infection with *C. pneumoniae*.

A method of preventing *Chlamydia pneumoniae* infection in a host is also provided comprising the steps of administering an effective amount of the above vaccine to a host in need thereof. Preferably the vaccine is mucosally administered via either an intranasal, intradermal or oral route.

25

Further improvements in the bacteria and blebs of the invention

The Gram-negative bacterium of the invention may be further genetically engineered by one or more processes selected from the following group: (a) a process of down-regulating expression of immunodominant variable or non-protective antigens, (b) a process of upregulating expression of protective OMP antigens, (c) a process of down-regulating a gene involved in rendering the lipid A portion of LPS toxic, (d) a process of upregulating a gene involved in rendering the lipid A portion of LPS less toxic, and (e) a process of down-regulating synthesis of an antigen which

shares a structural similarity with a human structure and may be capable of inducing an auto-immune response in humans. These processes are described in detail in WO 01/09350 (incorporated by reference herein).

Such bleb vaccines of the invention are designed to focus the immune response on a few protective (preferably conserved) antigens or epitopes - formulated in a multiple component vaccine. Where such antigens are integral OMPs, the outer membrane vesicles of bleb vaccines will ensure their proper folding. This invention provides methods to optimize the OMP and LPS composition of OMV (bleb) vaccines by deleting immunodominant variable as well as non protective OMPs, by creating conserved OMPs by deletion of variable regions, by upregulating expression of protective OMPs, and by eliminating control mechanisms for expression (such as iron restriction) of protective OMPs. In addition the invention provides for the reduction in toxicity of lipid A by modification of the lipid portion or by changing the phosphoryl composition whilst retaining its adjuvant activity or by masking it. Each of these new methods of improvement individually improve the bleb vaccine, however a combination of one or more of these methods work in conjunction so as to produce an optimised engineered bleb vaccine which is immuno-protective and non-toxic - particularly suitable for paediatric use.

(a) a process of down-regulating expression of immunodominant variable or non-protective antigens

Many surface antigens are variable among bacterial strains and as a consequence are protective only against a limited set of closely related strains. An aspect of this invention covers the reduction in expression, or, preferably, the deletion of the gene(s) encoding variable surface protein(s) which results in a bacterial strain producing blebs which, when administered in a vaccine, have a stronger potential for cross-reactivity against various strains due to a higher influence exerted by conserved proteins (retained on the outer membranes) on the vaccinee's immune system. Examples of such variable antigens include: for *Neisseria* - pili (PilC) which undergoes antigenic variations, PorA, Opa, TbpB, FrpB; for *H. influenzae* - P2, P5, pilin, IgA1-protease; and for *Moraxella* - CopB, OMP106.

Other types of gene that could be down-regulated or switched off are genes which, *in vivo*, can easily be switched on (expressed) or off by the bacterium. As outer membrane proteins encoded by such genes are not always present on the bacteria, the presence of such proteins in the bleb preparations can also be detrimental to the effectiveness of the vaccine for the reasons stated above. A preferred example to
5 down-regulate or delete is *Neisseria* Opc protein. Anti-Opc immunity induced by an Opc containing bleb vaccine would only have limited protective capacity as the infecting organism could easily become Opc⁻. *H. influenzae* HgpA and HgpB are other examples of such proteins.

10 In process a), these variable or non-protective genes are down-regulated in expression, or terminally switched off. This has the surprising advantage of concentrating the immune system on better antigens that are present in low amounts on the outer surface of blebs.

The strain can be engineered in this way by a number of strategies including
15 transposon insertion to disrupt the coding region or promoter region of the gene, or point mutations or deletions to achieve a similar result. Homologous recombination may also be used to delete a gene from a chromosome (where sequence X comprises part (preferably all) of the coding sequence of the gene of interest). It may additionally be used to change its strong promoter for a weaker (or no) promoter. All these
20 techniques are described in WO 01/09350 (published by WIPO on 8/2/01 and incorporated by reference herein).

(b) a process of upregulating expression of protective OMP antigens

This may be done by inserting a copy of such a protective OMP into the
25 genome (preferably by homologous recombination), or by upregulating expression of the native gene by replacing the native promoter for a stronger promoter, or inserting a strong promoter upstream of the gene in question (also by homologous recombination). Such methods can be accomplished using the techniques described in WO 01/09350 (published by WIPO on 8/2/01 and incorporated by reference herein).

30 Such methods are particularly useful for enhancing the production of immunologically relevant Bleb components such as outer-membrane proteins and lipoproteins (preferably conserved OMPs, usually present in blebs at low concentrations).

(c) a process of down-regulating a gene involved in rendering the lipid A portion of LPS toxic

The toxicity of bleb vaccines presents one of the largest problems in the use of blebs in vaccines. A further aspect of the invention relates to methods of genetically detoxifying the LPS present in Blebs. Lipid A is the primary component of LPS responsible for cell activation. Many mutations in genes involved in this pathway lead to essential phenotypes. However, mutations in the genes responsible for the terminal modifications steps lead to temperature-sensitive (*htrB*) or permissive (*msbB*) phenotypes. Mutations resulting in a decreased (or no) expression of these genes result in altered toxic activity of lipid A. Indeed, the non-lauroylated (*htrB* mutant) [also defined by the resulting LPS lacking both secondary acyl chains] or non-myristoylated (*msbB* mutant) [also defined by the resulting LPS lacking only a single secondary acyl chain] lipid A are less toxic than the wild-type lipid A. Mutations in the lipid A 4'-kinase encoding gene (*lpxK*) also decreases the toxic activity of lipid A.

Process c) thus involves either the deletion of part (or preferably all) of one or more of the above open reading frames or promoters. Alternatively, the promoters could be replaced with weaker promoters. Preferably the homologous recombination techniques are used to carry out the process. Preferably the methods described in WO 01/09350 (published by WIPO on 8/2/01 and incorporated by reference herein) are used. The sequences of the *htrB* and *msbB* genes from *Neisseria meningitidis* B, *Moraxella catarrhalis*, and *Haemophilus influenzae* are provided in WO 01/09350 for this purpose.

(d) a process of upregulating a gene involved in rendering the lipid A portion of LPS less toxic

LPS toxic activity could also be altered by introducing mutations in genes/loci involved in polymyxin B resistance (such resistance has been correlated with addition of aminoarabinose on the 4' phosphate of lipid A). These genes/loci could be *pmrE* that encodes a UDP-glucose dehydrogenase, or a region of antimicrobial peptide-resistance genes common to many enterobacteriaceae which could be involved in aminoarabinose synthesis and transfer. The gene *pmrF* that is present in this region

encodes a dolicol-phosphate manosyl transferase (Gunn J.S., Kheng, B.L., Krueger J., Kim K., Guo L., Hackett M., Miller S.I. 1998. *Mol. Microbiol.* 27: 1171-1182).

Mutations in the PhoP-PhoQ regulatory system, which is a phospho-relay two component regulatory system (f. i. PhoP constitutive phenotype, PhoP^c), or low Mg⁺⁺ environmental or culture conditions (that activate the PhoP-PhoQ regulatory system) lead to the addition of aminoarabinose on the 4'-phosphate and 2-hydroxymyristate replacing myristate (hydroxylation of myristate). This modified lipid A displays reduced ability to stimulate E-selectin expression by human endothelial cells and TNF- α secretion from human monocytes.

Process d) involves the upregulation of these genes using a strategy as described in WO 01/09350 (published by WIPO on 8/2/01 and incorporated by reference herein).

(e) a process of down-regulating synthesis of an antigen which shares a structural similarity with a human structure and may be capable of inducing an auto-immune response in humans

The isolation of bacterial outer-membrane blebs from encapsulated Gram-negative bacteria often results in the co-purification of capsular polysaccharide. In some cases, this "contaminant" material may prove useful since polysaccharide may enhance the immune response conferred by other bleb components. In other cases however, the presence of contaminating polysaccharide material in bacterial bleb preparations may prove detrimental to the use of the blebs in a vaccine. For instance, it has been shown at least in the case of *N. meningitidis* that the serogroup B capsular polysaccharide does not confer protective immunity and is susceptible to induce an adverse auto-immune response in humans. Consequently, process e) of the invention is the engineering of the bacterial strain for bleb production such that it is free of capsular polysaccharide. The blebs will then be suitable for use in humans. A particularly preferred example of such a bleb preparation is one from *N. meningitidis* serogroup B devoid of capsular polysaccharide.

This may be achieved by using modified bleb production strains in which the genes necessary for capsular biosynthesis and/or export have been impaired as described in WO 01/09350 (published by WIPO on 8/2/01 and incorporated by reference herein). A preferred method is the deletion of some or all of the *Neisseria*

meningitidis *cps* genes required for polysaccharide biosynthesis and export. For this purpose, the replacement plasmid pMF121 (described in Frosh et al.1990, *Mol. Microbiol.* 4:1215-1218) can be used to deliver a mutation deleting the *cpsCAD* (+ *galE*) gene cluster. Alternatively the *siaD* gene could be deleted, or down-regulated in
5 expression (the meningococcal *siaD* gene encodes alpha-2,3-sialyltransferase, an enzyme required for capsular polysaccharide and LOS synthesis). Such mutations may also remove host-similar structures on the saccharide portion of the LPS of the bacteria.

10 *Combinations of methods a) – e)*

It may be appreciated that one or more of the above processes may be used to produce a modified strain from which to make improved bleb preparations of the invention. Preferably one such process is used, more preferably two or more (2, 3, 4, or 5) of the processes are used in order to manufacture the bleb vaccine. As each
15 additional method is used in the manufacture of the bleb vaccine, each improvement works in conjunction with the other methods used in order to make an optimised engineered bleb preparation.

A preferred meningococcal (particularly *N. meningitidis* B) bleb preparation comprises the use of processes b), c) and e) (optionally combined with process a)).
20 Such bleb preparations are safe (no structures similar to host structures), non-toxic, and structured such that the host immune response will be focused on high levels of protective (and preferably conserved) antigens. All the above elements work together in order to provide an optimised bleb vaccine.

Similarly for *M. catarrhalis*, non-typeable *H. influenzae*, gonococcus, and non
25 serotype B meningococcal strains (e.g. serotype A, C, Y or W), preferred bleb preparations comprise the use of processes b) and c), optionally combined with process a).

Preferred Neisserial bleb preparations

30 One or more of the following genes (encoding protective antigens) are preferred for upregulation via process b) when carried out on a Neisserial strain, including gonococcus, and meningococcus (particularly *N. meningitidis* B): NspA (WO 96/29412), Hsf-like (WO 99/31132), Hap (PCT/EP99/02766), PorA, PorB,

OMP85 (WO 00/23595), PilQ (PCT/EP99/03603), PldA (PCT/EP99/06718), FrpB (WO 96/31618), TbpA (US 5,912,336), TbpB, FrpA/FrpC (WO 92/01460), LbpA/LbpB (PCT/EP98/05117), FhaB (WO 98/02547), HasR (PCT/EP99/05989), lipo02 (PCT/EP99/08315), Tbp2 (WO 99/57280), MltA (WO 99/57280), and ctrA
 5 (PCT/EP00/00135). They are also preferred as genes which may be heterologously introduced into other Gram-negative bacteria.

One or more of the following genes are preferred for downregulation via process a): PorA, PorB, PilC, TbpA, TbpB, LbpA, LbpB, Opa, and Opc (most preferably PorA).

10 One or more of the following genes are preferred for downregulation via process c): htrB, msbB and lpxK (most preferably msbB which removes only a single secondary acyl chain from the LPS molecule).

One or more of the following genes are preferred for upregulation via process d): pmrA, pmrB, pmrE, and pmrF.

15 One or more of the following genes are preferred for downregulation via process e): galE, siaA, siaB, siaC, siaD, ctrA, ctrB, ctrC, and ctrD (the genes are described in described in WO 01/09350 - published by WIPO on 8/2/01 and incorporated by reference herein).

Many of the above open reading frames and upstream regions are described in
 20 WO 01/09350 (incorporated by reference herein).

Preferred gonococcal genes to upregulate via process b) include one or more of the following:

25 *Neisseria gonorrhoeae* lactoferrin receptor precursor (lbpA) gene,
 complete cds.
 ACCESSION U16260
 VERSION U16260.1 GI:915277
 Source: *Neisseria gonorrhoeae*/strain="FA19"
 gene="lbpA" nucleotides: 278..3109
 30 protein_id="AAC13780.1"/db_xref="GI:915278"
 /translation="MNKKHGFPLTLTALAIAATAFPAYAAQAGAAALDAAQSQSLKEVT
 VRAAKVGRRSKEATGLGKIVKTSETLNKEQVLGIRDLTRYDPGVAVVEQGNGASGGYS
 35 IRGVDKNRVAVSVDGVAQIQAF TVQGSLSGYGGRGGSGAINEIEYENISTVEIDKGAG
 SSDHGSGALGGAVAFRTKEADLISDGKSWG IQAKTAYGSKNRQFMKSLGAGFSKDGW
 40 EGLLIRTERQGRETRPHGDIADGVEYGIDRLDAFRQTYDIKRKTTEPFFLVEGENTLK
 PVAKLAGYGIYLNRLNRWVKERIEQNQPLSAEEEEQVREAQARHENLSAQAYTGCCR

ILPDPMDYRSGSWLAKLGYRFGGRHYVGGVFEDTKQRYDIRDMTEKQYYGTDEAEKFR
 DKSGVYDGDGDFRDGLYFVFNIEEWKGDKNLVKGIGLKYSRTKFIDEHRRRRRMGLLYR
 5 YENEKYSNDNWADKAVLSFDKQGVATDMNTLKLNCVYPAVDKSCRASADKPYSYDSSD
 RFHYREQHNVLNASFEKSLKNKWTKHHLTLGFGYDASKAVSRPEQLSHNAARISESTG
 10 FDEKNQDKYRLGKPEVVEGSVCGYIETLSRRCVPRKINGSNIHISLNDRFSIGKYFD
 FSLGGRYDRKNFTTSEELVRSGRYADRSWNSGIVFKPNRHFVSYSRASSGFRTSPFQE
 15 LFGIDIYHDYPKGWQRPALKSEKAANREIGLQWKDGFLEISSFRNRYTDMIADVADQ
 KTKLPDSAGRLTEIDIRDYYNAQNMSLQGINILGKIDWNGVYGLPEGLYTTLAYNRI
 KPKSVSNRPDLSLSRYALDAVQPSRYVLGFGYDQPEGKWGANIMLTYSKGKNPDELAY
 20 LAGDQKRYRAGRTSSWKTADVSAAYLNLKKRLTLRAAIYNIGNYRYVTWESLRQTAES
 TANRHGGDSNYGRYAAPGRNFSLALEMKF"

1 ctccgggataa cggcatcaat ctttcgggaa atgggttcgac taatcctcaa agtttcaaag
 25 61 ccgacaatct tcttgtaacg ggcggctttt acggcccgca ggcggcgga ttggggcgga
 121 ctattttcaa taaggatggg aaatctcttg gtataactga agatattgaa aatgaagttg
 181 aaaatgaagc tgatgttggc gaacagttag aacctgaagt taaaccccaa ttcggcggtg
 241 tattcggtgc gaagaaagat aataaagg tggaataatg aataagaaac acggttttcc
 301 gctgactttg acggcggttg ccattgcaac cgcttttccg gcttatgctg cccaagcggg
 361 ggcggcgga cttgatggcg cgcaaagtca atcattgaaa gaggttaccg tccgtgccgc
 421 caaagtggga cggcgatcga aagaggcgac aggtttgggc aaaatcgtca aaacgtcgga
 481 aacgttgaac aaagaacagg tactcggtat ccgcgacctg acgcgctacg atccggcggt
 541 ggcgggttgc gaacaggga acggcgcgag cggcggtac tcgatacgcg gcgtagataa
 601 aaacgtgtg ggcgtttcgg ttgacggcgt tgcccaaata caggcggtta ccgtgcaggg
 35 661 atcggtgagc ggatacggcg gacgcggcg cagcgcgca atcaacgaaa tcgaatatga
 721 aaacatcagc acggtggaaa tcgacaaagg ccgcggttcg tccgatcagc gcagcggcgc
 781 actcgcggc gcggtcgctt tccgcaccaa agaggcgga gacctgattt cagacggcaa
 841 aagctggggg atacaggcaa aaaccgctta cggcagtaaa aaccgcaat ttatgaagtc
 901 gctcgcgcg ggggttcagca aagacggttg ggaagggtg ctaatccgaa ccgaacgcca
 40 961 agggcgggaa acgcgcccgc acggcgatat tgccgacggg gtggaatacg gcatagaccg
 1021 tttggacgcg ttccgccaga catacgatat taaacgcaag acaacagagc catttttctt
 1081 agtagagggc gagaatacac tcaagcccggt ggcaaaattg gcggggtacg ggatatattt
 1141 gaaccgccag ctcaaccgct gggtaaaaga acgtattgaa caaaatcagc ctttaagtgc
 1201 tgaagaagag ggcgaggtgc gggaggcgca ggcgcccac gaaaacctgt ccgcccagc
 45 1261 ctacacgggc ggcggcagga tattgccgga tccgatggat taccgcagcg gctcttggct
 1321 tgccaagctg ggctaccgct tcggcgagc gcattatgtc ggcggcggtg ttgaggatac
 1381 caaacagcgt tacgacatcc gcgatatgac ggaaaaacag tattacggtg cggacgaggc
 1441 ggaaaaagttt agagacaaga gcggggtgta cgacggcgac gatttccgcg acggcttgta
 1501 ttttgtgccg aatatagaag agtggaaggg cgataaaaaat ttggtcaagg gcataggtt
 50 1561 gaaatatcc cgcaccaaatt ttattgacga acatcacgcg ccgcccgta tgggtttgct
 1621 gtaccgttat gaaaatgaga aatactcgga caactggcg gataaggcg tgttgcgtt
 1681 tgacaaacag ggcgtggcaa ccgacaacaa cagctgaag ctgaattgcg ccgtgtatcc
 1741 tgccgtggac aaatcctgcc gcgcgtcgcc ggacaaaccg tattcctacg acagcagcga
 1801 ccgtttccac taccgcgaac agcacaatgt tttgaatgcc tcgtttgaga agtcgtgaa
 55 1861 aaacaaatgg acgaaacacc atctgacttt gggcttcggt tacgatgctt ccaaagcagt
 1921 atccccccca gaacagcttt ccacaaatgc ggcaaggatt tcggaatcca cgggattcga
 1981 tgaaaagaat caagataagt accgtttggg taagcccgaa gtcgtcgaag ggtcgtctg
 2041 cggctatata gaaaccctgc gttcccgcaa atgcgtgcca agaaaaatca acggcagcaa
 2101 tatccacatt tctttgaacg acggttttcc aatcggaata tattttggg
 60 2161 cggcaggtac gaccgaaaaa acttcaccac gtcggaagaa ctcgccgca gggcggtgta
 2221 tgccgaccgt tcgtggaaca gcggcatcgt gttcaaacgg aaccggcatt tttccgtgct
 2281 ttaccgcgcc tccagcggtc tcagaacgcc ttccttccaa gaacttttcg ggatagacat
 2341 ttatcacgat tatccgaaag gctggcagcg tcccgccttg aaatcggaag aggcagccaa
 2401 cggggaaatc ggtttgcagt ggaaggcgga tttcggtttt ttggaataca cgagtttccg
 65 2461 caaccgttat accgatatga ttgccgttgc cgatcaaaaa accaaattgc cggattcagc
 2521 aggacgattg acagagattg atatacgca ttattacaat gcccaaaata tgcgcttca

```

2581 aggcattcaac atcttgggga aaatcgactg gaacggcgta tacggcaaac tgcccgaagg
2641 cctgtacacc acattggcgt acaaccgtat caaaccgaaa tcggtatcca accggccgga
2701 cttgtccctc cgcagctatg ctttggatgc ggtacagccg tcggttatg ttttggggtt
2761 cggatacgac cagcccagg ggaatgggg cgcaaacatt atgctgacct attccaaagg
5 2821 gaaaaaccct gacgagcttg cttatctggc aggcgatcaa aaacgatatt cggcaggaag
2881 ggttacgtct tcttggaaaa cggcagatgt ttccgcttat ctgaatctga aaaaacggct
2941 gaccttgagg gcggctatct acaatatcgg caactaccgc tacgttactt gggaatcctt
3001 gcgccagact gcggaagca cggcaaacgc gcacggcggc gacagcaact atggaaggta
10 3061 tgccgcaccg ggcaggaact tcagcctcgc gctcgaaatg aagttttaaa ggaaatgccg
3121 tctggaagct tgatctgcac ccaaaaagtc ggactaaacc gccaaatgat taaggtgcag
3181 gtttttttga ttcaatataa acaagatttc cgccgtcatt cccgcgcagg cgggaatccg
3241 gacattcaat gctaaggcaa tttatcggaa atgactgaaa ctcaaaaaac cggattccca
//

```

15

Neisseria gonorrhoeae lactoferrin binding protein B precursor.

Source: *Neisseria gonorrhoeae*"/strain="FA19"

```

20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135 136 137 138 139 140 141 142 143 144 145 146 147 148 149 150 151 152 153 154 155 156 157 158 159 160 161 162 163 164 165 166 167 168 169 170 171 172 173 174 175 176 177 178 179 180 181 182 183 184 185 186 187 188 189 190 191 192 193 194 195 196 197 198 199 200 201 202 203 204 205 206 207 208 209 210 211 212 213 214 215 216 217 218 219 220 221 222 223 224 225 226 227 228 229 230 231 232 233 234 235 236 237 238 239 240 241 242 243 244 245 246 247 248 249 250 251 252 253 254 255 256 257 258 259 260 261 262 263 264 265 266 267 268 269 270 271 272 273 274 275 276 277 278 279 280 281 282 283 284 285 286 287 288 289 290 291 292 293 294 295 296 297 298 299 300 301 302 303 304 305 306 307 308 309 310 311 312 313 314 315 316 317 318 319 320 321 322 323 324 325 326 327 328 329 330 331 332 333 334 335 336 337 338 339 340 341 342 343 344 345 346 347 348 349 350 351 352 353 354 355 356 357 358 359 360 361 362 363 364 365 366 367 368 369 370 371 372 373 374 375 376 377 378 379 380 381 382 383 384 385 386 387 388 389 390 391 392 393 394 395 396 397 398 399 400 401 402 403 404 405 406 407 408 409 410 411 412 413 414 415 416 417 418 419 420 421 422 423 424 425 426 427 428 429 430 431 432 433 434 435 436 437 438 439 440 441 442 443 444 445 446 447 448 449 450 451 452 453 454 455 456 457 458 459 460 461 462 463 464 465 466 467 468 469 470 471 472 473 474 475 476 477 478 479 480 481 482 483 484 485 486 487 488 489 490 491 492 493 494 495 496 497 498 499 500 501 502 503 504 505 506 507 508 509 510 511 512 513 514 515 516 517 518 519 520 521 522 523 524 525 526 527 528 529 530 531 532 533 534 535 536 537 538 539 540 541 542 543 544 545 546 547 548 549 550 551 552 553 554 555 556 557 558 559 560 561 562 563 564 565 566 567 568 569 570 571 572 573 574 575 576 577 578 579 580 581 582 583 584 585 586 587 588 589 590 591 592 593 594 595 596 597 598 599 600 601 602 603 604 605 606 607 608 609 610 611 612 613 614 615 616 617 618 619 620 621 622 623 624 625 626 627 628 629 630 631 632 633 634 635 636 637 638 639 640 641 642 643 644 645 646 647 648 649 650 651 652 653 654 655 656 657 658 659 660 661 662 663 664 665 666 667 668 669 670 671 672 673 674 675 676 677 678 679 680 681 682 683 684 685 686 687 688 689 690 691 692 693 694 695 696 697 698 699 700 701 702 703 704 705 706 707 708 709 710 711 712 713 714 715 716 717 718 719 720 721 722 723 724 725 726 727 728 729 730 731 732 733 734 735 736 737 738 739 740 741 742 743 744 745 746 747 748 749 750 751 752 753 754 755 756 757 758 759 760 761 762 763 764 765 766 767 768 769 770 771 772 773 774 775 776 777 778 779 780 781 782 783 784 785 786 787 788 789 790 791 792 793 794 795 796 797 798 799 800 801 802 803 804 805 806 807 808 809 810 811 812 813 814 815 816 817 818 819 820 821 822 823 824 825 826 827 828 829 830 831 832 833 834 835 836 837 838 839 840 841 842 843 844 845 846 847 848 849 850 851 852 853 854 855 856 857 858 859 860 861 862 863 864 865 866 867 868 869 870 871 872 873 874 875 876 877 878 879 880 881 882 883 884 885 886 887 888 889 890 891 892 893 894 895 896 897 898 899 900 901 902 903 904 905 906 907 908 909 910 911 912 913 914 915 916 917 918 919 920 921 922 923 924 925 926 927 928 929 930 931 932 933 934 935 936 937 938 939 940 941 942 943 944 945 946 947 948 949 950 951 952 953 954 955 956 957 958 959 960 961 962 963 964 965 966 967 968 969 970 971 972 973 974 975 976 977 978 979 980 981 982 983 984 985 986 987 988 989 990 991 992 993 994 995 996 997 998 999 1000

```

```

1 mrklnyygia llplmlascg gnfgvqpve stptaypvtf kskdvptspp paepsvettp
25 61 vnrpavgaam rllrrntafh redgtaipds kqaeeclsfk egdvlflygs kgnklqqllks
121 eihkrdsdve irtsekenkk ygyefvdagy vytknkdei eqnsggkrft hrfgydgvfy
181 ysgerpsqsl psagtvkyfg nwqymtdakr hrtgkavasd dlgyitfygn digatsyaak
241 daddrekhpae eytvdfdkki lkgeliknqy vqkknppkpk ltiynitadl ngnrftgsak
30 301 vntevktrha dkeylffhtd adqrleggff gdngeelagr fisndngvfg vfagkqktna
361 sgtnpampfg khtkildslk isvdeatden prpfvstmp dfghpdkllv egreiplvsk
421 ektidladr kmtvsaccdf ltyvklgrik terpavkpka qdeedsginn geesedeeei
481 aeesevdevse ddngededei veeadeaeae ieeaeaeep eespeegng vsdgippape
541 alkgrdidlf lkgirtaead ipktgtahyt gtwearigep iqwdnkadka akaefdvdg
601 nksisgtlte qngvepafri engviegnf hptartrdng inlsngstn pqsfkadnll
35 661 vtggfygpqa aelggtifnk dgkslgited ienevenead vgeqlepevk pqfgvvfagk
721 kdnkevek

```

Neisseria gonorrhoeae transferrin-binding protein A (tbpA) gene, complete cds.

```

40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135 136 137 138 139 140 141 142 143 144 145 146 147 148 149 150 151 152 153 154 155 156 157 158 159 160 161 162 163 164 165 166 167 168 169 170 171 172 173 174 175 176 177 178 179 180 181 182 183 184 185 186 187 188 189 190 191 192 193 194 195 196 197 198 199 200 201 202 203 204 205 206 207 208 209 210 211 212 213 214 215 216 217 218 219 220 221 222 223 224 225 226 227 228 229 230 231 232 233 234 235 236 237 238 239 240 241 242 243 244 245 246 247 248 249 250 251 252 253 254 255 256 257 258 259 260 261 262 263 264 265 266 267 268 269 270 271 272 273 274 275 276 277 278 279 280 281 282 283 284 285 286 287 288 289 290 291 292 293 294 295 296 297 298 299 300 301 302 303 304 305 306 307 308 309 310 311 312 313 314 315 316 317 318 319 320 321 322 323 324 325 326 327 328 329 330 331 332 333 334 335 336 337 338 339 340 341 342 343 344 345 346 347 348 349 350 351 352 353 354 355 356 357 358 359 360 361 362 363 364 365 366 367 368 369 370 371 372 373 374 375 376 377 378 379 380 381 382 383 384 385 386 387 388 389 390 391 392 393 394 395 396 397 398 399 400 401 402 403 404 405 406 407 408 409 410 411 412 413 414 415 416 417 418 419 420 421 422 423 424 425 426 427 428 429 430 431 432 433 434 435 436 437 438 439 440 441 442 443 444 445 446 447 448 449 450 451 452 453 454 455 456 457 458 459 460 461 462 463 464 465 466 467 468 469 470 471 472 473 474 475 476 477 478 479 480 481 482 483 484 485 486 487 488 489 490 491 492 493 494 495 496 497 498 499 500 501 502 503 504 505 506 507 508 509 510 511 512 513 514 515 516 517 518 519 520 521 522 523 524 525 526 527 528 529 530 531 532 533 534 535 536 537 538 539 540 541 542 543 544 545 546 547 548 549 550 551 552 553 554 555 556 557 558 559 560 561 562 563 564 565 566 567 568 569 570 571 572 573 574 575 576 577 578 579 580 581 582 583 584 585 586 587 588 589 590 591 592 593 594 595 596 597 598 599 600 601 602 603 604 605 606 607 608 609 610 611 612 613 614 615 616 617 618 619 620 621 622 623 624 625 626 627 628 629 630 631 632 633 634 635 636 637 638 639 640 641 642 643 644 645 646 647 648 649 650 651 652 653 654 655 656 657 658 659 660 661 662 663 664 665 666 667 668 669 670 671 672 673 674 675 676 677 678 679 680 681 682 683 684 685 686 687 688 689 690 691 692 693 694 695 696 697 698 699 700 701 702 703 704 705 706 707 708 709 710 711 712 713 714 715 716 717 718 719 720 721 722 723 724 725 726 727 728 729 730 731 732 733 734 735 736 737 738 739 740 741 742 743 744 745 746 747 748 749 750 751 752 753 754 755 756 757 758 759 760 761 762 763 764 765 766 767 768 769 770 771 772 773 774 775 776 777 778 779 780 781 782 783 784 785 786 787 788 789 790 791 792 793 794 795 796 797 798 799 800 801 802 803 804 805 806 807 808 809 810 811 812 813 814 815 816 817 818 819 820 821 822 823 824 825 826 827 828 829 830 831 832 833 834 835 836 837 838 839 840 841 842 843 844 845 846 847 848 849 850 851 852 853 854 855 856 857 858 859 860 861 862 863 864 865 866 867 868 869 870 871 872 873 874 875 876 877 878 879 880 881 882 883 884 885 886 887 888 889 890 891 892 893 894 895 896 897 898 899 900 901 902 903 904 905 906 907 908 909 910 911 912 913 914 915 916 917 918 919 920 921 922 923 924 925 926 927 928 929 930 931 932 933 934 935 936 937 938 939 940 941 942 943 944 945 946 947 948 949 950 951 952 953 954 955 956 957 958 959 960 961 962 963 964 965 966 967 968 969 970 971 972 973 974 975 976 977 978 979 980 981 982 983 984 985 986 987 988 989 990 991 992 993 994 995 996 997 998 999 1000

```

/translation="MQQQHLFRFNILCLSLMTALPAYAENVQAGQAQEKQLDTIQVKA

```

KKQKTRRDNEVTGLGKLVKTADTLSEKQVLDIRDLTRYDPGIATVEQGRGASSGYSIR
50 GMDKNRVSLTVDGLAQISYTAQAALGGTRTAGSSGAINIEYENVKAVEISKGSNSV
EQSGALAGSVAFTKTADDVIGRQWGIQSKTAYSCKNRGLTQSIAGRIGGAEA
55 LLIRTGRHAGEIRAHEAAGRGVQSFNRLAPVEDGSDYAYFVVEGECPDGYAACKDKPK
KDVVGEDKRQTVSTRDYTGPNRFLADPLSYESRSWLFRPGFRFENKRHYIGGILERTQ
QTFDTRDMTPAFLTKAVFDANSKQAGSLRGNGKYAGNHKYGLFTNGENNAPVGAEY
60 GTGVFYDETHKSRYLEYVYTNADKDTWADYARLSYDRQGIGLDNHFQQTHCSADGS

```

DKYCRPSADKPFSYKSDRVIYGESHRLLQAAFKKSFDTAKIRHNL SVN LGYDRFGSN
5 LRHQDYQQSANRAYS LKTPPQNGKKTSPYVWSIGRGNVVTGQICRSGNNTYTDCTP
RSINGKSYAAVRDNVRLGRWADVGAGLRYDYRSTHSDGVSSTGTHRTL SWNTGIVL
KPADWLDLTYRTSTGFRLP SFAEMYGWRSGDKIKAVKIDPEKSFNKEAGIVFKGDFGN
10 LEASWFDNAYRDLIVRGYAEIKNGKEQAKGAPAYLNAQSARITGINILGKIDWNGVW
DKLPEGWYSTFAYNRVRVDIKKRADRTDIQSHLFD AIQPSRYVVGSGYDQPEGKWGV
15 NGMLTYSKAKEITELLGSRALLNGNSRNTKATARRTRPWIYVDVSGYYTVKKHFTLRA
GVYNLLNHRVYTWENVRQTAAAGAVNQHKNVGVYNRYAAPGRNYTFSLEMKF"

1 cgaagagttg ggcggatggt ttgcctatcc gggcaatgaa caaacgaaaa atgcgcaagc
20 61 ttcacccggc aatggaaatt cagcaggcag cgcgaccgtg gtattcgggt cgaaacgccca
121 aaagcttgtg caataagcac ggctgccgaa caatcgagaa taaggcttca gacggcatcg
181 ttcctgccga ttccgtctga aagcgaagat tagggaaaca ctatgcaaca gcaacatttg
241 ttccgattca atattttatg cctgtcttta atgactgcgc tgcccgttta tgcagaaaaat
301 gtgcaagccg gacaagcaca ggaaaaacag ttggacacca tacaggtaaa agccaaaaaa
361 cagaaaaccc gccgcgataa cgaagtaacc ggtttgggca aattgggtcaa aaccgccgac
25 421 aactcagca aagaacaggt actcgacatc cgcgacctga cgcgttacga ccccgccatc
481 gccgtcgtcg aacaggggcg cggcgcaagc tccggctact cgatacgcg tatggacaaa
541 aaccgcgtct ccttgacggt ggacggcttg gcgcaaatc agtcctacac cgcgcaggcg
601 gcattgggcg ggacgaggac ggcgggcagc agcggcgcaa tcaatgaaat cgagtatgaa
661 aacgttaagg ctgtcgaaat cagcaaaagg tcaaaactcg tcgaacaagg cagcggcgca
30 721 ttggcgggtt cggctcgatt tcaaaccaa accgcagac atgttatcgg ggaaggcagg
781 cagtggggca ttcagagtaa aaccgcctat tccggcaaaa accgggggct taccatcc
841 atcgcgttg cggggcgcat cggcggtgag gaggctttgc tgatccgcac cggccggcac
901 gcgggggaaa tccgcgcca cgaagccgcc ggacgcggcg ttcagagctt taacaggctg
961 gcgcccgttg aagacggcag tgactatgcc tattttgtgg tcgaaggaga atgccctgat
35 1021 ggatatgcgg cttgtaaaga caaacgaaa aaagatggtg tcggcgaaaga caaacgtcaa
1081 acggtttcca cccgagacta caccggcccc aaccgcttcc ttgccgatcc gctttcatac
1141 gaaagccggt cgtggctggt ccgccgggt tttcgttttg agaataagcg gcactacatc
1201 ggcggcatac tcgaacgcac gcaacaaact ttcgacacgc gcgatatgac ggttccggca
1261 ttcctgacca aggcgggttt tgatgcaaat tcaaaacagg cgggttcttt gcgcggcaac
40 1321 ggcaaatacg cgggcaacca caaatcggc gggctgttta ccaacggcga aaacaatgcg
1381 ccggtgggcg cggaaatcgg tacggcggtg ttttacgac agacgcacac caaaagccgc
1441 tacggtttg aatatgtcta taccaatgcc gataaagaca cttgggcgga ttatgccgc
1501 ctctcttacg accggcagg catcggtttg gacaaccatt ttcagcagac gcactgttct
1561 gccgacgggt cggacaaata ttgcgcccc agtgccgaca agcgttttcc ctattacaaa
45 1621 tccgaccgcg tgatttacgg ggaagccac aggcctctgc aggcggcatt caaaaaatcc
1681 ttcgataccg ccaaaatccg ccacaacctg agcgtgaatc tcggttacga ccgcttcggc
1741 tctaactcgc gccatcagga ttattattat caaagtgcc accgcgccta ttcgttgaaa
1801 acgccccctc aaaaacaagg caaaaaaac agccctatt gggtcagcat aggcagggga
1861 aatgtcggtta cggggcaaat ctgccgctcg ggcaacaata cttatacggc ctgcacgcg
50 1921 cgcagcatca acggcaaaag ctattacgag gcggtccggg acaatgtccg tttgggcagg
1981 tgggcggatg tcggcgcggg cttgcgctac gactaccgca gcacgcattc ggacgacggc
2041 agcgtttcca ccggcacgca ccgcaccctg tcctggaaca ccggcatcgt cctcaaacct
2101 gccgactggc tggatttgac ttaccgcact tcaaccggct tccgcctgcc ctcgtttgcg
2161 gaaatgtacg gctggcggtc gggcgataaa ataaaagccg tcaaaatcga tccggaaaaa
55 2221 tcgttcaaca aagaagccgg catcgtgttt aaaggcgatt tcggcaactt ggaggcaagt
2281 tggttcgaca atgcctaccg cgatttgatt gtccgggggt atgaagcgga aattaaaac
2341 ggcaaaagac aagccaaagg cgcggcggt tacctcaatg ccaaaagcgc gcggtattac
2401 ggcatcaata ttttgggcaa aatcgattgg aacggcgat gggataaatt gcccgagggt
2461 tggatttcta catttgccca taatcgtgtc cgtgtccgag acatcaaaaa acgcgcagac
60 2521 cgcaccgata ttcaatcaca cctgtttgat gccatccaac cctcgcgcta tgcgtcggc
2581 tcgggctatg accaaccgga aggc aaatgg ggcgtgaacg gtatgctgac ttattccaaa
2641 gccaaaggaa tcacagagtt gttgggcagc cgggctttgc tcaacggcaa cagccgcaat
2701 acaaaagcca ccgcgcgcgc taccgcctc tggatatatt tggatgtgtc cgttattac
2761 acggttaaaa aacacttcac cctccgtgag ggcgtgtaca acctcctcaa ccacgcctat
65 2821 gttacttggg aaaatgtgag gcaaaactgc gccggcgag tcaaccaaca caaaaatgtc
2881 ggcgtttaca accgatatgc cgccccggc gcgaactaca catttagctt ggaaatgaag

2941 ttctaaacgt ccgaacgccg caaatgccgt ctgaaaggct tcagacggcg ttttttacac
3001 aatccccacc gtttcccatc cttcccgata caccg

5 *Neisseria gonorrhoeae* strain UU1008 transferrin-binding protein 2
(tbpB) gene, complete cds.
ACCESSION U65222
VERSION U65222.1 GI:2286066
Source: *Neisseria gonorrhoeae*/strain="UU1008"
10 gene="tbpB" coding sequence: 1..2052
/protein_id="AAB64243.1"
/db_xref="GI:2286067"
/translation="MNNPLVNQAAMVLPVFLLSACLGGGGSFDLDSVDTEAPRAAPKY
15 QDVPSKKPEARKDQGGYGFMRFKRRNWYRAANENEVKLKESDWEQTDDEIKNPFKQ
KNIINALPGNEGELLQDSSQQGKGTSKVRDHHDFKYVWSGFFYKRIKITTKKDESHKI
IERSGPDGYIFYKGRNPSRKLPSVGEVITYKGTWDFLTDVKNQKFTDLGNASTKSGD
20 QYSAFSGELDYIVKKEEDKKEKHKGLGLTTEITVDFEKKTLIGKLIKNNMLINNNTKP
TTQYYSLEAQVTGNRFSKGAMATEKGENKQHPFVSDSSSLSGGFFGPGQEELGFRFLS
25 DDGKVAVVGSAKTKDETASSGGTSGGASVSTNGAAGTSSSENKLTTVLDAVELTPNGK
KIKDLNFSNAAQLVVDGIMIPLLPKDSESGGSHTDKGENGKTAFIYETTYTPESDKE
DAQTGMATNGVQTVSNTAGGTSGKTKTHYEVQACCSNLNLYKYGILLTRKNSSQADAKM
30 GQVEQSMFLQGERTDEKEIPQEONVVYSGTWYGHIAITNGTSWTREASDQENGNRANFD
VNFKDKRITGTLTAENRSEATFTIEAMIEGNGFKGTAKTGNGGFAPDQNSSTGTHKVH
35 ITNAAVQGGFYGPNAEELGGWFAYPGNGQTKNAQTSSGNGNSAGSATVVFGAKRQQLV
K"
1 atgaacaatc cattggtgaa tcaggctgct atggtgctgc ccgtgttttt gttgagcgc
40 61 tgtctgggcg gaggcggcag ttctgatctt gattctgtcg ataccgaagc cccgcgtgcc
121 ggcgcaaaagt atcaagatgt tccttccaaa aaaccggaag cccgaaaaga ccaaggcggg
181 tacggtttcg cgatgcgctt caagcggcgg aattggtatc gggcggcaaa cgaaaacgag
241 gttaaaactga aagagagtga ttgggaacaa acggatgatg atgagatcaa aaaccctttc
301 aaacaaaaaa atattattaa tgccttacct ggaaatgagg gggaattatt gcaagattcc
361 agtcaacaag gtaagggtac atctaagggt agggaccatc acgattttaa atacgtatgg
45 421 tcgggttttt ttataaaacg gattaagatt acaactaaaa aagacgaatc tcataaaaata
481 atcgaagcca gaagcggctc tgacggttat attttttata aaggcagaaa tccctcgaga
541 aaacttcctg tttaggggga ggttacgtac aaaggtaactt gggatttttt aactgatgtg
601 aaagcaaatc agaaatttac agatttagga aatgcttcta cgaaatccgg agaccaatat
661 agtgcttttt cgggggagtt ggattatata gtcaaaaaag aggaggataa aaaagaaaag
50 721 cacaagggtt tgggattaac aacggaaata acggttgatt ttgagaaaaa aaccctgatc
781 ggaaaattaa ttaaaaacaa catgttaatc aataataaca ctaaacccac cacccaatat
841 tacagccttg aggctcaagt aacaggcaac cgcttcagcg gcaaggcgat ggcaaccgaa
901 aaaggcgaaa acaacaaca tccctttggt tccgactcgt cttctctgag cggcggcttt
961 ttcggcccgc aggttgagga attgggtttc cgctttttga gcgacgatgg aaaagttgcc
55 1021 gttgtcggca gcgcgaaaac caaagacgaa accgcaagca gtggcggcac ttcgggagggt
1081 gcaagcgttt ccacatcaaa cgtgacggca ggcacgtcgt ctgaaaacaa gctgaccacg
1141 gttttggatg cggttgaatt gacaccaaac ggcaagaaaa tcaaatgatc cgacaacttc
1201 agcaacgccg ccaactggt tgcgacggc attatgattc cgctcctgcc caaggattcc
1261 gaaagcgggg gcagtcatac agataaaggt gaaaacggca aaacagcctt tatctacgaa
60 1321 acaacctaca cgccggaaag tgataaagaa gacgctcaaa caggtatggc gaccaatggc
1381 gtgcaaacgg tttcaaatac ggcaggcggc acaagtggca aaacaaaaac ccattatgaa
1441 gtccaagcct gctgttccaa cctcaattat ctgaaatacg ggttgctgac gcgtaaaaac
1501 agtagtcaag ctgacgctaa aatgggacaa gttgaacaaa gtatgttcc ccaaggcgag
1561 cgcaccgatg aaaaagaaat tccacaagaa caaatgtcg tttattcagg cacttggtac
65 1621 gggcatattg ccaccaacgg cacaagttgg acccgcaag cctccgatca ggaaaatgg

1681 aatcgggcaa attttgacgt gaatttcaaa gacaaaagaa ttaccggcac gttaaccgct
 1741 gaaaacaggt cggaggcaac ctttaccatt gaagccatga ttgagggcaa cggctttaa
 1801 ggtagggcga aaaccggtaa tggcggcttt gcgccggatc aaaacagcag caccggtaca
 1861 cataaagtgc acatcacaaa tgccgcggtg cagggcggtt tttacgggcc taacgccgaa
 5 1921 gagttgggcg gttggtttgc ctatccgggc aatggacaaa cgaaaaatgc gcaacttca
 1981 tccggcaatg gaaattcagc aggcagcgcg accgtggtat tcggtgcgaa acgccaacag
 2041 cttgtgaaat aa

10

Neisseria gonorrhoeae pilus biogenesis gene cluster, pilO, pilP and
 pilQ genes, complete cds.

ACCESSION U40596
 15 VERSION U40596.1 GI:1173872
 source : Neisseria gonorrhoeae/strain="MS11"
 gene="pilO" coding sequence 22..669
 /protein_id="AAC43601.1"
 /db_xref="GI:1173873"
 20 /translation="MASKSSKTNLDLNNLHLLNLPARLFIALLVAAVLGLGYAGLFLK
 SQMESLBEYEAKETELKNTYKQKSIDAASLNNLRDELASIRSAFDIMLKQLPTDAEIP
 25 NLVQELHQAGSSNGLRLDSVMPQPPVDDGPIKLPYSISITGNYEQISQFTRDVGSL
 RIITLESKIAQSPENGGNPDGKSSILNLSAIATTYQAKSIEELAAEAQNAEQK"
 gene="pilP" coding sequence 687..1229
 /protein_id="AAC43602.1"
 30 /db_xref="GI:1173874"
 /translation="MKHYALLISFLALSACSQSSDLNEWMAQTRREAKAEIIPFQAP
 TLPVAPVYSPPQLTGPNAFDFFRMETAKKGENAPDTKRIKETLEKFSLENMRYVGILK
 35 SGQKVS GFIEAGYVYTVGVGNLYLGQNYGRIESITDDSIILNELIEDSTGNWVSRKAE
 LLLNSSDKNTEQAAQPEEQN"
 gene="pilQ" coding sequence 1248..3410
 /protein_id="AAC43603.1"
 40 /db_xref="GI:1173875"
 /translation="MNTKLTKIISGLFVATAAFQTASAGNITDIKVSSLPNKQKIVKV
 SFDKEIVNPTGFVTSSPARIALDFEQTGISMDQOVLEYADPLLISKISAAQNSSRARLV
 45 LNLNKPQGYNTEVRGNKVWIFINESDDTVSAPARPAVKAAPAAPAKQQAAPFTESV
 SVSAPFSPAKQQAASAKQQAATPAKQTNIDFRKDGKNAGIIELAALGFAGQPDISQQ
 50 HDHIIVTLKNHTLPTALQRLDVA DFKTPVQKVT LKRLNNDTQLIITTTGNWELVNKS
 AAPGYFTFQVLPKKQNLES GGVNNAPKTFTGRKISLDFQDVEIRTI LQILAKESGMNI
 VASDSVSGKMTLSLKDVPWDQALDLVMQARNLDMRQQGNIVNMAPRAACQRQSLLTS
 55 GKRHCRSGRAVF PKLP IETIQKCGRIPQHPALDNADTTGNRNTLVSGRGSVLIDPATNT
 LIVTDTRSVIEKFRKLIDELDVPAQQVMIEARIVEADGFSRDLGVKFGATGRKKLKN
 60 ETSAFGWGVNSGFGGDKWEAKPKSTCRLPCRKH FAGARDFSGALNLELSASESLSK
 TKTLANPRVLTQNRKEAKIESGYEIPFTVT TTRSGGNSTNTELKAVLGLTVTANITP
 65 DGQIIMTVKINKDSPRQCASGNNTILCISTKSLNTQAMVENG GTLIVGGIYBENNGNT
 LTKVPLLATSPLSATSLKHSGKNRPPRTAD FQLPPREL"

	1	aaacgcacag	gaggaaactg	aatggcttct	aaatcatcta	aaaccaactt	ggatctcaac
	61	aaccttcacc	tgtctaacct	tcctgccagg	ctttttatcg	ccctgctggg	cgttgccgcc
5	121	gtgctggggc	tcggttatgc	cggattgttc	aaaagccaga	tggatccct	tgaggaatat
	181	gaagcaaaag	aaaccgaact	gaaaaacacc	tacaaacaga	aaagtatcga	cgcggccagc
	241	ctgaacaacc	ttagggacga	acttgccctca	atccgctctg	ccttcgatata	catgttgaaa
	301	cagctgccga	cagatgcaga	aattcccaat	ttgggttcaag	agcttcatca	ggcgggttcg
	361	agcaacggtc	tgcgcttggg	cagcggttatg	ccccaacctc	ccgtagatga	cgttcccatc
10	421	aaaaaattac	cctattccat	ttccattacc	ggaaattacg	aacagatcag	ccaatttacc
	481	cgcgatgtcg	gcagtctctc	ccgaatcatt	acccttgagt	cgctgaaaat	cgcccaatct
	541	ccggaaaacg	gcggcaatcc	tgacggcaag	agcagtatcc	tgaacctcag	cgccattgcc
	601	accacctacc	aagcaaaatc	catagaagag	cttgccgcag	aagcggcaca	aaatgccgag
	661	caaaaataac	ttacgttagg	gaaaccatga	aacactatgc	cttactcatc	agctttctgg
15	721	ctctctccgc	gtgttcccaa	agttctgaag	acctaaacga	atggatggca	caaacgcgac
	781	gcgaagccaa	agcagaaatc	atacctttcc	aagcacctac	cctgccgggt	gcgccgggtat
	841	acagcccggc	gcagcttaca	gggccgaacg	cattcgactt	ccgccgcag	gaaaccgcca
	901	aaaaagggga	aaatgccccc	gacaccaagc	gtattaaaga	aacgctggaa	aaattcagtt
	961	tggaaaaatat	gcgttatgtc	ggcattttga	agtccggaca	gaaagtctcc	ggcttctcag
20	1021	aggctgaagg	ttatgtctac	actgtcggtg	tcggcaacta	tttgggacaa	aactacggta
	1081	gaatcgaaag	cattaccgac	gacagcatca	tcctgaacga	gctgatagaa	gacagcacgg
	1141	gcaactgggt	ttcccgtaaa	gcagaactgc	tggtgaattc	ttccgacaaa	aacaccgaac
	1201	aagcggcaca	gcctgaggaa	caaaatttaag	aagaggatta	ctccattatg	aataccaaac
25	1261	tgacaaaaat	catttcgggt	ctctttgtcg	caaccgcgcg	ctttcagacg	gcctcggcag
	1321	gaaacattac	agacatcaaa	gtttcctccc	tgcccaacaa	acagaaaatc	gtcaaatgca
	1381	gctttgacaa	agagattgtc	aacccgaccg	gcttcgtaac	ctcctcaccg	gcccgcacgc
	1441	ccttggactt	tgaacaaacc	ggcatttcca	tggtatcaaca	ggtagctgaa	tatgccgatc
	1501	ctctgttgag	caaaatcagt	gccgcacaaa	acagcagccg	tgccgctctg	gttctgaatt
	1561	tgaacaaacc	gggccaatcc	aataccgaag	tacgcgggaa	caaagtittg	atattcatta
30	1621	acgaatcgga	cgataccgtg	tcgcgccccg	ccgcgccagc	cgtaaaaagc	gcgcctgcgc
	1681	caccggcaca	acaacaggct	gccgcaccgt	ttaccgagtc	cgtagtatcc	gtatccgcac
	1741	cgttcagccc	ggcaaaaaca	caggcagcgg	catcggcaca	acaacaggcg	gcgacaccgg
	1801	caaaacaaac	caatatcgat	ttccgcgaag	acggcaaaaa	tgccggcatt	atcgaattgg
	1861	cggcattggg	ctttgccggg	cagcccgaca	tcagccaaca	gcacgaccac	atcatcgtaa
35	1921	cgctgaaaaa	ccataccctg	ccgaccgcgc	tccaacgcag	tttggatgtg	gcagacttca
	1981	aaacaccggg	tcaaaagggt	acgctgaac	gcctcaataa	cgacaccag	ctgattatca
	2041	caacaaccgg	caactgggaa	ctcgtcaaca	aatccgcgcg	gcccggatcc	tttacccttc
	2101	aagtcctgcc	gaaaaaacaa	aacctcgagt	caggcggcgt	gaacaatgag	cccaaaacct
	2161	tcacaggccg	gaaaatctcc	cttgacttcc	aagatgtcga	aatccgcacc	atcctgcaga
40	2221	ttttggcaaa	agaatccggg	atgaacattg	ttgccagcga	ctccgtcagc	ggcaaaatga
	2281	ccctctccct	caaagacgta	ccttgggatc	aggctttgga	tttgggtatg	caggcgcgca
	2341	acctcgatat	gcgccagcaa	gggaacatcg	tcaacatggc	cccgcgacga	gctgcttgcc
	2401	aaagacaaaag	ccttcttaca	agcggaaaaa	gacattgccg	atctggggcg	gctgtattcc
	2461	caaaacttcc	aattgaaata	caaaaatgtg	gaagaattcc	gcagcatcct	gctttggaca
45	2521	atgccgacac	gaccggaaac	cgcaacacgc	ttgtcagcgg	caggggcagc	gtgtgatcgc
	2581	atcccgcac	caacaccctg	attgttaccg	ataccgcag	cgatcatgaa	aaattccgca
	2641	aactgattga	cgaattggac	gtaccgcgcg	aacaagtgat	gattgaggcg	cgtatcgtcg
	2701	aagcggcaga	cggcttctcg	cgcgatttgg	gcgttaagtt	cggcgcgaca	ggcaggaaaa
	2761	aactgaaaaa	tgagacgagc	gcattcgggt	ggggcgtgaa	ctccggcttc	gggggcggcg
50	2821	ataaatggga	ggccaaacca	aaatcaacct	gccggttgcc	gtgccgcaaa	cagcatttgc
	2881	ctggtgcgcg	cgatttctcc	ggcgcgttga	atttgggaatt	gtccgcaccc	gagtcgcttt
	2941	caaaaaccaa	aacgcttgcc	aatccgcgcg	tgctgaccca	aaaccgcaaa	gaggccaaaa
	3001	tcgaatccgg	ttacgaaatt	ccttttaccg	taactacacg	ctcggggcgc	ggcaactcta
	3061	ccaacacgga	actcaaaaaa	gccgtcttgg	ggctgaccgt	tacggcgaaac	atcacgcccc
55	3121	acggacaaaat	catcatgacc	gtcaaaaatca	acaaagactc	gcctcgacaa	tgtgcttcag
	3181	gcaacaacac	aatcctatgt	atttcgacca	aaagcctgaa	tacgcaggct	atgggtgaaa
	3241	acggcggcac	tttgattgtc	ggcgggtattt	atgaagaaaa	caacggcaat	acgctgacca
	3301	aagtcacctc	gttggctaca	tccccgttat	cggcaacctc	tttaaaacac	tcgggaaaaa
	3361	accgaccgcc	gcgaactgct	gattttcaat	tacccccgag	ggaattatag	atacggcgca
60	3421	acagcctgcg	ctattgatgc	gtcaaaaataa	gggcataatgt	tttacagcat	atgccctttc
	3481	tttatgcttt	ttgccgcgac	cgaaatgccg	tcattcccg	gagcgaatcc	aacttgtccg
	3541	gtttcgggtg	tttttcgtct	cgtaactttt	gagccgctcat	ccccgcgaaa	tcggaaatcc
	3601	agtccgttca	gtttcgggtc	tttcggataa	attcctgttg	cttttcatct	ctagattccc
	3661	actttcgtgg	aataacggcg	gaagggataa	atcctcgcaa	tccaaagcct	gctcatttcc
65	3721	acaaaaaaca	gcaacccgaa	acaccccgct	attcccgagc	aggcgggaatc	tagaacggca
	3781	acgccaggaa	tctgtcggat	acggctgaaa	ccgaacgact	ggattccccg	

NspA
Neisseria gonorrhoeae outer membrane protein gene, complete cds
ACCESSION U52069
VERSION U52069.1 GI:1808968
5 source Neisseria gonorrhoeae/strain="B2"
Gene "NspA" coding sequence : 141..665
/protein_id="AAB41581.1"
/db_xref="GI:1808969"
10 /translation="MKKALAALIALALPAAALAEAGSGFYVQADAAHAKASSSLGSAK
GFSPRISAGYRINDLRFAVDYTRYKNYKAPSTDFKLYSIGASVIYDFDTQSPVKPYFG
ARLSLNRSAHLGGSDSFSKTSAGLGLVAGVSYAVTPNVLDAGYRYNYVGKVNTVKN
15 VRSGELSAGVRVKF"
1 cggcaagca gccgcatgcc gccgcgtatc ttgaggcatt gaaaatatta cgatgcaaaa
61 agaaaatttc agtataatac ggcaggattc tttaacggat tattaacaat ttttctccct
121 gaccataaag gaaccaaagt atgaaaaaag cacttgccgc actgattgcc ctgcgactcc
20 181 cggccgcccgc actggcggaa ggcgcacccg gcttttacgt ccaagccgat gccgcacacg
241 ccaaagcctc aagctcttta ggttctgcca aaggcttcag cccgcgcacg tccgcaggct
301 accgcatcaa cgacctccgc ttcgcgcgtcg attacacgcg ctacaaaaac tataaagccc
361 catccaccga tttcaaaact tacagcatcg gcgcgtccgt catttacgac ttcgacaccc
421 aatcgcccgt caaacggtat ttcggcgcgc gcttgagcct caaccgcgct tccgcccact
25 481 tggggcggcag cgacagcttc agcaaaacct ccgcccgcct cggcgatttg gcgggcgtaa
541 gctatgccgt taccgccaat gtcgatttgg atgccgggta ccgctacaac tacgtcggca
601 aagtcaacac tgtcaaaaac gtccgttccg gcgaactgtc cgccggcggtg cgcgtcaaat
661 tctgatatac gcgttattcc gcaaaccgcc gagccttcgg cggttttttg
Neisseria gonorrhoeae outer membrane protein (omp85) gene, complete
30 cds.
ACCESSION U81959
VERSION U81959.1 GI:1766041
Source: Neisseria gonorrhoeae/strain="FA19"
35 gene="omp85" coding sequence 1..2379
/protein_id="AAC17600.1"
/db_xref="GI:1766042"
/translation="MKLKQIASALMMLGISPLAFADFTIQDIRVEGLQRTPESTVFNY
40 LPVKVGDYNDTHGSAIIKSLYATGFFDDVRVETADGLLLLTIVCPTIGSLNITGAK
MLQNDIAKKNLSEFGLAQSQYFNQATLNQAVAGLKEEYLGRGKLNIIQITPKVTKLARN
45 RVDIDITIDEGKSAKITDIEFEGNQVYSRKLMRQMSLTEGGIWTWLTRSDRFRDQKF
AQDMEKVTDIFYQNNGYDFRILDTDIQTNEDKTRQTIKITYHEGGRFRWGKVSIEGDT
NEVPKAELEKLLTMKPGKWYERQQMTAVLGEIQNRMGSAGYAYSEISVQPLPNAGTKT
50 VDFVLHIEPGRKIYVNEIHITGNNKTRDEVVRRELQMESAPYDTSKLQSKERVELL
GYFDNVQFDAVPLAGTPDKVDLNMSLTERSTGSLDLSAGWVQDTGLVMSAGVSQDNLF
55 GTGKSAALRASRSKTTLNGSLSFDPYFTADGVSLGYDIYGKAFDPRKASTSVKQYKT
TTAGGGVVRMGIPVTEYDRVNFGLAAEHLTVNTYNKAPKRYADFIKQYGKTDGADGSFK
GLLYKGTVGWGRNKTDLSALWPTRGYLTGVNAEIALPGSKLQYYSATHNQTWFFPLSKT
60 FTLMLGGEVGIAGGYGRTKEIPFFENFYGGGLGSGVRGYESGTLGPKVYDEYGEKISYG
GNKKANVSAELLPMPGAKDARTVRLSLFADAGSVWDGRITYTAAENGNNKSVYSENAH
65 KSTFTNELRYSAGGAVTWLSPLGPMKFIYAYPLKKKPEDEIQRFFQFQLGTTF"

1 atgaaactga aacagattgc ctccgcactg atgatgttgg gcatatcgcc tttggcattt
 61 gccgacttca ccatccaaga catccgtgtc gaaggcttgc agcgtaccga gccgagcacc
 121 gtattcaact acctgcccggt caaagtcggc gacacctaca acgacacaca cggcagtgcc
 181 atcatcaaaa gcctgtacgc caccggtttc tttgacgacg tacgagtcga aactgaggac
 241 gggctgcttc tgctgaccgt tatcgtatgc cctaccatcg gctcgtctaa catcaccggc
 301 gccaaaatgc tgcagaacga cgccatcaag aaaaacctcg aatcggtcgg gctggcgag
 361 tcgcaatact ttaatcaggc gacactcaac caggcagtcg ccggcctgaa agaagaatat
 421 ctccggcgcg gcaaaactcaa tatccaaatc acgcccacaa taaccacaaat cgcccgcac
 481 cgcgtcgaca tcgacatcac gattgacgag ggcaaatccg ccaaaatcac cgacatcgaa
 541 tttgaaggca accaagtcta ttccgaccgc aaactgatgc ggcagatgtc gctgaccgaa
 601 ggcggcattt ggacatggct gacacgaagc gaccgggttcg accgccagaa attcgcccaa
 661 gacatggaaa aagtaaccga cttctaccag aacaacggct acttcgattt ccgtatcctc
 721 gataccgaca tccaaaccaa cgaagacaaa accaggcaga ccatcaaaat caccgtccac
 781 gaaggcggac gtttccgctg gggcaaagtg tcgattgaag gcgacaccaa cgaagtcccc
 841 aaggccgaac tggaaaaact gctgaccatg aagcccggca aatggtacga acgccagcag
 901 atgaccgccc ttttgggtga gattcagaac cgcattgggt ccggcaggcta cgcatacagc
 961 gaaatcagcg tacagccgct gccgaacgcc ggaacccaaa ccgtcgattt cgtcctgcac
 1021 atcgaaccgg gcagaaaaat ctacgtcaac gaaatccaca tcaccggcaa caacaaaacc
 1081 cgcgacgaag tcgtgcgcgg cgaattgcgc caaatggaat ccgcgcctta cgacacctcc
 1141 aagctgcaac gctccaaaga gcgcgtcgag cttttgggt acttcgacaa cgtacagttt
 1201 gatgccgtcc cgttgcgcgg tacgcccagc aaagtgcatt tgaacatgag cctgaccgaa
 1261 cgttccaccg gctcgtcga cttgagcggc ggctgggttc aggtacggga agtcggccgc cctgcgcgc
 1321 tccgccggcg tatcgcagg caacctgttc ggtacgggca agtcggccgc cctgcgcgc
 1381 tcgcaagca aaaccacgct caacggctcg ctgtcgttta ccgaccgta cttcacggca
 1441 gacggggtca gcctgggcta cgatatttac ggaaaagcct tcgaccgcgc caaagcatcg
 1501 accagcgtca aacaatataa aaccaccacc gccggcggcg gcgtaaggat gggatatccc
 1561 gttaccgaat acgaccgct caatttcggg ctggcggcg aacacctgac cgtcaacacc
 1621 tacaacaaag caccacaaac ctatgccgac tttatcaaac aatacggcaa aaccgacggc
 1681 gcagacggca gtttcaaagg cctgctgtac aaaggcactg tcggctgggg gcgcaacaag
 1741 accgacagcg ccttatggcc gacgcgcggc tacctgaccg gcgtaaatgc cgaaatcgcc
 1801 ctgcccggca gcaaaactgca atactactcc gccaccaca accaaacctg gttcttccc
 1861 ttaagcaaaa ctttcacgct gatgctcggc ggcaagtcg gcattgcggc cggctacggc
 1921 agaaccaaaag aaatcccctt ctttgaaaac ttctacggcg gcggcctggc ttcgggtgcg
 1981 ggctacgaaa gcggcacgct cggcccgaat gtgtatgacg aatacggcga aaaaatcagc
 2041 tacggcggca acaaaaaagc caacgtctcc gccgagctgc tcttcccgat gcccggtgcg
 2101 aaagacgcac gcaccgtccg cctgagcctg tttgccgacg caggcagcgt gtgggacggc
 2161 agaaccctata ccgccgcga aaacggtaac acaaatcgg tttactcgga aaacgcgcac
 2221 aaatccacct ttaccaacga attgcgctat tccgccggcg gcgcggttac cgtgctctcg
 2281 ctttggggcc cgatgaaatt catctacgcc taccgctga agaaaaaac ggaagacgaa
 2341 atccaacgct tccaattcca gctcggcagc acgttctaa

45 PldA1 homolog in Neisseria gonorrhoeae
 Source: U. of Oklahoma sequencing project
 PldA1-like coding sequence:

>GONOGT01_15 Continuation (15 of 22) of gonogt01 from base 140001
 ATGAATACACGAAATATGCGCTATATCTTTGACAGGACTGTTGCCGACGGCATCCGCT
 TTTGGAGAGACCGCGCTGCAATGCGCCGCTTTGACGGACAATGTTACGCGTTTGCGCTGT
 50 TACGACAGGATTTTTCGGGCACAGCTTCCGCTCTTCGGCAGGGCAGGAAGGGCAGGAGTCG
 AAAGCCGTACTCAATCTGACGGAACCGTCCGACGAGCTTGGATAAGGGCAGGCGGTC
 ATTGTTGTTGAAAAAGGCGGGGATGCGCTTCTGCCGACAGTGCGGGCGAAACCGCCGAT
 ATCTATACGCCTTTGAGCCTGATGTACGACTTGGACAAAAACGATTTGCGCGGGCTGTTG
 55 GGCGTACGCGAACACAATCCGATGTACCTTATGCCGTTTGGTATAACAATTCGCCCAAC
 TATGCCCCGAGTTCGCCGACGCGCGGTACGACTGTACAGGAAAAATTCGGACAGCAGAAA
 CGTGCGGAAACCAAAATTGCAGGTTTCGTTCAAAAAGCAAAATTGCCGAAAAATTTGTTTAAA
 ACCCGCGCGGATCTGTGTTTCGGCTACACCCAAAGATCCGATTGGCAGATTTACAACCAA
 GGCAGGAAATCCGCGCCGTTCCGCAATACGGAATTACAAACCTGAAATTTTCTGACCCAG
 CCTGTGAAGGCGGATTTGCCGTTCCGGCGGAGGCTGCGTATGCTCGGTGCGGTTTGTGTC
 60 CACCAGTCCAACGGACAGAGCCGTCCCGAATCGCGTTCTGTGAACAGGATTTATGCCATG
 GCAGGCATGGAATGGGGCAAATTGACGGTGATTCCGCGCGTGTGGGTGCGTGCGTTTCGAT
 CAGAGCGGCGATAAAAAACGACAATCCCGATATTGCCGACTATATGGGGTATGGCGACGTG
 AAGCTGCAGTACCGCCTGAACGACAGGCGAGAATGTGTATTCCGTATTGCGCTACAACCCC
 AAAACGGGCTACGGCGCGATTGAAGCCGCTACACGTTTCCGATTAAGGGCAAACTCAAA

GGCGTGGTACGCGGATTCCACGGTTACGGCGAGAGCCTGATCGACTACAACCACAAGCAG
AACGGTATCGGTATCGGGTTGATGTTCAACGACTGGGACGGCATCTGA

- 5 PldA1-like amino acid sequence
MNTRNMRYLLTGLLPTASAFGETALQCAALTDNVTRLACYDRIFAAQLPSSAGQEGQESKAVLNLTE
TVRSSLDKGEAV
IVVEKGGDALPADSAGETADIYTPLSLMYDLKNDLRGLLGVRHNPMYLMPFWYNNSPNYAPSSPT
RGTTVQEKFGQK
10 RAETKLQVSFKSKIAENLFKTRADLWFGYTQRSDWQIYNQGRKSAPFRNTDYKPEIFLTQPVKADLPFG
GRLRMLGAGFV
HQSNGQSRPESRSWNRIYAMAGMEWGKLTVIPRVWVRAFDQSGDKNDNPDIADYMGYGDVKLQYRL
NDRQNVYSVLRYP
KTGYGAIEAAYTFPIKGKLGKGVVRGFGHYGESLIDYNHKQNGIGIGLIMFNDWDGI.

15

1000 base pairs upstream PldA1-like sequence (usable for replacing the promoter for a stronger sequence)
>GONOGT01_15 Continuation (15 of 22) of gonocgt01 from base 140001

- TTTTGGCTTCCAGCGTTTCGTTGTTTTCGTACAAGTCGTAAGTCAGCTTCAGATTGTTGG
20 CTTTTTAAAGTCTTCGACCGTACTCTCGTCAACATAATTCGACCAGTTGTAGATGTTCA
GAGTATCGGTGGCAGCGGCTTCGGCATTGGCAGCAGGTGCGCTGCCTGCTTGAGGCTGCA
CGGCGTTTTTTTCGCTGCCGCCGAGGCTGCCAGAGACAGCGCGCCAAAACCGCTAATA
CGGATTTTTTCATACGGGCAGATTCTGTATGAAAGAGGTTGGAAAAAAGAAAAACCCCGC
25 GCCCCATAAACACCCCGCGCAAGGTTTGGGTATTGTAAAGTAAATTTGTGCAAACTCAA
AGCGATATTGGCCTGATTTTCCTAAAAAATTACCCTGTTTCCAAAAAAGGGGGGAAACG
GCCGCCCGATTTTGCCGTTTTTTTGCGCCGTCAGGTTGTCCGACGGGCGGATAGAGAAAA
AAGGCTTGCATATAATGTAAACCCCTTTAAAAATTGCGCGTTTACAGAATTTATTTTTCT
TTCAGGAGATTCCAATATGGCAAACAGCGCACAAGCACGCAACGTGCCCGCCAGTCCGT
30 CAAACAACGCGCCCAACGCTAGCCTGCGTACCGCATTCCGCACCGCAGTGAAAAAAGT
ATTGAAAGCAGTCTGAAGCAGGCGATAAAGCTGCCGCACAAGCGGTTTACCAAGAGTCCGT
CAAAGTCATCGACCGCATCGCCGACAAAGGCGTGTTCATAAAAAACAAAGCGGCTCGCCA
CAAAAGCCGCCTGTCTGCAAAAGTAAAGCACTGGCTTGATTTTGCAAAACCGCCAAGG
CGGTTGATACGCGATAAGCGGAAAACCTGAAGCCCGACGGTTTCGGGGTTTTCTGTATT
35 TCGGGGGTAAAGTTCGAAATGGCGGAAAGGTTGCGGTTTTTTATCCGAATCCGCTATAAA
ATGCCGTTTGAAAACCAATATGCCGACAATGGGGGCGGAG

Preferred gonococcal genes to downregulate via process a) include one or more of the
following:

40

Neisseria gonorrhoeae iron-regulated outer membrane protein preFrpB
(frpB) gene, complete cds.

ACCESSION U13980

VERSION U13980.1 GI:833694

45

Source: *Neisseria gonorrhoeae*/strain="FA19"

gene="frpB" coding sequence: 318..2459

/protein_id="AAC43332.1"

50

/db_xref="GI:833695"

/translation="MNAPFFRLSLSLTLAAGFAHAAENNANVALDVTVTVKGDRQGSK

55

IRTNIVTLQQKDESTATDMRELLKEEPSIDFGGNGTSQFLTLRGMQNSVDIKVDNA

YSDSQILYHQGRFIVDPALVKVSVQKGAGSASAGIGATNGAIIAKTVDAQDLLKGLD

KNWGVRLNSGFAGNNGASYGASVFGKEGNFDGLFSYNRNDKDYEAGKGFRNDNGGKT
 VPYSALDKRSYLAKIGTTFGDGDHRIVLSHMKDQHRGIRTVREEFAVSEKNSRITIKR
 5 QAPSYRETTQSNNTNLAYTGKDLGFVEKLDANAYVLEKKRYSADDDKNGYAGNVKGPNH
 TRIATSRMNFNFD SRLAEQTLLKYGINYRHOEIKPQAFNLSEFEIKDKEKATNEEKKK
 10 NRENEKIAKAYRLTNPTKTDGTGAYIEAIEHIDGFTLTGGLRYDRFKVKTHDGKTVSSS
 SLNPSFGVIWQPREHWSFSASHNYAGRSPLRYDALQTHGKRGIIISIADGTKAERARNT
 EIGFNYNDGTFAANGSYFRQTIKDALANPQNRHDSVAVREAVNAGYIKNHGYELGASY
 15 RTGGLTAKVGVSHSKPRFYDTHKDKLLSANPEFGAQVGRWTWASLAYRFKNPNLEIGW
 RGRYVQKAVGSILAAGQKDRDGKLENVVRQGFVNDVFANWKPLGKDTLNVNLSVNNV
 FDKFYYPHSQRWTNTLPGVGRDVR LGVNYKF"
 20 1 aaaccggtac ggcgttgccc cgccttagct caaagagaac gattccctaa ggtgctgaag
 61 caccgagtga atcgggttccg tactatttgt actgtctgcg gcttcgccgc cttgtcctga
 121 tttttgtag tccacatata catttccgac aaaacctgtc aacaaaaaac aacgcttcgc
 181 aaataaaaaac gataatcagc tttacacaac cccccccgc taatataaac aaaaataatt
 241 attattattt tttcttatcc tgccaaacct taacgggttg gcttaacttc cttcataca
 25 301 ctcaaaagga cgaacaaatg aacgccccgt ttttcgcct cagcctgctc tcgctcacac
 361 ttgccgccgg ctttgcccac gcggcagaaa ataatgccaa tgcgcattg gataccgta
 421 ccgtaaaagg cgaccgccaa ggcagcaaaa tccgtaccaa catcgttacg cttcaaaaa
 481 aagacgaaag caccgcaacc gatatgcgcg aactcttaaa agaagagccc tccatcgatt
 30 541 tcggcgggcg caacggcacg tcccaattcc tgacgctgcg cggtatgggt cagaactctg
 601 tcgacatcaa ggtggacaac gcctattccg acagccaaat cctttaccac caaggcagat
 661 ttattgtcga tcccgtttg gttaaagtgc tttcgtaca gaaaggcgcg ggttcgcct
 721 ctgccggtat cggcgcgacc aacggcgca tcatcgccaa aaccgtcgat gcccaagacc
 781 tgctcaaagg cttggataaa aactggggcg tgcgcctcaa cagcggttt gccggcaaca
 35 841 acggcgcaag ctacggcgca agcgtattcg gaaaagagg caacttcgac ggtttgttct
 901 cttacaaccg caacgatgaa aaagattacg aagccggcaa aggtttccgc aatgacaacg
 961 gcggcaaaac cgtaccgtac agcgcgctgg acaaacgcag ctacctcgcc aaaatcggaa
 1021 caaccttcgg cgacggcgac caccgcatcg tgttgagcca tatgaaagac caacaccggg
 1081 gcatccgcac tgtgctgaa gagtttgccg tcagcgaaaa aaattcacgg ataactatta
 40 1141 aacgccaaagc cccatcttac cgcgaaacca ctcaatcaa caccaacttg gcgtacaccg
 1201 gcaaagattt gggctttgtc gaaaaactgg atgccaacgc ctatgtgttg gaaaagaaac
 1261 gctattccgc cgatgacaaa gataacggct acgcaggcaa tgtaaaaggc cccaaccata
 1321 cccgaatcgc cactcggagt atgaacttca acttcgacag ccgccttgcc gaacaaacc
 1381 tgttgaaata cggcatcaac taccgccatc aggaaatcaa accgcaagcg tttttgaact
 45 1441 cggaaattga aataaaagat aaagaaaaag caactaatga agagaaaaag aagaaccgtg
 1501 aaatgaaaa aattgccaaa gcctaccgcc tgaccaaaccc gacaaaaacc gataccggcg
 1561 cgatatatga agccattcac gagattgacg gctttaccct gaccggcggg ctgctgtacg
 1621 accgcttcaa ggtgaaaacc cagcagggca aaaccgtttc aagcagcagc ctcaaccga
 50 1681 gtttcggcgt gatttggcag ccgcgcgaac actggagctt cagcgcgagc cacaactacg
 1741 ccggccgcag ccgcgcctg tatgacgctc tgcaaaccca cggcaagcgc ggcacatct
 1801 cgattgccga cggcacgaaa gccgaacgcg cgcgcaatac cgaaatcggc ttcaactaca
 1861 acgacggcac gtttgccgca aacggcagct acttcggca gaccatcaaa gacgcgcttg
 1921 ccaatccgca aaaccgccac gactccgtcg ccgtccgcga agccgtcaac gccggtaca
 1981 tcaaaaacca cggttacgaa ttgggcgcgt cctaccgcac cggcggcctg accgcaaaag
 55 2041 tcggcgtaag ccacagcaaa ccgcgctttt acgatacgca caaagacaag ctggtgagcg
 2101 cgaaccctga atttggcgca caagtcggcc gcaactggac ggctccctt gcctaccgct
 2161 tcaaaaacc gaatctggaa atcggtcgcc gcggtcgta tgttcaaaaa gccgtgggtt
 2221 cgatattggc ggcaggtcaa aaagaccgcg acggcaaat ggaaaacgtt gtacgcaag
 2281 gtttcgggtg gaacgatgtc ttcgccaact ggaaaccgct gggcaagagc acgctcaatg
 60 2341 ttaatctttc ggttaacaac gtgttcgaca agttctacta tccgcacagc caacgctgga
 2401 ccaataccct gccgggcgtg ggacgtgatg tacgcctggg cgtgaactac aagttctaaa
 2461 acgcacatcc cgaaaaaatg ccgtctgaaa gcctttcaga cggcatctgt cctgataatt
 2521 tgatatatag tggattaaca aaaaccggta cggcggtgac ccgccttagc tcaaagggaa
 2581 cgattcccta aggtgctgaa

N. gonorrhoeae structural gene for gonococcal protein III (PIII).

ACCESSION X05105

VERSION X05105.1 GI:44889

source:Neisseria gonorrhoeae/db_xref="taxon:485"

5 Gene PIII coding sequence: 103..813

/protein_id="CAA28752.1"

/db_xref="GI:44890"

/db_xref="SWISS-PROT:P07050"

10 /translation="MTKQLKLSALFVALLASGTAVAGEASVQGYTVSGQSNEIVRNNY

GECWKNAYFDKASQGRVECGDAVAVPEPEPAPVAVVEQAPQYVDETISLSAKTLFGFD

KDSLRAEAQDNLKVLQRLSRTNVQSVRVEGHTDFMGSEKYNQALSERRAYVVANNLV

15 SNGVPASRISAVGLGESQAQMTQVCQAEVAKLGAKASKAKKREALIACIEPDRRDVK
IRSIVTRQVVPARNHHQH"

1 gaattcctat ccgatttgcc gccatgtttc tacagcggcc tgtatgttgg caattcagca
20 61 gttgcttctg tatctgctgt acaaactctaa tgagggaata aaatgaccaa acagctgaaa
121 ttaagcgcac tattcggtgc attgctcgct tccggcactg ctggttgcggg cgaggcgctcc
181 gttcaggggtt acaccgtaag cggccagtcg aacgaaatcg tacgcaacaa ctatggagaa
241 tgctggaaaa acgcctactt tgataaagca agccaagggtc gcgtagaatg cggcgatgag
301 gttgcccgtcc ccgagcccga acccgcgctt gtcgcccgtt tggagcaggc tcctcaatat
25 361 gttgatgaaa ccatttccct gtctgccaaa accctgttcg gtttcgataa ggattcattg
421 cgcgccgaag ctcaagacaa cctgaaagta ttggcgcaac gcctgagtcg aaccaatgtc
481 caatctgtcc gcgtcgaagg ccataccgac tttatgggtt ctgaaaaata caatcaggct
541 ctgtccgaac gccgcgcata cgtagtgga aacaacctgg tcagcaacgg cgtacctgct
601 tctagaattt ctgctgtcgg cttgggcgaa tctcaagcgc aaatgactca agtttgtcaa
30 661 gccgaagtgt ccaaactggg tgcgaaagcc tctaaagcca aaaaacgtga ggctctgatt
721 gcatgtatcg aacctgaccg ccgcgtatag gtgaaaatcc gcagcatcgt aaccgctcag
781 gttgtgcccg cagcgaatca tcaccaacac taaggctagg taatatcttg ccgatgcatg
841 aggttagcgg attttgtacc gggtagctgt gcaatattcg tgaaacgtcg gccggatcgt
901 atgatgtgaa acaaaccctg cttttgcggg gtttgttttt ttgggtggtt ttctgaaacg
35 961 gctatcgtca gaatcggggg gcagggttcg attcggattc agattcatgt ttgtgtccca
1021 ttgccgcgct ttatagtga ttaacaaaaa tcaggacaag gcgacgaagc cgcagacagt
1081 acaatagtac ggcaaggcga ggcaacgcg taccgggtta aatttaatcc actatatcgg
1141 ttgaaactct gattttaagg cggtaggatg tgggtttgcc catagcaagg gaatccttc
1201 tgtatcaagc cccgaaaggg ataattcata caaattcacg cctttccccc tcattgggaa
40 1261 atggatggaa tcgtgcccg tgtgtgcggc actgtatgcc ggatattggt ttatcatcat
1321 cccttttcgg ttgaaacccc gcggaattc

Preferred *Pseudomonas aeruginosa* bleb preparations

45 One or more of the following genes (encoding protective antigens) are preferred for upregulation via process b): PcrV, OprF, OprI. They are also preferred as genes which may be heterologously introduced into other Gram-negative bacteria.

Preferred *Moraxella catarrhalis* bleb preparations

50 One or more of the following genes (encoding protective antigens) are preferred for upregulation via process b): OMP106 (WO 97/41731 & WO 96/34960), HasR (PCT/EP99/03824), PilQ (PCT/EP99/03823), OMP85 (PCT/EP00/01468), lipo06 (GB 9917977.2), lipo10 (GB 9918208.1), lipo11 (GB 9918302.2), lipo18 (GB

9918038.2), P6 (PCT/EP99/03038), ompCD, CopB (Helminen ME, et al (1993) Infect. Immun. 61:2003-2010), D15 (PCT/EP99/03822), Omp1A1 (PCT/EP99/06781), Hly3 (PCT/EP99/03257), LbpA and LbpB (WO 98/55606), TbpA and TbpB (WO 97/13785 & WO 97/32980), OmpE, UspA1 and UspA2 (WO 93/03761), FhaB (WO 99/58685) and Omp21. They are also preferred as genes which may be heterologously introduced into other Gram-negative bacteria.

One or more of the following genes are preferred for downregulation via process a): CopB, OMP106, OmpB1, TbpA, TbpB, LbpA, and LbpB.

One or more of the following genes are preferred for downregulation via process c): htrB, msbB and lpxK (most preferably msbB).

One or more of the following genes are preferred for upregulation via process d): pmrA, pmrB, pmrE, and pmrF.

Many of the above open reading frames and upstream regions are described in WO 01/09350 (incorporated by reference herein).

Preferred *Haemophilus influenzae* bleb preparations

One or more of the following genes (encoding protective antigens) are preferred for upregulation via process b): D15 (WO 94/12641), P6 (EP 281673), TbpA, TbpB, P2, P5 (WO 94/26304), OMP26 (WO 97/01638), HMW1, HMW2, HMW3, HMW4, Hia, Hsf, Hap, Hin47, Iomp1457 (GB 0025493.8), YtfN (GB 0025488.8), VirG (GB 0026002.6), Iomp1681 (GB 0025998.6), OstA (GB 0025486.2) and Hif (all genes in this operon should be upregulated in order to upregulate pilin). They are also preferred as genes which may be heterologously introduced into other Gram-negative bacteria.

One or more of the following genes are preferred for downregulation via process a): P2, P5, Hif, IgA1-protease, HgpA, HgpB, HMW1, HMW2, Hxu, TbpA, and TbpB.

One or more of the following genes are preferred for downregulation via process c): htrB, msbB and lpxK (most preferably msbB).

One or more of the following genes are preferred for upregulation via process d): pmrA, pmrB, pmrE, and pmrF.

Many of the above open reading frames and upstream regions are described in WO 01/09350 (incorporated by reference herein).

Preparations of membrane vesicles (blebs) of the invention

The manufacture of bleb preparations from any of the aforementioned modified strains may be achieved by harvesting blebs naturally shed by the bacteria, or by any of the methods well known to a skilled person (e.g. as disclosed in EP 301992, US 5,597,572, EP 11243 or US 4,271,147). For *Neisseria*, the method described in the Example below is preferably used

A preparation of membrane vesicles obtained from the bacterium of the invention is a further aspect of this invention. Preferably, the preparation of membrane vesicles is capable of being filtered through a 0.22 μm membrane.

A sterile (preferably homogeneous) preparation of membrane vesicles obtainable by passing the membrane vesicles from the bacterium of the invention through a 0.22 μm membrane is also envisaged.

Vaccine Formulations

A preferred embodiment of the invention is the formulation of the bleb preparations of the invention in a vaccine which may also comprise a pharmaceutically acceptable excipient.

Vaccine preparation is generally described in Vaccine Design ("The subunit and adjuvant approach" (eds Powell M.F. & Newman M.J.) (1995) Plenum Press New York).

The bleb preparations of the present invention may be adjuvanted in the vaccine formulation of the invention. Suitable adjuvants include an aluminium salt such as aluminum hydroxide gel (alum) or aluminium phosphate, but may also be a salt of calcium (particularly calcium carbonate), iron or zinc, or may be an insoluble suspension of acylated tyrosine, or acylated sugars, cationically or anionically derivatised polysaccharides, or polyphosphazenes.

Suitable Th1 adjuvant systems that may be used include, Monophosphoryl lipid A, particularly 3-de-O-acylated monophosphoryl lipid A, and a combination of monophosphoryl lipid A, preferably 3-de-O-acylated monophosphoryl lipid A (3D-MPL) together with an aluminium salt. An enhanced system involves the combination of a monophosphoryl lipid A and a saponin derivative particularly the combination of QS21 and 3D-MPL as disclosed in WO 94/00153, or a less reactogenic composition

where the QS21 is quenched with cholesterol as disclosed in WO96/33739. A particularly potent adjuvant formulation involving QS21 3D-MPL and tocopherol in an oil in water emulsion is described in WO95/17210 and is a preferred formulation.

The vaccine may comprise a saponin, more preferably QS21. It may also
5 comprise an oil in water emulsion and tocopherol. Unmethylated CpG containing oligo nucleotides (WO 96/02555) are also preferential inducers of a TH1 response and are suitable for use in the present invention.

The vaccine preparation of the present invention may be used to protect or treat a mammal susceptible to infection, by means of administering said vaccine via
10 systemic or mucosal route. These administrations may include injection *via* the intramuscular, intraperitoneal, intradermal or subcutaneous routes; or *via* mucosal administration to the oral/alimentary, respiratory, genitourinary tracts. Thus one aspect of the present invention is a method of immunizing a human host against a disease caused by infection of a gram-negative bacteria, which method comprises
15 administering to the host an immunoprotective dose of the bleb preparation of the present invention.

The amount of antigen in each vaccine dose is selected as an amount which induces an immunoprotective response without significant, adverse side effects in typical vaccinees. Such amount will vary depending upon which specific immunogen
20 is employed and how it is presented. Generally, it is expected that each dose will comprise 1-100µg of protein antigen, preferably 5-50µg, and most typically in the range 5 - 25µg.

An optimal amount for a particular vaccine can be ascertained by standard studies involving observation of appropriate immune responses in subjects.
25 Following an initial vaccination, subjects may receive one or several booster immunisations adequately spaced.

Ghost or Killed Whole cell vaccines

The inventors envisage that the above modified bacterial strains may not only
30 be useful in generating bleb preparations useful in vaccines – they may also be easily used to make ghost or killed whole cell preparations and vaccines (with identical advantages). Methods of making ghost preparations (empty cells with intact envelopes) from Gram-negative strains are well known in the art (see for example WO

92/01791). Methods of killing whole cells to make inactivated cell preparations for use in vaccines are also well known. The terms 'bleb preparations' and 'bleb vaccines' as well as the processes described throughout this document are therefore applicable to the terms 'ghost preparation' and 'ghost vaccine', and 'killed whole cell
5 preparation' and 'killed whole cell vaccine', respectively, for the purposes of this invention.

EXAMPLES

The examples below are carried out using standard techniques, which are well known and routine to those of skill in the art, except where otherwise described in detail. The
 5 examples are illustrative, but do not limit the invention.

Example 1: Previously reported examples

Examples describing: Construction of a *Neisseria meningitidis* serogroup B strain lacking capsular polysaccharides; Construction of versatile gene delivery
 10 vectors (the pCMK series) targeting integration in the *porA* locus of *Neisseria meningitidis*; Construction of a *Neisseria meningitidis* serogroup B strain lacking both capsular polysaccharides and the major immunodominant antigen PorA; Up-regulation of the NspA outer membrane protein production in blebs derived from a recombinant *Neisseria meningitidis* serogroup B strain lacking functional *porA* and
 15 *cps* genes; Up-regulation of the D15/Omp85 outer membrane protein antigen in blebs derived from a recombinant *Neisseria meningitidis* serogroup B strain lacking functional *cps* genes but expressing PorA; Construction of versatile promoter delivery vectors; Fermentation processes for producing recombinant blebs; Identification of bacterial promoters suitable for up-regulation antigens-coding genes; Up-regulation of
 20 the *N. meningitidis* serogroup B *Omp85* gene by promoter replacement; Up-regulation of the Hsf protein antigen in a recombinant *Neisseria meningitidis* serogroup B strain lacking functional *cps* genes but expressing PorA; *Expression of the Green Fluorescent Protein in a recombinant Neisseria meningitidis serogroup B strain lacking functional cps genes but expressing PorA*; Up-regulation of the *N. meningitidis* serogroup B *NspA* gene by promoter replacement; Up-regulation of the
 25 *N. meningitidis* serogroup B *pldA (omplA)* gene by promoter replacement; Up-regulation of the *N. meningitidis* serogroup B *tbpA* gene by promoter replacement; Up-regulation of the *N. meningitidis* serogroup B *pilQ* gene by promoter replacement; Construction of a *kanR/sacB* cassette for introducing “clean”, unmarked mutations in
 30 the *N. meningitidis* chromosome; Use of small recombinogenic sequences (43bp) to allow homologous recombination in the chromosome of *Neisseria meningitidis*; Active protection of mice immunized with WT and recombinant *Neisseria meningitidis* blebs; and Immunogenicity of recombinant blebs measured by whole cell

& specific ELISA methods have been described in WO 01/09350 (incorporated by reference herein).

5 **Example 2: Gonococcal blebs expressing *Chlamydia trachomatis* proteins on its surface for use in a vaccine composition**

Both *Chlamydia trachomatis* and *N. gonorrhoeae* cause sexually transmitted diseases, including urethritis, cervicitis, salpingitis and pelvic inflammatory disease. Mixed infection with both CT and GC does occur. Therefore, in the design of a vaccine targeting one, or more of these diseases, the possibility to afford protection against both organisms with one single formulation creates a technical advantage.

Protection against *N. gono.*

15 A *N. gonorrhoeae* OMV vaccine can be obtained from bleb producing strain(s) in which the expression of one or several genes have been up and/or down regulated. A list of genes encoding *N. gonorrhoeae* proteins for which it is particularly useful to up/down regulate expression is provided above.

20 A successful vaccine for the prevention of infection by *N. gono* may require more than one of the following elements: generation of serum and/or mucosal antibodies to facilitate complement mediated killing of the gonococcus, and/or to enhance phagocytosis and microbial killing by leukocytes such as polymorphonuclear leukocytes, and/or to prevent attachment of the gonococci to the host tissues; induction of a cell mediated immune response may also participate to protection.

25 The potential of a bleb gono vaccine preparation can be evaluated by analyzing the induced immune response for serum and/or mucosal antibodies that have antiadherence, and/or opsonizing properties, and/or bactericidal activity, as described by others (McChesney D et al, Infect. Immun. 36: 1006, 1982; Boslego J et al: Efficacy trial of a purified gonococcal pilus vaccine, in Program and Abstracts of the 24th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, American Society for Microbiology, 1984; Siegel M et al, J. Infect. Dis 145: 300, 1982; de la Pas, Microbiology, 141 (Pt4): 913-20, 1995).

30 A mouse model of genital infection by *N. gono* has recently been described (Plante M, J. Infect. Dis., 182: 848-55, 2000). The efficiency of a bleb gono vaccine

could also be evaluated by its ability to prevent or to reduce colonization by *N. gono* in this mouse model of infection.

Protection against CT

5 A GC/CT bleb vaccine can be obtained from a strain expressing one or several Chlamydia genes, preferably selected from the above list of genes encoding predicted outer membrane proteins.

Other genes of interest for overexpression in *Neisseria* are *C. trachomatis* genes for which no homolog has been found in *C. pneumoniae*. Such a set of genes
10 has been described in Richard S.; p:9-27, Stephens Stephens Ed. ASM Press, Washington DC, Chlamydia: Intracellular Biology, Pathogenesis, and Immunity ISBN: 1-55581-155-8 pages: 380.

Most preferred combinations of *Chlamydia trachomatis* genes are as follows: Major outer membrane protein MOMP (from one or several different serovars) and
15 the Outer membrane Protein Analog (also known as PorB), MOMP (from one or several different serovars) and the Putative Outer Membrane Protein G (pmpG); & PorB and pmpG.

Although the immunity to CT is not fully understood, there is evidence that Ab play a role in protection. Ab to CT in genital fluids have been associated with
20 immunity to CT (Brunham RC, Infect Immun. 1983 Mar;39(3):1491-4.). A protective role of serum antibody in immunity to chlamydial genital infection has also been shown (Rank RG, Infect Immun. 1989 Jan;57(1):299-301.). Antibodies, e.g. MOMP specific antibodies, have been shown to be capable to neutralize CT infection in vitro and in vivo (Caldwell et al. 1982 Infect. Immun. 38: 745-54, Lucero et al, 1985,
25 Infect. Immun. 50: 595-97, Zhang et al. 1987 J. Immunol. 138: 575-581). The MOMP surface antigen of CT has been shown to bear non linear surface epitopes which are target of neutralizing antibodies (Fan J, J. Infect Dis 1997, 176(3):713-21).

Thus, an important objective in the design of a protective chlamydia vaccine includes the identification of formulation(s) of the CT antigens able to optimize the
30 induction of a chlamydia specific antibody responses. Optimization of the Ab response includes targeting to the genital mucosa, and/or presentation of properly folded Chlamydia antigens, and/or combination of several antibody targets.

Mucosal targeting of the immune response to Chlamydia antigen can be achieved by mucosal administration of the vaccine. Intranasal administration of an outer membrane vesicle vaccine can induce persistent local mucosal antibodies and serum antibodies with strong bactericidal activity in humans.

5 For certain B cell epitopes, such as non linear epitopes, the presentation of the antigen to the immune system in a properly folded manner is critical. A bleb vaccine prepared from a strain expressing Chlamydia antigen(s) offers to chlamydia OMP an outer membrane environment which can be critical to maintain these antigens in a properly folded structure.

10 Combination of several antibody targets can create an increased efficacy by tackling the infection at different steps of the life cycle of the bacteria, such as adhesion to the host cell, internalization by the host cell and/or interference with further steps of the intracellular development.

The induction and recruitment of Th1 cells into the local genital mucosae are
15 important for immunity against Chlamydia. Thus, an important objective in designing a protective anti-chlamydia vaccine includes the identification of formulation(s) of CT antigen(s) able to optimize the induction of chlamydia specific Th1 cells, and preferably recruitment of these cells into the genital mucosae. A bleb vaccine prepared from a strain expressing chlamydia antigen(s) can induce a chlamydia specific CMI
20 response. Antigen-specific T-cell responses can be induced in humans after intranasal immunization with an outer membrane vesicle vaccine.

A particular advantage of a GC/CT bleb vaccine is its capability to induce both Ab and CMI responses.

The efficacy of the GC/CT bleb vaccine can be evaluated by its ability to elicit
25 Ag or Chlamydia-specific Ab and/or CMI responses. Ab responses can be evaluated by classical techniques such as ELISA or western blot. Preferably, the induced antibodies can neutralize the infectivity of Chlamydia in an in vitro assay (Byrne G. et al. (J Infect Dis. 1993 Aug;168(2):415-20). Preferably, the CMI response is biased toward the Th1 phenotype. A Th1 biased immune response can be assessed by
30 elevated antigen-specific IgG2a/ IgG1 ratios in mice (Snapper et al. 1987, Science 236:944-47). Elevated ratio of Th1/Th2 cytokine, e.g. elevated IFN-gamma/IL-5, ratio upon in vitro restimulation of immune T cells with the antigen(s) can also indicate such a biased Th1 response.

The ability of the formulation to elicit Ag specific mucosal Ab is of particular interest, and can be demonstrated by detection of antibodies, such as IgG and/or IgA in mucosal fluids, such as genital tract secretions, vaginal lavages. To this end, certain route of administration of the vaccine may be particularly desired such as intranasal, oral, intravaginal, intradermal, deliveries.

The efficacy of the GC/CT bleb vaccine can be evaluated by its ability to induce protection against a Chlamydia challenge in animal model(s). Examples of such animal models have been described in the literature: genital infection with MoPn in mice (Barron et al. J. Infect. Dis. 1143:63-66), genital infection with human strains in mice (Igietseme et al. 2000, Infect. Immun. 68:6798-806, Tuffrey et al. 1992 J. Gen. Microbiol. 138: 1707-1715), Tuffrey), genital infection with GPIC strain in guinea pigs (Rank et al. 1992 Am. J. Pathol. 140:927-936). Protection against infection can be assessed by reduction of shed Chlamydia from the infected site and/or reduction of the histopathological reactions after a challenge infection in immunized animals.

The advantage of combining two or more Chlamydia antigens (as described above) can be evaluated by one or more of the following techniques:

- Ability to elicit a multi-target Ab and/or T cell protective response
- Ability to elicit Ab titers in an in vitro neutralizing assay, and/or neutralizing Ab against multiple strains (antigenically distinct)
- Ability to elicit a protective immune response against Chlamydia in a mouse model of genital infection as assessed by reduced shedding of bacteria and/or pathology after challenge.

Example 3: Expression of heterologous antigens (*Chlamydia trachomatis* MOMP and PorB) in blebs derived from a recombinant *Neisseria meningitidis* serogroup B strain lacking functional *porA* and *cps* genes.

Other genes of interest for over-expression in *Neisseria* are *Chlamydia trachomatis* genes for which no homologue has been found in *Chlamydia pneumoniae*. Among those, the major outer membrane protein (MOMP) and the outer membrane protein analog (PorB) have been shown to play a protective role against

chlamydial genital infection. Optimization of the Ab response could be achieved by presentation of properly folded proteins.

MenB bleb vesicles may be used as delivery vectors to express heterologous membrane protein antigens under the control of the engineered *porA-lacO* promoter described in WO 01/09350. Expressed in the bleb context, recombinant MOMP and PorB from *Chlamydia trachomatis* serovar D and K can be correctly folded in the membrane and exposed at the surface. *Neisseria meningitidis* strains lacking functional *cps* genes are advantageously used as recipient strains to express the heterologous antigens (WO 01/09350).

PCR amplifications of the genes coding for MOMP (*Chlamydia trachomatis*).

Murine McCoy cells (ATCC) infected either, with *Chlamydia trachomatis* Serovar K (UW31-CX-serK), or Serovar D (UW31-CX-serD), were lysed in 400µl of lysis buffer: 50mM KCl, 10mM Tris-HCl pH 8.3, 2.5mM MgCl₂, 0.45% Nonidet P40, 0.45% Tween 20 containing 60µg/ml proteinase K, 3 hours at 56°C. Ten µl of the lysate were used as template to amplify the corresponding genes. The gene coding for MOMP (Serovar K) (SEQID N°1 below) was PCR amplified using the CYK/OMP/5/NDE and CYKD/OMP/3/BG oligonucleotide primers (see table 1). The gene coding for MOMP (Serovar D) (SEQID N°2 below) was PCR amplified using the CYD/OMP/5/NRU and CYKD/OMP/3/BG oligonucleotide primers (see table 1). The conditions used for PCR amplification were those described by the supplier (HiFi DNA polymerase, Boehringer Mannheim, GmbH). Thermal cycling was the following: 25 times (94°C 1min., 52°C 1min., 72°C 3min.) and 1 time (72°C 10min., 4°C up to recovery). The corresponding amplicons (1194bp) were digested with either *NdeI/BglII* or *NruI/BglII* restriction enzymes and can be cloned in the corresponding restriction sites of pCMK (+) delivery vector (as described in WO 01/09350).

PCR amplifications of the genes coding for PorB (*Chlamydia trachomatis*).

Murine McCoy cells (ATCC) infected either, with *Chlamydia trachomatis* Serovar K (UW31-CX-serK), or Serovar D (UW31-CX-serD), were lysed in 400µl of lysis buffer: 50mM KCl, 10mM Tris-HCl pH 8.3, 2.5mM MgCl₂, 0.45% Nonidet P40, 0.45% Tween 20 containing 60µg/ml proteinase K, 3 hours at 56°C. Ten µl of the lysate were used as template to amplified the corresponding genes.

PorB sequences are highly conserved amongst serovar D and K (SEQID N°3 below). The same primers were used to amplify the corresponding genes in both serovars: CYD/PORB/5/NRU and CYD/PORB/3/BG (see table 1). The conditions used for PCR amplification were those described by the supplier (HiFi DNA polymerase, 5 Boehringer Mannheim, GmbH). Thermal cycling was the following: 25 times (94°C 1min., 52°C 1min., 72°C 3min.) and 1 time (72°C 10min., 4°C up to recovery). The corresponding amplicons (1035bp) were digested with *NruI/BglII* restriction enzymes and can be cloned in the corresponding restriction sites of pCMK (+) delivery vector (as described in WO 01/09350).

10

Transformation

Linearized recombinant pCMK plasmids can be transformed within a *Neisseria meningitidis* serogroup B strain lacking functional *cps* genes (described in WO 01/09350). Integration resulting from a double crossing-over between the pCMK 15 vectors and the chromosomal *porA* locus can be selected by a combination of PCR and Western Blot screening as described in WO 01/09350.

Table 1: Oligonucleotides used in this work

Oligonucleotides	Sequence	Remark(s)
CYK/OMP/5/NDE	5'-GGG AAT CCA TAT GAA AAA ACT CTT GAA ATC GG-3'	<i>NdeI</i> cloning site
CYKD/OMP/3/BG	5'-GGA AGA TCT TTA GAA GCG GAA TTG TGC AT-3'	<i>Bgl</i> II cloning site
CYD/OMP/5/NRU	5'-CTG CAG AAT CGC GAA TGA AAA AAC TCT TGA AAT CGG-3'	<i>NruI</i> cloning site
CYD/POR/5/NRU	5'-CTG CAG AAT CGC GAA TGA GTA GCA AGC TAG TGA AC-3'	<i>NruI</i> cloning site
CYD/POR/3/BG	5'- AGG AGA TCT TTA GAA TTG GAA TCC TCC GG-3'	<i>Bgl</i> II cloning site

20

SEQID N°1:

Nucleotide sequence of DNA coding for *Chlamydia trachomatis* MOMP serovar K protein.

25 atgaaaaaactcttgaaatcggtatttagtattgcccgtttgagttctgcttcctcttgcaagctctgcctgtggggaa
tctgtctgaaccaagccttatgatcgacggaattctgtgggaagggttcggcggagatccttgcatccttgaccactt
ggtgtgacgctatcagcatcgcggttggtactacggagactttgtttcgaccgtgtttgaaaactgatgtgaataaa
gaatttcagatgggagcggcgcctactaccagcgatgtagaaggcttacaacgatccaacaacaaatgtgtcgtcgc

SUBSTITUTE SHEET (RULE 26)

5 aaatcccgccttatggcaaacacatgcaagatgctgaaatgtttacgaacgctgcttacatggcattaaatatctgggatc
 gttttgatgtattttgtacattgggagcaactaccggttatttaagaggaaactccgcttccttcaacttagttggatta
 ttcggaacaaaaacacaataattctaagtttaatacagcgaatctgttcttaacactgcttggatcgagctgtgtgtga
 gctttatacagacaccacctttgcttggagcgtaggtgctcgtgcagctctctgggaatgtgggtgtgcaacgttaggag
 10 ctcttcccaatatgctcaatctaaacctaaagtagaagagttaaatgttcttgaatgcatccgaatttactattaat
 aagccgaaaggatatgttgggtggaattccacttgatattaccgcaggaacagaagctgcgacagggactaaggatgc
 ctctattgactacatgagtggcaagcaagtttagccctttctacagattaaatatgttcactccttaccattggagtta
 aatggtctagtagtaagttttgatgccgacacgatccgatcgtcagcctaaattggctgaagcaatcttggatgctact
 actctaaaccgaccatcgctggtaaaggagctgtgtgtcttccggaagcgataacgaactggctgatacaatgcaaat
 15 cgttccctgcagttgaacaagctgaaatctagaaaatcttgcggtattgcagtaggaacgactattgtagatgcagata
 aatacgcagttacagttgagactcgttgatcgatgagagagcagctcacgtaaatgcacaattccgcttctaa

SEQID N°2:

15 **Nucleotide sequence of DNA coding for *Chlamydia trachomatis* MOMP serovar D protein.**

20 atgaaaaactcttgaaatcggtattagttatgtccgctttagtctgcttctccttgaagctctgcctgtggggaa
 tcctgctgaaccaagccttatgatcgacggaattctgtgggaagggttcggcgagatccttgcgatccttgcgccactt
 ggtgtgacgctatcagcatgcgtgtgttactacggagactttgtttcgaccgtgtttgaaaactgatgtgaataaa
 gaatttcagatgggtgccaaagcctacaactgatacaggcaatagtcagctccatccactcttacagaagagagaatcc
 tgcttacggccacatatgcaggatgctgagatgtttacaaatgccgcttgcatggcattgaatatttgggatcgtttg
 atgtattctgtacattaggagccaccagtgatattctaaaggaaactctgcttcttcaatttagttgattgtttgga
 25 gataatgaaaatcaaaaacgggtcaagcgagctgtaccaaataatgagctttgatcaatctgtgtgtgagttgtatc
 agatactacttttgcgtggagcgtcggcgctcgcgcagctttgtgggaatgtggatgtgcaactttaggagcttcattcc
 aatatgctcaatctaaacctaaagtagaagaattaaacgttctctgcaatgcagcagagttactattaataaacctaaa
 gggtatgtaggttaaggagtttctcttgatcttacagcaggaacagatgctgcgacaggaactaaggatgcctctattga
 ttaccatgaatggcaagcaagtttagctctcttacagactgaatatgttcactccctacattggagttaaatggtctc
 gagcaagctttgatgccgatacagattcgtatagcccagccaaaatcagctacagctatitttgatactaccacgcttaac
 30 ccaactatttgcgtggagctggcgatgtgaaaactggcgagagggtcagctcgagacacaatgcaaatcgtttccttga
 attgaacaagatgaaatctagaaaatcttgcggtattgcagtaggaacaactattgtggatgcagacaaatcgcagtta
 cagttgagactcgttgatcgatgagagagcagctcacgtaaatgcacaattccgcttctaa

SEQID N°3:

35 **Nucleotide sequence of DNA coding for *Chlamydia trachomatis* PorB serovar D protein.**

40 atgagtagcaagctagtgaactatctccgttgactttcctatcttttttagggatcgcacttacttcattagacgctat
 gcctgcggggaaatccggcggttccagtcacccggggattaattgaacagaaaaatgcctgttcttcgatttatgta
 attcttatgatgtactatccgcactgtccggaacctgaagctctgcttctgcggagattatctttcagaagaagct
 caggtaaaagatgtccctgtcgttacctctgtgacaacagctggggttggtccttctcctgatattacttcgacaaccaa
 aacgcgaaatttcgatctcgtgaactgtaatctcaatacaaaactgtgtagctgtagcttttcccttctgatcgttcgc
 tgagcgcgattcctctgtttgatgtgagtttcgaagtgaagtaggaggactgaacaatactaccgcttccatgaat
 45 gcctatcgagacttcacctcggaaacctctcaattctgaatcagaagttacggacgggatgattgaagtacagtccaatta
 cggatttgttgggatgttagcttgaaaaaagtcatatggaaagatggcggttcttcttaggcgtcggtgcagactatc
 gccatgcttcttgcctattgactacatcattgcaaacagtcgaagctaatccagaagtattcatcgtgactcggatggg
 aaactgaactcaaggagtgagtgctgcgttaggtcttactacatgtgaatgactacgttcttcttacttagcgtt
 ttctataggagtggttctcgccaagctccggacgacagcttcaaaaaattagaagatcgcttcaactaacctcaaatfta
 50 aagttcgtaaaattaccagctctcatcgtgaaacatctgcatcggagcgacaaactatgtcgcgataacttctctac

aacgtagaaggaagatggggaagccagcgctgtgaacgtctccggaggattccaattctaa

Example 4: Isolation and purification of blebs from meningococci devoid of capsular polysaccharide

Recombinant blebs can be purified as described below. The cell paste (42gr) is suspended in 211 ml of 0.1M Tris-Cl buffer pH 8.6 containing 10 mM EDTA and 0.5% Sodium Deoxycholate (DOC). The ratio of buffer to biomass should be 5/1 (V/W). The biomass is extracted by magnetic stirring for 30 minutes at room temperature. Total extract is then centrifuged at 20,000g for 30 minutes at 4°C (13,000 rpm in a JA-20 rotor, Beckman J2-HS centrifuge). The pellet should be discarded. The supernatant is ultracentrifuged at 125,000g for 2 hours at 4°C (40,000 rpm in a 50.2Ti rotor, Beckman L8-70M ultracentrifuge) in order to concentrate vesicles. The supernatant should be discarded. The pellet is gently suspended in 25 ml of 50 mM Tris-Cl buffer pH 8.6 containing 2 mM EDTA, 1.2% DOC and 20% sucrose. After a second ultracentrifugation step at 125,000g for 2 hours at 4°C, vesicles are gently suspended in 44 ml of 3% sucrose and stored at 4°C. All solutions used for bleb extraction and purification contained 0.01% thiomersalate. As illustrated in WO 01/019350, this procedure yields protein preparations highly enriched in outer-membrane proteins.

Example 5: Models for testing protection against gonococcal and *C. trachomatis* infection

This can be done as described above in Example 2. In addition Whittum-Hudson et al. (Vaccine 2001 Jul 16;19(28-29):4061-71) "The anti-idiotypic antibody to chlamydial glycolipid exoantigen (GLXA) protects mice against genital infection with a human biovar of *Chlamydia trachomatis*" is a vaginal inoculation model for *C. trachomatis* (incorporated by reference herein) which can also be used to test vaccine efficacy.

We Claim:

1. A Gram-negative bacterial bleb presenting on its surface the PorB outer membrane protein from *Chlamydia trachomatis*.
5
2. The Gram-negative bleb of claim 1 further presenting on its surface the PmpG outer membrane proteins from *Chlamydia trachomatis*.
3. The Gram-negative bleb of claim 1 further presenting on its surface MOMP from
10 one or more serovars from *Chlamydia trachomatis*.
4. A Gram-negative bleb presenting on its surface both the PmpG and MOMP (from one or more serovars) outer membrane proteins from *Chlamydia trachomatis*.
- 15 5. The bleb of claims 1-4 which are gonococcal blebs.
6. The bleb of claim 5 which has been derived from a gonococcal strain which has been modified to upregulate one or more protective gonococcal outer membrane antigens.
20
7. The bleb of claims 5 and 6 derived from a gonococcal strain which has been modified to downregulate one or more immunodominant variable or non-protective gonococcal outer membrane antigens.
- 25 8. The bleb of claims 5-7 derived from a strain which has a detoxified lipid A portion of bacterial LPS, due to the strain having been engineered to reduce or switch off expression of one or more genes selected from the group consisting of: htrB, msbB and lpxK.
- 30 9. The bleb of claims 5-8 wherein the bleb preparation is derived from a strain which has a detoxified lipid A portion of bacterial LPS, due to the strain having been engineered to express at a higher level one or more genes selected from the group consisting of: pmrA, pmrB, pmrE and pmrF.

10. A vaccine composition comprising the bleb of claims 1-9 and a pharmaceutically suitable excipient or carrier.
- 5 11. The vaccine of claim 10, additionally comprising a mucosal adjuvant.
12. A method of preventing *Chlamydia trachomatis* infection in a host comprising the steps of administering an effective amount of the vaccine of claim 10 or 11 to a host in need thereof.
- 10 13. The method of claim 12 where in the vaccine is mucosally administered via either a intranasal, oral, or intravaginal route.
14. A Gram-negative bleb presenting on its surface a protective antigen from
15 *Chlamydia pneumoniae*.
15. A Gram-negative bleb presenting on its surface both the PorB and MOMP outer membrane proteins from *Chlamydia pneumoniae*.
- 20 16. A Gram-negative bleb presenting on its surface both MOMP and one or more Pmp outer membrane proteins from *Chlamydia pneumoniae*.
17. A Gram-negative bleb presenting on its surface both PorB and one or more Pmp outer membrane proteins from *Chlamydia pneumoniae*.
- 25 18. A Gram-negative bleb presenting on its surface both the PorB and Npt1 proteins from *Chlamydia pneumoniae*.
19. A Gram-negative bleb presenting on its surface both Npt1 and one or more Pmp
30 proteins from *Chlamydia pneumoniae*.
20. A Gram-negative bleb presenting on its surface both Npt1 and MOMP proteins from *Chlamydia pneumoniae*.

21. The bleb of claims 14-20 which are meningococcal blebs.
22. The bleb of claim 21 derived from a meningococcal strain that has been modified
5 to upregulate one or more protective meningococcal outer membrane antigens.
23. The bleb of claim 21 or 22 derived from a meningococcal strain that has been
modified to downregulate one or more immunodominant variable or non-
protective meningococcal outer membrane antigens.
- 10 24. The bleb of claims 21-23 derived from a strain which has a detoxified lipid A
portion of bacterial LPS, due to the strain having been engineered to reduce or
switch off expression of one or more genes selected from the group consisting of:
htrB, msbB and lpxK.
- 15 25. The bleb of claims 21-24 wherein the bleb preparation is derived from a strain
which has a detoxified lipid A portion of bacterial LPS, due to the strain having
been engineered to express at a higher level one or more genes selected from the
group consisting of: pmrA, pmrB, pmrE and pmrF.
- 20 26. A vaccine composition comprising the bleb of claims 14-25 and a
pharmaceutically suitable excipient or carrier.
27. The vaccine of claim 26, additionally comprising a mucosal adjuvant.
- 25 28. A method of preventing *Chlamydia pneumoniae* infection in a host comprising the
steps of administering an effective amount of the vaccine of claim 26 or 27 to a
host in need thereof.
- 30 29. The method of claim 28 where in the vaccine is mucosally administered via either
an intranasal, or oral route.